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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
 
Nanotechnology and Medicine 
 Nanotechnology is an area of science devoted to the manipulation of atoms and 
molecules leading to the assembly of structures in the nanometer (1 to 1000 nm) scale 
size range.  Research in the “nanorealm” began in physics and chemistry in the early 
1970’s but soon spread into medicine and biology.  Specifically, a wide array of 
nanotechnologies is beginning to change the foundations of disease diagnosis, treatment, 
and prevention.  These advanced innovations, referred to as nanomedicine by the 
National Institutes of Health1, have the potential for widespread patient benefits.  Because 
molecules and structures inside cells operate at the nano- and micro-scale, the evolution 
of nanomedicine as an offshoot of nanotechnology has become a key component for the 
future of research in medical intervention.  A few of the current nanomedical approaches 
include carbon nanotubes that act as biological mimetics2, polymeric nanoconstructs for 
tissue engineering3,4, and nanoscale microfabrication-based devices5.  Furthermore, the 
use of nanoparticulate technologies as targeted forms of diagnostics, drug, and gene 
delivery is at the forefront of nanomedicine, and it has led to collaborative efforts 
between disciplines that were typically segregated: engineering and molecular biology, 
chemistry and virology, physics and surgery. 
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Drug Development and Limitations in Protein and Peptide Trafficking 
In recent years, biotechnology derived drugs including peptides, proteins, and 
monoclonal antibodies/fragments have become a central focus of pharmaceutical research 
and developmental efforts6.  The fate of these drugs after administration in vivo are 
determined by a combination of several processes:  distribution, metabolism, and 
elimination when given intravenously (systemically) while an local (topical), 
extravascular dose, is controlled by absorption, distribution, metabolism, and 
elimination7. 
Bioavailability, the ratio of drug accumulation at its site of action to the amount 
delivered to the body, is a significant limitation in the use of protein or peptide biologics.  
Typically, these molecules have a short half-life in blood plasma or other biological 
fluids, 1.5 min to 150 min for some peptides.  Drug distribution among various tissues is 
equally important.  Thus, the use of naked proteins/peptides in vivo has limited utility, 
necessitating advanced delivery systems which can act locally.  The carrier platform 
should be non-toxic, compatible with the drug applied, preserve its activity, and deliver 
the payload with reproducible pharmacodynamics.  This criteria is especially critical for 
substances that are labile and sensitive to components in biological fluids8. Drug 
incorporation into delivery systems offers many advantages, particularly the enhancement 
of the therapeutic potential of many drugs, alteration of pharmacokinetics and 
biodistribution, and sustained release reservoirs.   
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  Other benefits include:  
• in vivo predictability of release rate for optimization of plasma levels and   
reduction of adverse reactions 
• decreased dosing frequency and improved patient compliance 
• reduction of systemic drug toxicity9 
• drug stabilization10 
• effective accumulation in a target tissue11 
The development of formulations that can combine these benefits with a low cost, simple 
design is critical for highly efficient delivery systems.  
 
 Nanoplatforms for Targeted Drug Delivery 
Nanoparticles (NPs), first observed around 1970, are defined as solid colloidal 
particles less than 1 µm in size consisting of macromolecular compounds.  They were 
initially devised as carriers for vaccines and anticancer drugs. NPs can be fabricated from 
a multitude of materials, including synthetic polymers and biopolymers (proteins and 
polysaccharides).  Drug integration of peptide segments, proteins, and/or small molecules 
with both targeting and therapeutic abilities into delivery systems in the form of 
nanoparticulate polymer matrices offers many benefits.  These benefits include controlled 
drug release and protection, prolonged blood circulation times, and countless other 
adjustable characteristics12,13. 
There are numerous engineered constructs, assemblies, architectures, and 
particulate systems being studied as drug delivery platforms.  These include polymeric 
micelles, dendrimers, virus-derived capsid nanoparticles, polyplexes, and liposomes14-18.  
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Incorporation of therapeutic and diagnostic agents can be achieved by encapsulation, 
covalent attachment, or surface adsorption.  Many carriers can be engineered for 
activation by pH, chemical stimuli, radiation, magnetic fields, or heat.  Many systems are 
being designed for multifuctionality that combine targeted tissue delivery, organelle 
trafficking, and imaging19,20.  These nanovehicles do not behave similarly; their behavior 
within the biological microenvironment, stability, extracellular and cellular distribution 
varies with their chemical makeup, morphology and size.   
The advantages of using nanoparticles for drug delivery result from their two 
basic properties.  First, NPs, due to their small size, penetrate within even small 
capillaries and are taken up within cells, which allows for efficient drug accumulation at 
the target sites in the body21,22.  Second, the use of biodegradable materials for NP 
preparation allow for the sustained drug release within the target site over a period of 
days or even weeks after injection23, establishing many of the concepts described above.  
Table 1-1 introduces some nanovehicular drug delivery approaches. 
 
Table 1-1.  Current drug delivery platforms 
 
NP Platform Size(nm) Therapeutic Application 
Polymeric  10-1000 Brain tumors24-26, bone healing27, vaccine adjuvant28, 
restenosis29, 30, diabetes31 
Ceramic <100 Photodynamic32, insulin delivery33 
Metallic <50 Cancer34, 35, imaging36 
Polymer Micelle <100 Solid tumors37-39, anti-fungal40 
Liposome 50-100 HIV41, tumors42, 43, vaccine delivery44 
Dendrimer <10 Bacterial infections45, cancer46, 47, HIV treatment48 
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Polymer-based Nanoparticles and Polyelectrolyte Complex Dispersions 
Most NP systems, particularly polymer-based, can be formed from a variety of 
preparation techniques, many of which are derived from potentially toxic components 
and harmful solvents.  The most common methods involve polymerization reactions, 
such as emulsion, dispersion, and inverse microemulsion polymerization using both 
biodegradable and non-biodegradable polymers49.  Some of these polymerization 
techniques use mineral oils and strong organic solvents, which may remain in the 
formulation along with other unreacted monomers, initiators, and surfactants, and  these 
present safety issues in the final product. In particular, a widely used polymer for NP 
systems, polylactide-glycolide co-polymer (PLGA), uses a toxic organic solvent 
(methylene chloride), which adds regulatory approval problems.  Alkylcyanoacrylate 
(ACA) nanotechnology suffers from toxic breakdown products50.   
One strategy to circumvent these processing limitations has involved the use of 
water-soluble, biodegradable, polymeric, polyelectrolyte NPs.  This technology is a type 
of NP that has evolved because of the limitations of the currently available systems.  
Biodegradable polymeric polyelectrolytes degrade at a very slow rate and do not alter 
normal cell function51,52.  The polyelectrolytes permit the environmentally attractive use 
of water as a solvent, a major advantage for products that may be used as drug delivery 
systems in humans.  These nanoparticulate architectures, termed polyelectrolyte complex 
dispersions (PECs), result from strong electrostatic interactions between charged 
microdomains of at least two oppositely charged polyelectrolytes53.  The mixing of 
solutions of polyanions and polycations leads to the spontaneous formation of insoluble 
PECs under certain conditions.  The formation of PECs are governed by the strength and 
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location of ionic sites, polymer chain rigidity, precursor chemistries, pH, temperature, 
ionic strength, mixing intensity, and other controllable factors which will affect the PEC 
product.  Classically, PECs have been applied in gene delivery54-56 and 
microencapuslation of various cell and tissue types57,58.  
The most predominant molecular forces for PEC assembly are the strong 
electrostatic interactions.  However, hydrogen bonding, hydrophobic interactions and van 
der Waals forces complement PEC formation, and they are related to the physical 
characteristics listed previously59.   Two major steps dictate PEC complexation:  (1) the 
kinetic diffusion process of mutual entanglement between polymers, occurring at 
relatively short times, depending on molar size differences, and (2) thermodynamic 
rearrangement of the already formed simplex aggregate due to conformational changes 
and disentanglement.  The latter process occurs at rather long times leading to a source of 
instability in the PEC, and it is a consequence of phase separation in aqueous medium.  
Stop flow measurements showed that the PEC formation takes place in less than 5 ms, 
nearly corresponding to the diffusion-controlled collision of polyion coils60. 
Three different types of PECs have been prepared in water61:  
• soluble PEC, i.e. macroscopically homogeneous systems containing small 
PEC aggregates 
• turbid colloidal, PEC systems in the transition range to phase separation 
exhibiting an observable light scattering or Tyndall effect 
• two-phase systems of supernatant liquid and precipitated PEC, which are 
readily separated as a solid after washing and drying (not desirable). 
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As borderline cases for the resulting structures of PECs, two models are discussed in 
literature, dictated by the characteristics of the polyion groups, stoichiometry, and 
molecular weights:  (1) the ladder-like structure, where complex formation takes place on 
a molecular level via conformational adaptation, and (2) the scrambled-egg model, where 
a high number of chains are incorporated into particle architecture60.  The ladder-like 
structure consists of hydrophilic single-stranded and hydrophobic double-stranded 
segments.  These phenomena result from the mixing of polyelectrolytes having weak 
ionic groups and large differences in molecular dimensions and can lead to populations of 
water-soluble and insoluble PECs, an unwanted consequence.  The oppositely charged 
ions complex according to a "zip" mechanism where there is often insufficient ion 
pairing.  In some cases, a high molecular weight polyion with a weak charge density is 
titrated into a shorter, smaller molecular weight counterion (oligomer) 
nonstoichiometrically to form initially soluble PECs.  Through continued addition of the 
high molecular weight polyion, insoluble PECs can form62.    The scrambled-egg model 
refers to complexes that are the product of the combination of polyions with strong ionic 
groups and comparable molar masses yielding insoluble and highly aggregated 
complexes under a strict 1:1 stoichiometry.   Figure 1-1 shows, schematically, these 
representations.  
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Figure 1-1.  Schematic representation of ladder and scrambled egg structures.    Black 
represents the large polyion (negative) while gray represents a polyion of opposite charge 
(positive).  (A) shows the ladder representation where insufficient ion pairing occurs 
under certain stoichiometric conditions leading to macromolecular aggregates, insoluble, 
and soluble PECs.  (B) shows the scrambled egg model where polymers of comparable 
size complex yielding insoluble PECs under certain conditions.     
 
 
As the stoichiometry is adjusted under dilute conditions (10-4 g/ml), colloidal, 
Tyndall effect PECs consisting of a neutral and stoichiometric core surrounded by excess 
binding polyelectrolytes are stabilized against aggregation, and they provide a practical 
nano-and micro-scale product53.  The excess polyelectrolyte provides stability in different 
medium conditions63, i.e. surplus cation bound to a neutralized anionic core leads to 
stability at low pH.  Both the routes ladder and scrambled egg assemblies share the same 
steps of polyelectrolyte interaction, but they only result in the desired structures 
(insoluble stoichiometric complexes) under certain conditions.  An important stride 
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towards functional and practical use of PEC complexes for drug delivery would be 
assemblies that form under easily understood and controllable conditions such as simple 
stream mixing in a continuous or batch design. 
 
Nanoparticle/PEC Size and Zeta Potential Drive Cellular Interactions 
The size of nanoparticulate or PEC species is critical for cell binding and 
internalization64-66.  Due to their sub-cellular and sub-micron size, NPs introduced 
intravascularly can penetrate deep into tissues through fine capillaries. They are generally 
taken up by cells and have a higher intracellular uptake compared to microparticles30.  
For example, 100 nm size NPs showed 2.5 fold greater uptake compared to 1 µm 
particles and they had 6 fold higher uptake compared to 10 µm particles in Caco-2 
(human colon) cells67.  This type of behavior, increased intracellular uptake, has been 
observed not only in Hepa 1-6, Hep G2, and KLN 205 cell lines, but also in perfused rat 
tissues68.   
Intracellular uptake studies have mostly focused on liposome69-71 and polymer 
delivery systems27,72,73, process that are driven by endocytosis: a means of cellular 
ingestion by which the plasma membrane folds inward to bring substances inside cells.  
The process of endocytosis begins with diffusion of particles to the cell surface and 
binding either to receptors or via electrostatic interactions between the anionic cell 
surface and cationic charge domains.  Subsequent to the binding, NPs can remain bound 
to the surface, dissociate, or accumulate in coated or non-coated invaginations.  
Following this size-dependent event, NPs may be delivered to lysosomes where their 
contents may be degraded by lysosomal peptidases and hydrolases.  Another possible fate 
 10 
may be nanovehicle fusion with the endosomal membrane and pH-dependent 
release/degradation of the NP30,74.  Endocytosis has been shown to be concentration, 
energy, time, and size dependent, but saturable.  Specific mechanisms may include 
phagocytosis, fluid phase pinocytosis, or receptor-mediated uptake74 and may be probed 
by applying various inhibitor strategies75.   Figure 1-2 schematizes the NP internalization 
process. 
 
  
 
  
 
    
 
 
 
 
 
 
Figure 1-2. Potential fates of PECs.  (1)  PECs diffuse and (2) attach to the cell surface 
via receptors or ionic interactions .  Upon binding to the membrane, PECs can remain 
bound at the cell surface, dissociate, or (3) accumulate in coated or non-coated 
invaginations.  Following (4) size-dependent endocytosis, PECs can be delivered to (b) 
lysosomes, after endosomal acidification, where their contents may be degraded by 
lysosomal peptidases and hydrolases.  Another possibility, following acidification of the 
endosomal lumen, PECs are designed to either (d) fuse with the endosomal membrane, 
(e) releasing their contents or escaping directly into the cytoplasm, or become 
destabilized and subsequently destabilize the endosomal membrane (c) resulting in 
leakage of the endosomal contents into the cytosol.  Receptors may be recycled back to 
the cell surface (a) or targeted for degradation in the lysosome (b). 
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Zeta potential, or mean surface charge, is a surrogate marker for the colloidal 
stability of PECs/NPs76,77.  The charge develops as a function of the excess polymer and 
is controlled by an ordered PEC assembly process.  Zeta potential is rarely addressed 
mechanistically in the literature, since it is easily altered by modification of 
environmental conditions, but it has important connotations for surface modification, size 
retention/aggregation, and targeting.  The classical colloidal theory has long held that one 
of the major interactive forces that controls particle stability in aqueous liquid suspension 
is electrostatic forces at the particle surface represented by zeta potential76-78.  Simply put, 
the presence of significantly positive or negative surface charge causes charge repulsion 
and prevents further aggregation by virtue of fewer collisions and ionic attraction.  This 
range of stable zeta potential in aqueous suspension has been empirically defined as 
greater than |±30| mV78.  Therefore, it is of great interest for biological systems to have a 
sufficient zeta potential for preservation of colloidal stability and nano-scale size for drug 
delivery.   
Variation of the surface charge could potentially control binding and direct NPs to 
cellular compartments both in vivo and in vitro.  Cellular surfaces are dominated by 
negatively charged sulfated proteoglycans, molecules that play pivotal roles in cellular 
proliferation, migration, and motility79.  Proteoglycans consist of a core protein anchored 
to the membrane and linked to one or more glycosaminoglycans side chains (heparan, 
dermatan, and chondroitin sulfates) to produce a structure that extends away from the cell 
surface. Glycosaminoglycans are highly anionic, and the interactions between 
proteoglycans and NP shells, if positively charged, tend to be largely ionic80.  Once inside 
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the cell, degradation of polymers may occur, but targeting specific intracellular 
organelles is possible depending on the surface charge and attached ligands30.   
 
Specific Modes of Endocytosis 
 Small molecules, such as amino acids, sugars, and ions, can traverse the plasma 
membrane through the action of membrane protein pumps or channels.  Larger 
macromolecular species must be carried into the cell in membrane-bound vesicles 
derived by the invagination and pinching-off of pieces of the plasma membrane.  
Virtually all cells use endocytosis to take up nutrients from the external environment and 
modulate the expression of cell surface molecules.  Endocytosis occurs through two 
broad mechanisms which are delineated by the size of the payload:  phagocytosis (cell 
eating) for large particles and pinocytosis (cell drinking) for uptake of fluid and solutes.  
The specific endocytic modes are phagocytosis, macropinocytosis, clathrin-mediated, 
caveolin-mediated, and clathrin/caveolin-independent endocytosis81. 
 Phagocytosis is conducted primarily by specialized cells, including macrophages, 
monocytes, and neutrophils, which function to clear pathogens such as bacteria, yeast and 
large debris usually larger than 1 µm.  It is an active and highly regulated process that 
involves cell-surface receptors and intracellular signaling cascades, followed by actin-
controlled engulfment of the particle to be internalized82.  There are multiple modes of 
phagocytosis that are determined by the particle to be ingested and the receptor 
recognition mechanism. 
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Similar to phagocytosis, macropinocytosis is an actin-driven process that 
accompanies growth factor and signaling cascades.  Membrane protrusions and ruffling 
result in the formation of macropinosomes.  Macropinosomes (~250 nm in diameter) 
form at the site of ruffling and fuse with the plasma membrane resulting in non-selective 
endocytosis of solute macromolecules83. 
 Caveolae, ~70 nm in diameter, are flask-shaped invaginations of the plasma 
membrane and are theorized to mediate the transcellular shuttling of serum proteins from 
or extracellular environment.  They are dynamic elements, largely postulated to be 
regulated by the molecule dynamin, and will fuse with macromolecules after initial 
binding resulting in a vesicular structure84.  The size and shape of caveolae are 
determined by caveolin, a dimeric protein that binds cholesterol, and self-associates to 
form a striated caveolin coat on the surface of membrane invaginations81.  Caveolae are 
activated by tyrosine phosphorylation and slowly internalized. 
 Clathrin-mediated endocytosis, also dynamin-directed, occurs constitutively in all 
mammalian cells and carries out the continuous uptake of essential nutrients, such as low 
density lipoprotein and transferrin; its size limit has been observed to be as high as 120 
nm.  The process is controlled by high affinity transmembrane receptors and their bound 
ligands into ‘coated pits’ on the plasma membrane that are formed by the accumulation of 
cytosolic coat proteins, the main unit being clathrin.  Clathrin monomers assemble into a 
lattice structure which helps to deform the plasma membrane into a coated pit.  The 
extracellular cargo fuses with the coated pit, an invagination, followed a ‘pinching off’ of 
the endocytic vesicle.  The process and its components can be recycled by an uncoating 
reaction after internalization of the payload85. 
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 The mechanisms that govern caveolae- and clathrin-independent endocytosis 
remain poorly understood.  It is likely that these pathways fulfill unique functions in the 
cell and varies mechanistically not only in how the vesicles are formed, but in terms of 
which cargo molecules they transport, to what intracellular destination their cargo is 
delivered, and how their entry is regulated.  These processes are possibly controlled by 
the formation of lipid rafts, 40-50 nm in diameter, that diffuse freely on the cell surface 
and can be presumably captured by, and internalized within any endocytic vesicle86. 
  
Current Polymeric Targeting Strategies and Approach For PECs 
  Great progress has been made in targeted drug delivery.  It is now possible to 
deliver agents (peptides, nucleotides, hydrophobic drugs) to selected extracellular and 
intracellular targets87.  The blood circulatory system is the container and distributor of 
oxygen and nutrients throughout the body, and thus the normal function of each cell 
vitally depends on the mechanisms that operate at the level of blood vessels.  All blood 
vessels are lined with endothelial cells, making them accessible to circulatory 
macromolecules88.  Strategies have included coupling of surface ligands to liposomal 
systems43,89,90 (active targeting) and the enhanced permeability and retention effect 
(EPR)91,92 (passive targeting), a unique pathophysiology of the tumor vasculature.  Some 
example systems include dendrimer47,93, polymeric94,95, and liposomal90 nanoparticles 
conjugated with folate for specificity to cancer cells that overexpress its receptor.  Other 
polymeric nanostructures96,97, PECs98, and liposomes43 target cellular adhesion 
molecules, integrins, expressed on vascular endothelial cells in solid tumors.  
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Liposomes22, PECs55, and polymer conjugates97 have utilized vascular endothelial growth 
factor  (VEGF) for targeting the VEGF receptor on the  vasculature. 
 The process of new and remodeled blood vessels, defined as angiogenesis, is a 
promising targeting strategy due the presence of unique, tissue-specific markers 
accessible to circulation.  These vascular networks are lined with endothelial cells (ECs), 
critical players in a number of pathological processes: cancer (dysregulated 
angiogenesis), wound healing, inflammation, oxidative stress, and thrombosis43,99.  For 
instance, angiogenesis is critical for tumor metastasis (cancer) to distant tissues and for 
expansion of small clusters of malignant cells into a clinically relevant tumor.  Cancer 
cells can co-opt host vessels and sprout new vessels from existing ones and recruit EC 
from bone marrow (vasculogenesis).  The resultant vasculature is structurally and 
functionally abnormal and the endothelial lining has an aberrant morphology.  Structural 
irregularities contribute to temporal and spatial heterogeneity in tumor blood flow.  The 
result is an abnormal tumor microenvironment with endothelial cells unique to the 
disease state100.  During angiogenesis, endothelial cells show increased expression of cell 
surface molecules that potentiate cell invasion and proliferation that can be used as 
targets for soluble and particulate ligands101.  Furthermore, the accessibility of these 
endothelial cells from the blood stream is an important advantage over other target 
candidates such as tumor cells.  
 Several extracellular molecules have moieties that interact with the vascular 
endothelium and have been exploited as an anti-angiogenic strategy.  One of these 
molecules, thrombospondin-1 (TSP-1), is a large, multimeric molecule that associates 
with cells and the extracellular matrix through multiple interactions that are revealed in 
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specific domains of the macromolecule102,103.  Intact TSP-1 suppresses angiogenesis by 
interaction with the CD36 receptor, leading to apoptosis of endothelial cells, and the 
collapse of the tumor vasculature104.  Although, the 450 kDa TSP-1 macromolecule can 
diminish tumor growth by affecting the vasculature, its use clinical use is limited due to 
its size, complications in large-scale preparations, and concerns about side effects.  Small, 
TSP-1 derived peptide mimetics that can be targeted to a specific receptor offer an 
attractive alternative.  TSP521, a peptide derived from the type 1 repeat of TSP-1, binds 
cell surface heparan sulfate proteoglycans (HSPG), which are overexpressed on tumor 
endothelial cells105,106.  In addition to HSPG affinity, TSP521 can act as an angiostatic 
agent by interfering with growth factor binding, translocation and, therefore, cell 
proliferation.  Additionally, TSP521 has shown selective accumulation in the vasculature 
in experimental brain tumor models107, leading to its application as a ligand for a PEC 
targeting strategy.  The incorporation of TSP521 into NPs/PECs can be performed by two 
methods: 
• passive entrapment after addition of polyethylene glycol (PEG) to achieve 
both a geometric and flexible presentation87, decreased susceptibility to 
circulatory proteolytic enzymes, improved phamacokinetic properties108 
• direct coupling by 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide 
(EDAC)/N-hydroxysuccinimide (NHS) two-step, zero-length cross-
linking109 of the aspartic acid carboxylic acid to surface PEC amines. 
Both approaches may allow for heparin binding site of TSP521 to interact efficiently with 
ubiquitous HSPGs present in vascular endothelial models.  Figure 1-3 is a representation 
of the strategy. 
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Figure 1-3.  Targeted PEC conceptualization.   PECs can be directed to overexpressed 
HSPG groups omnipresent on the tumor endothelium by functionalization of the complex 
with TSP521.  Ideally, targeted PECs are administered intravenously and home to the 
tumor vasculature.  PECs, due to their nanoscale architecture, are internalized and the 
payload (DNA, drug, peptide, protein) delivered. 
 
 
Binding Theory 
 The interactions of biological macromolecules, in terms of ligands with cell 
surface receptors, can often be described by a model of reversible binding and 
characterized by an equilibrium constant.  At equilibrium, the chemical reaction between 
free receptor (equation 1-1), where [Rfree], [Lfree] are the free receptor and ligand, 
respectively, and [R:L] is the bound, [Bound], receptor:ligand complex:  
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At equilibrium, the mass action expression becomes equation 1-2, where Kd is the 
equilibrium dissociation constant (binding constant): 
 
 
Equation 1-2 can be rewritten, after substitution of [RFree], as equation 1-3, where Rtotal 
represents the sum of [RFree] and [Bound]: 
 
 
Rearrangement yields a Michaelian expression as shown in equation 1-4, where the 
brackets are dropped only for convenience: 
 
 
Equation 1-4 is the equation for a rectangular hyperbola with a horizontal asymptote 
corresponding to 100% saturation of Rtotal, such that [Bound]=[Rtotal].  Experimentally, 
the relevant parameters are collected with concentration-dependent, saturation binding 
experiments.  The quantitation of physical constants defining classical ligand-receptor 
interactions must follow assumptions from the law of mass action (Clark’s Theory)110:  
(1) the interaction of ligand and receptor is reversible, association is bimolecular while 
the dissociation is unimolecular; (2) all receptor molecules homogeneous and 
independent; (3) the biological response is proportional to the number of occupied 
receptor sites; (4) interaction and response are measured after the reaction has reached 
equilibrium; and (5) the ligand only exists as free, unbound, or attached to the receptor 
and it does not undergo degradation or participate in other reactions. 
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 Saturation data that follow these assumptions and equation 1-4 is classically 
linearized by Scatchard’s plots111.  Scatchard representations plot the ratio bound to free 
ligand on x-axis versus bound ligand on the abscissa.  Linearity of this transformation 
yields a slope of -1/Kd and y-intercept of Rtotal/Kd.  This allows graphical assessment of 
the parameters in equation 1-4 and relative ligand affinities.  Countless studies have 
applied this analysis for summarizing receptor-ligand interactions, the prominent work 
being for epidermal growth factor112,113.  Currently, there are no Scatchard analyses of 
nanoparticulate drug delivery vehicles, with or without active targeting moieties. 
 
Overview of Dissertation 
 The work contained herein is focused on the development of nanoparticulate 
polyelectrolyte complex formulations for targeted delivery to endothelial cells. Recent 
research to avoid use of harmful materials has involved application of water-soluble, 
biodegradable, polymeric, polyelectrolyte nanoparticles and the results appear to be 
promising due to the biocompatibility and complete degradability of polymers114,115.  
Rationalizing the assembly mechanisms and tailoring the size, charge, and loading 
capability to desirable levels are essential to advance biodegradable, polymeric, 
polyelectrolyte nanoparticles as efficient drug delivery vehicles. The current technology 
applied in this study has utilized a water-based approach for producing the PECs under 
the prevailing assembly and complexation theory.  Typically, one interacting pair of 
oppositely charged polymers does not result in a thermodynamically stable system.  
Therefore, the PECs are produced using a multipolymeric mixture with a minimum of 
two pairs.  This inherently increases the number of possible reacting pairs.  The 
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electrostatic interaction of the polymer pairs also allows controlled incorporation of 
molecules such as proteins or targeting peptides.  Also, the multipolymeric nature allows 
more rational selection of polymers to meet specific criteria essential for creating a 
uniform process for preparing biodegradable, water-based PECs for targeted delivery.  
 According to the literature, there are several PEC characteristics favorable for 
cellular uptake and colloidal stability, including hydrodynamic diameter less than or 
equal to 200 nm30,54, surface charge of greater than 30 mV or less than –30 mV, spherical 
morphology, and a low polydispersity index indicative of a homogeneous size 
distribution76,78,116.  The PEC properties of size, charge, polydispersity index (PDI), and 
morphology, are highly dependent on environmental complexation properties and 
molecular parameters of the polyions used.  In particular, the complexation process 
between polyelectrolytes having significantly different molecular weights leads to the 
formation of water-insoluble aggregates117-119.  This effect is undesirable because 
structures with diameter greater than 1000 nm can cause blockage of blood capillaries 
and inflammatory tissue responses30,120,121.   
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Based on these considerations, the following foci have been investigated and will 
be addressed in subsequent chapters: 
1. Determine the PEC system (similar or dissimilar molecular weights) that 
will provide the most suitable and controllable product for further in vitro 
testing. Systems will be examined based on the following qualifications:  
spherical morphology via TEM, decreased hydrodynamic radius with a 
goal of 200 nm (good for cellular uptake), low PDI of approximately 
0.200, and zeta potential greater than +30 mV or less than -30 mV, the 
benchmark for colloidal stability. 
2. Establish PEC stability as a function of pH for dissimilar and similar 
molecular weight chemistry by measuring the size and zeta potential 
during and after processing/centrifugation steps.  Systems must be stable 
at physiological pH (pH=7.4). 
3. Evaluate PEC binding and uptake mechanisms for naked and targeted 
particles using fluorescent labeling in vitro, human microvascular 
endothelial cells (HMVEC-1) while separately measuring protein release 
from the polyelectrolyte complex.  Compare two methods of TSP521 
incorporation:  (1) passive PEG-conjugated TSP521 and (2) direct 
conjugation of TSP521 by EDAC/NHS isopeptide linkage to coronal PEC 
amines.  Demonstrate protein loading and measure release kinetics for 
proteins carrying acidic and basic isoelectric points.  Investigate the 
biocompatibility in vitro and in vivo.  Systems must meet the engineering 
criteria defined in aim 1 and be stable at biological pH. 
 22 
4. Assess the scale up ability by applying Kenics static mixer technology 
under simple two-stream mixing at laminar flow conditions. 
 23 
References 
 
1. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. "Nanomedicine: current status and 
future prospects" Faseb Journal 2005, 19, 311-330. 
2. Bianco, A.; Kostarelos, K.; Prato, M. "Applications of carbon nanotubes in drug 
delivery" Current Opinion In Chemical Biology 2005, 9, 674-679. 
3. Khademhosseini, A.; Langer, R.; Borenstein, J.; Vacanti, J. P. "Microscale 
technologies for tissue engineering and biology" Proceedings Of The National 
Academy Of Sciences Of The United States Of America 2006, 103, 2480-2487. 
4. Lavik, E.; Langer, R. "Tissue engineering: current state and perspectives" Applied 
Microbiology And Biotechnology 2004, 65, 1-8. 
5. Catimel, B.; Domagala, T.; Nerrie, M.; Weinstock, J.; White, S.; Abud, H.; Heath, 
J.; Nice, E. "Recent applications of instrumental biosensors for protein and 
peptide structure-function studies" Protein And Peptide Letters 1999, 6, 319-340. 
6. Tang, L.; Persky, A. M.; Hochhaus, G.; Meibohm, B. "Pharmacokinetic aspects of 
biotechnology products" Journal Of Pharmaceutical Sciences 2004, 93, 2184-
2204. 
7. Barratt, G. "Colloidal drug carriers: achievements and perspectives" Cellular and 
Molecular Life Sciences 2003, 60, 21-37. 
8. Baldwin, S. P.; Saltzman, W. M. "Materials for protein delivery in tissue 
engineering" Advanced Drug Delivery Reviews 1998, 33, 71-86. 
9. Herman, E. H.; Zhang, J.; Hasinoff, B. B.; Chadwick, D. P.; Clark, J. R.; Ferrans, 
V. J. "Comparison of the protective effects against chronic doxorubicin 
cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and 
other bisdiketopiperazines" Cancer Chemotherapy And Pharmacology 1997, 40, 
400-408. 
10. Yokoyama, M.; Fukushima, S.; Uehara, R.; Okamoto, K.; Kataoka, K.; Sakurai, 
Y.; Okano, T. "Characterization of physical entrapment and chemical conjugation 
of adriamycin in polymeric micelles and their design for in vivo delivery to a 
solid tumor" Journal Of Controlled Release 1998, 50, 79-92. 
11. Cleland, J. L.; Daugherty, A.; Mrsny, R. "Emerging protein delivery methods" 
Current Opinion In Biotechnology 2001, 12, 212-219. 
12. Taylor, S.; Qu, L. W.; Kitaygorodskiy, A.; Teske, J.; Latour, R. A.; Sun, Y. P. 
"Synthesis and characterization of peptide-functionalized polymeric 
nanoparticles" Biomacromolecules 2004, 5, 245-248. 
 24 
13. Vinogradov, S. V.; Bronich, T. K.; Kabanov, A. V. "Nanosized cationic hydrogels 
for drug delivery: preparation, properties and interactions with cells" Advanced 
Drug Delivery Reviews 2002, 54, 135-147. 
14. Kramer, M.; Stumbe, J. F.; Grimm, G.; Kaufmann, B.; Kruger, U.; Weber, M.; 
Haag, R. "Dendritic polyamines: simple access to new materials with defined 
treelike structures for application in nonviral gene delivery" Chembiochem 2004, 
5, 1081-1087. 
15. Allen, T. M.; Cullis, P. R. "Drug delivery systems: entering the mainstream" 
Science 2004, 303, 1818-1822. 
16. Haag, R.; Vogtle, F. "Highly branched macromolecules at the interface of 
chemistry, biology, physics, and medicine" Angewandte Chemie-International 
Edition 2004, 43, 272-273. 
17. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. "Long-circulating and target-
specific nanoparticles: Theory to practice" Pharmacological Reviews 2001, 53, 
283-318. 
18. Verderone, G.; van Craynest, N.; Boussif, O.; Santaella, C.; Bischoff, R.; Kolbe, 
H. V. J.; Vierling, P. "Lipopolycationic telomers for gene transfer: synthesis and 
evaluation of their in vitro transfection efficiency" Journal Of Medicinal 
Chemistry 2000, 43, 1367-1379. 
19. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. "Rapid endo-
lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for 
drug and gene delivery" Faseb Journal 2002, 16. 
20. Drummond, D. C.; Zignani, M.; Leroux, J. C. "Current status of pH-sensitive 
liposomes in drug delivery" Progress In Lipid Research 2000, 39, 409-460. 
21. Winet, H.; Hollinger, J. O.; Stevanovic, M. "Incorporation of polylactide-
polyglycolide in a cortical defect - neoangiogenesis and blood-supply in a bone 
chamber" Journal of Orthopaedic Research 1995, 13, 679-689. 
22. Monsky, W. L.; Fukumura, D.; Gohongi, T.; Ancukiewcz, M.; Weich, H. A.; 
Torchilin, V. P.; Yuan, F.; Jain, R. K. "Augmentation of transvascular transport of 
macromolecules and nanoparticles in tumors using vascular endothelial growth 
factor" Cancer Research 1999, 59, 4129-4135. 
23. Guzman, M.; Molpeceres, J.; Garcia, F.; Aberturas, M. R. "Preparation, 
characterization and in vitro drug release of poly-epsilon-caprolactone and 
hydroxypropyl methylcellulose phthalate ketoprofen loaded microspheres" 
Journal of Microencapsulation 1996, 13, 25-39. 
 
 25 
24. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S. E.; Engelhardt, B.; 
Alyautdin, R.; von Briesen, H.; Begley, D. J. "Direct evidence that polysorbate-
80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via 
specific mechanisms requiring prior binding of drug to the nanoparticles" 
Pharmaceutical Research 2003, 20, 409-416. 
25. Olivier, J. C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchelli, R.; Couet, W. 
"Indirect evidence that drug brain targeting using polysorbate 80-coated 
polybutylcyanoacrylate nanoparticles is related to toxicity" Pharmaceutical 
Research 1999, 16, 1836-1842. 
26. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. "Nanogels for 
oligonucleotide delivery to the brain" Bioconjugate Chemistry 2004, 15, 50-60. 
27. Labhasetwar, V.; Bonadio, J.; Goldstein, S. A.; Levy, J. R. "Gene transfection 
using biodegradable nanospheres: results in tissue culture and a rat osteotomy 
model" Colloids and Surfaces B-Biointerfaces 1999, 16, 281-290. 
28. Coester, C.; Nayyar, P.; Samuel, J. "In vitro uptake of gelatin nanoparticles by 
murine dendritic cells and their intracellular localisation" European Journal Of 
Pharmaceutics And Biopharmaceutics 2006, 62, 306-314. 
29. Guzman, L. A.; Labhasetwar, V.; Song, C. X.; Jang, Y. S.; Lincoff, A. M.; Levy, 
R.; Topol, E. J. "Local intraluminal infusion of biodegradable polymeric 
nanoparticles - a novel approach for prolonged drug delivery after balloon 
angioplasty" Circulation 1996, 94, 1441-1448. 
30. Panyam, P.; Labhasetwar, V. "Biodegradable nanoparticles for drug and gene 
delivery to cells and tissue" Advanced Drug Delivery Reviews 2003, 55, 329-347. 
31. Watnasirichaikul, S.; Davies, N. M.; Rades, T.; Tucker, I. G. "Preparation of 
biodegradable insulin nanocapsules from biocompatible microemulsions" 
Pharmaceutical Research 2000, 17, 684-689. 
32. Roy, I.; Ohulchanskyy, T. Y.; Pudavar, H. E.; Bergey, E. J.; Oseroff, A. R.; 
Morgan, J.; Dougherty, T. J.; Prasad, P. N. "Ceramic-based nanoparticles 
entrapping water-insoluble photosensitizing anticancer drugs: A novel drug-
carrier system for photodynamic therapy" Journal Of The American Chemical 
Society 2003, 125, 7860-7865. 
33. Cherian, A. K.; Rana, A. C.; Jain, S. K. "Self-assembled carbohydrate-stabilized 
ceramic nanoparticles for the parenteral delivery of insulin" Drug Development 
And Industrial Pharmacy 2000, 26, 459-463. 
34. Bergen, J. M.; Von Recum, H. A.; Goodman, T. T.; Massey, A. P.; Pun, S. H. 
"Gold nanoparticles as a versatile platform for optimizing physicochemical 
parameters for targeted drug delivery" Macromolecular Bioscience 2006, 6, 506-
516. 
 26 
35. Wang, S. Z.; Gao, R. M.; Zhou, F. M.; Selke, M. "Nanomaterials and singlet 
oxygen photosensitizers: potential applications in photodynamic therapy" Journal 
Of Materials Chemistry 2004, 14, 487-493. 
36. Gao, X. H.; Cui, Y. Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. M. "In vivo 
cancer targeting and imaging with semiconductor quantum dots" Nature 
Biotechnology 2004, 22, 969-976. 
37. Kataoka, K.; Harada, A.; Nagasaki, Y. "Block copolymer micelles for drug 
delivery: design, characterization and biological significance" Advanced Drug 
Delivery Reviews 2001, 47, 113-131. 
38. Yamamoto, Y.; Nagasaki, Y.; Kato, Y.; Sugiyama, Y.; Kataoka, K. "Long-
circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles 
with modulated surface charge" Journal Of Controlled Release 2001, 77, 27-38. 
39. Yokoyama, M.; Miyauchi, M.; Yamada, N.; Okano, T.; Sakurai, Y.; Kataoka, K.; 
Inoue, S. "Characterization and anticancer activity of the micelle-forming 
polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-
poly(aspartic acid) block copolymer" Cancer Research 1990, 50, 1693-1700. 
40. Yu, F. Q.; Liu, Y. P.; Zhu, R. X. "A novel method for the preparation of core-
shell nanoparticles and hollow polymer nanospheres" Journal of Applied Polymer 
Science 2004, 91, 2594-2600. 
41. Kamps, J.; Swart, P. J.; Morselt, H. W. M.; Pauwels, R.; DeBethune, M. P.; 
DeClercq, E.; Meijer, D. K. F.; Scherphof, G. L. "Preparation and characterization 
of conjugates of (modified) human serum albumin and liposomes: drug carriers 
with an intrinsic anti-HIV activity" Biochimica Et Biophysica Acta-
Biomembranes 1996, 1278, 183-190. 
42. Deverdiere, A. C.; Dubernet, C.; Nemati, F.; Poupon, M. F.; Puisieux, F.; 
Couvreur, P. "Uptake of doxorubicin from loaded nanoparticles in multidrug-
resistant leukemic murine cells" Cancer Chemotherapy And Pharmacology 1994, 
33, 504-508. 
43. Hallahan, D.; Geng, L.; Qu, S. M.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, 
X.; Clanton, J. "Integrin-mediated targeting of drug delivery to irradiated tumor 
blood vessels" Cancer Cell 2003, 3, 63-74. 
44. Talsma, S. S.; Babensee, J. E.; Murthy, N.; Williams, I. R. "Development and in 
vitro validation of a targeted delivery vehicle for DNA vaccines" Journal Of 
Controlled Release 2006, 112, 271-279. 
45. Chen, C. Z. S.; Cooper, S. L. "Interactions between dendrimer biocides and 
bacterial membranes" Biomaterials 2002, 23, 3359-3368. 
 27 
46. Kukowska-Latallo, J. F.; Candido, K. A.; Cao, Z. Y.; Nigavekar, S. S.; Majoros, I. 
J.; Thomas, T. P.; Balogh, L. P.; Khan, M. K.; Baker, J. R. "Nanoparticle 
targeting of anticancer drug improves therapeutic response in animal model of 
human epithelial cancer" Cancer Research 2005, 65, 5317-5324. 
47. Thomas, T. P.; Majoros, I. J.; Kotlyar, A.; Kukowska-Latallo, J. F.; Bielinska, A.; 
Myc, A.; Baker, J. R. "Targeting and inhibition of cell growth by an engineered 
dendritic nanodevice" Journal Of Medicinal Chemistry 2005, 48, 3729-3735. 
48. Witvrouw, M.; Fikkert, V.; Pluymers, W.; Matthews, B.; Mardel, K.; Schols, D.; 
Raff, J.; Debyser, Z.; De Clercq, E.; Holan, G.; Pannecouque, C. "Polyanionic 
(i.e., polysulfonate) dendrimers can inhibit the replication of human 
immunodeficiency virus by interfering with both virus adsorption and later steps 
(reverse transcriptase/integrase) in the virus replicative cycle" Molecular 
Pharmacology 2000, 58, 1100-1108. 
49. Vauthier-Holtzscherer, C.; Benabbou, S.; Spenlehauer, G.; Veillard, M.; 
Couvreur, P. "Methodology for the preparation of of ultra-dispersed  polymer 
systems" 1991, 2, 109-116. 
50. Cruz, T.; Gaspar, R.; Donato, A.; Lopes, C. "Interaction between 
polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT 
metabolism, NBT reduction, and NO production" Pharmaceutical Research 1997, 
14, 73-79. 
51. Hanafusa, S.; Matsusue, Y.; Yasunaga, T.; Yamamuro, T.; Oka, M.; Shikinami, 
Y.; Ikada, Y. "Biodegradable plate fixation of rabbit femoral-shaft osteotomies - a 
comparative-study" Clinical Orthopaedics and Related Research 1995, 315, 262-
271. 
52. Matsusue, Y.; Hanafusa, S.; Yamamuro, T.; Shikinami, Y.; Ikada, Y. "Tissue 
reaction of bioabsorbable ultra-high strength poly(L-lactide) rod - a long-term 
study in rabbits" Clinical Orthopaedics and Related Research 1995, 317, 246-
253. 
53. Schatz, C.; Lucas, J. M.; Viton, C.; Domard, A.; Pichot, C.; Delair, T. "Formation 
and properties of positively charged colloids based on polyelectrolyte complexes 
of biopolymers" Langmuir 2004, 20, 7766-7778. 
54. Carlesso, G.; Kozlov, E.; Prokop, A.; Unutmaz, D.; Davidson, J. M. 
"Nanoparticulate system for efficient gene transfer into refractory cell targets" 
Biomacromolecules 2005, 6, 1185-1192. 
55. Fisher, K. D.; Ulbrich, K.; Subr, V.; Ward, C. M.; Mautner, V.; Blakey, D.; 
Seymour, L. W. "A versatile system for receptor-mediated gene delivery permits 
increased entry of DNA into target cells, enhanced delivery to the nucleus and 
elevated rates of transgene expression" Gene Therapy 2000, 7, 1337-1343. 
 28 
56. Wolfert, M. A.; Dash, P. R.; Nazarova, O.; Oupicky, D.; Seymour, L. W.; Smart, 
S.; Strohalm, J.; Ulbrich, K. "Polyelectrolyte vectors for gene delivery: Influence 
of cationic polymer on biophysical properties of complexes formed with DNA" 
Bioconjugate Chemistry 1999, 10, 993-1004. 
57. Thu, B.; Bruheim, P.; Espevik, T.; Smidsrod, O.; SoonShiong, P.; SkjakBraek, G. 
"Alginate polycation microcapsules.1. Interaction between alginate and 
polycation" Biomaterials 1996, 17, 1031-1040. 
58. Wang, T.; Lacik, I.; Brissova, M.; Anilkumar, A. V.; Prokop, A.; Hunkeler, D.; 
Green, R.; Shahrokhi, K.; Powers, A. C. "An encapsulation system for the 
immunoisolation of pancreatic islets" Nature Biotechnology 1997, 15, 358-362. 
59. Dragan, S.; Cristea, M.; Luca, C.; Simionescu, B. C. "Polyelectrolyte 
complexes.1. synthesis and characterization of some insoluble polyanion-
polycation complexes" Journal of Polymer Science Part a-Polymer Chemistry 
1996, 34, 3485-3494. 
60. Dautzenberg, H. "Light scattering studies on polyelectrolyte complexes" 
Macromolecular Symposia 2000, 162, 1-21. 
61. Webster, L.; Huglin, M. B.; Robb, I. D. "Complex formation between 
polyelectrolytes in dilute aqueous solution" Polymer 1997, 38, 1373-1380. 
62. Kabanov, A. V.; Kabanov, V. A. "DNA complexes with polycations for the 
delivery of genetic material into cells" Bioconjugate Chemistry 1995, 6, 7-20. 
63. Dautzenberg, H.; Kriz, J. "Response of polyelectrolyte complexes to subsequent 
addition of salts with different cations" Langmuir 2003, 19, 5204-5211. 
64. Foged, C.; Brodin, B.; Frokjaer, S.; Sundblad, A. "Particle size and surface charge 
affect particle uptake by human dendritic cells in an in vitro model" International 
Journal Of Pharmaceutics 2005, 298, 315-322. 
65. Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D. "Size-dependent 
internalization of particles via the pathways of clathrin-and caveolae-mediated 
endocytosis" Biochemical Journal 2004, 377, 159-169. 
66. Wood, K. C.; Little, S. R.; Langer, R.; Hammond, P. T. "A family of 
hierarchically self-assembling linear-dendritic hybrid polymers for highly 
efficient targeted gene delivery" Angewandte Chemie-International Edition 2005, 
44, 6704-6708. 
67. Desai, M. P.; Labhasetwar, V.; Walter, E.; Levy, R. J.; Amidon, G. L. "The 
mechanism of uptake of biodegradable microparticles in Caco-2 cells is size 
dependent" Pharmaceutical Research 1997, 14, 1568-1573. 
 29 
68. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V. "Residual polyvinyl 
alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their 
physical properties and cellular uptake" Journal of Controlled Release 2002, 82, 
105-114. 
69. Salvage, J. P.; Rose, S. F.; Phillips, G. J.; Hanlon, G. W.; Lloyd, A. W.; Ma, I. Y.; 
Armes, S. P.; Billingham, N. C.; Lewis, A. L. "Novel biocompatible 
phosphorylcholine-based self-assembled nanoparticles for drug delivery" Journal 
Of Controlled Release 2005, 104, 259-270. 
70. Wang, J. C.; Goh, B. C.; Lu, W. L.; Zhang, Q.; Chang, A.; Liu, X. Y.; Tan, T. M. 
C.; Lee, H. S. "In vitro cytotoxicity of Stealth liposomes co-encapsulating 
doxorubicin and verapamil on doxorubicin-resistant tumor cells" Biological & 
Pharmaceutical Bulletin 2005, 28, 822-828. 
71. Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; 
Langer, R. "Biodegradable long-circulating polymeric nanospheres" Science 
1994, 263, 1600-1603. 
72. Bulmus, V.; Woodward, M.; Lin, L.; Murthy, N.; Stayton, P.; Hoffman, A. "A 
new pH-responsive and glutathione-reactive, endosomal membrane-disruptive 
polymeric carrier for intracellular delivery of biomolecular drugs" Journal Of 
Controlled Release 2003, 93, 105-120. 
73. Davda, J.; Labhasetwar, V. "Characterization of nanoparticle uptake by 
endothelial cells" International Journal Of Pharmaceutics 2002, 233, 51-59. 
74. Panyam, J.; Labhasetwar, V. "Dynamics of endocytosis and exocytosis of 
poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells" 
Pharmaceutical Research 2003, 20, 212-220. 
75. Huth, U. S.; Schubert, R.; Peschka-Suss, R. "Investigating the uptake and 
intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-
imaging" Journal Of Controlled Release 2006, 110, 490-504. 
76. Chern, C. S.; Lee, C. K.; Chang, C. J. "Electrostatic interactions between 
amphoteric latex particles and proteins" Colloid and Polymer Science 2004, 283, 
257-264. 
77. Trimaille, T.; Pichot, C.; Elaissari, A.; Fessi, H.; Briancon, S.; Delair, T. 
"Poly(D,L-lactic acid) nanoparticle preparation and colloidal characterization" 
Colloid and Polymer Science 2003, 281, 1184-1190. 
78. Sugrue, S. "Predicting and controlling colloid suspension stability using 
electrophoretic mobility and particle size measurements" American Laboratory 
1992, 24, 64-71. 
 30 
79. Bernfield, M.; Gotte, M.; Park, P. W.; Reizes, O.; Fitzgerald, M. L.; Lincecum, J.; 
Zako, M. "Functions of cell surface heparan sulfate proteoglycans" Annual 
Review Of Biochemistry 1999, 68, 729-777. 
80. Mislick, K. A.; Baldeschwieler, J. D. "Evidence for the role of proteoglycans in 
cation-mediated gene transfer" Proceedings Of The National Academy Of 
Sciences Of The United States Of America 1996, 93, 12349-12354. 
81. Conner, S. D.; Schmid, S. L. "Regulated portals of entry into the cell" Nature 
2003, 422, 37-44. 
82. Aderem, A.; Underhill, D. M. "Mechanisms of phagocytosis in macrophages" 
Annual Review Of Immunology 1999, 17, 593-623. 
83. Swanson, J. A.; Watts, C. "Macropinocytosis" Trends In Cell Biology 1995, 5, 
424-428. 
84. Schnitzer, J. E. "Caveolae: from basic trafficking mechanisms to targeting 
transcytosis for tissue-specific drug and gene delivery in vivo" Advanced Drug 
Delivery Reviews 2001, 49, 265-280. 
85. Mukherjee, S.; Ghosh, R. N.; Maxfield, F. R. "Endocytosis" Physiological 
Reviews 1997, 77, 759-803. 
86. Edidin, M. "Shrinking patches and slippery rafts: scales of domains in the plasma 
membrane" Trends In Cell Biology 2001, 11, 492-496. 
87. Lu, J.; Jeon, E.; Lee, B. S.; Onyuksel, H.; Wang, Z. J. J. "Targeted drug delivery 
crossing cytoplasmic membranes of intended cells via ligand-grafted sterically 
stabilized liposomes" Journal Of Controlled Release 2006, 110, 505-513. 
88. Simionescu, M.; Gafencu, A.; Antohe, F. "Transcytosis of plasma 
macromolecules in endothelial cells: a cell biological survey" Microscopy 
Research And Technique 2002, 57, 269-288. 
89. Farokhzad, O. C.; Jon, S. Y.; Khadelmhosseini, A.; Tran, T. N. T.; LaVan, D. A.; 
Langer, R. "Nanopartide-aptamer bioconjugates: a new approach for targeting 
prostate cancer cells" Cancer Research 2004, 64, 7668-7672. 
90. Gabizon, A.; Horowitz, A. T.; Goren, D.; Tzemach, D.; Mandelbaum-Shavit, F.; 
Qazen, M. M.; Zalipsky, S. "Targeting folate receptor with folate linked to 
extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies" 
Bioconjugate Chemistry 1999, 10, 289-298. 
91. Schraa, A. J.; Kok, R. J.; Moorlag, H. E.; Bos, E. J.; Proost, J. H.; Meijer, D. K. 
F.; de Leu, L.; Molema, G. "Targeting of RGD-modified proteins to tumor 
vasculature: a pharmacokinetic and cellular distribution study" International 
Journal Of Cancer 2002, 102, 469-475. 
 31 
92. Verbaan, F. J.; Oussoren, C.; Snel, C. J.; Crommelin, D. J. A.; Hennink, W. E.; 
Storm, G. "Steric stabilization of poly(2-(dimethylamino)ethyt methacrytate)-
based polyplexes mediates prolonged circulation and tumor targeting in mice" 
Journal Of Gene Medicine 2004, 6, 64-75. 
93. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; 
Thomas, T.; Mule, J.; Baker, J. R. "Design and function of a dendrimer-based 
therapeutic nanodevice targeted to tumor cells through the folate receptor" 
Pharmaceutical Research 2002, 19, 1310-1316. 
94. Kim, S. H.; Jeong, J. H.; Chun, K. W.; Park, T. G. "Target-specific cellular uptake 
of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate 
conjugate" Langmuir 2005, 21, 8852-8857. 
95. Kim, S. H.; Jeong, J. H.; Joe, C. O.; Park, T. G. "Folate receptor mediated 
intracellular protein delivery using PLL-PEG-FOL conjugate" Journal Of 
Controlled Release 2005, 103, 625-634. 
96. Suh, W.; Han, S. O.; Yu, L.; Kim, S. W. "An angiogenic, endothelial-cell-targeted 
polymeric gene carrier" Molecular Therapy 2002, 6, 664-672. 
97. Kim, W. J.; Yockman, J. W.; Lee, M.; Jeong, J. H.; Kim, Y. H.; Kim, S. W. 
"Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-
angiogenesis" Journal Of Controlled Release 2005, 106, 224-234. 
98. Park, J. H.; Kwon, S. G.; Nam, J. O.; Park, R. W.; Chung, H.; Seo, S. B.; Kim, I. 
S.; Kwon, I. C.; Jeong, S. Y. "Self-assembled nanoparticles based on glycol 
chitosan bearing 5 beta-cholanic acid for RGD peptide delivery" Journal of 
Controlled Release 2004, 95, 579-588. 
99. Hood, J. D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R. A.; Xiang, R.; 
Cheresh, D. A. "Tumor regression by targeted gene delivery to the 
neovasculature" Science 2002, 296, 2404-2407. 
100. Jain, R. K. "Normalization of tumor vasculature:  an emerging concept in 
antiangiogenic therapy" Science 2005, 307, 58-62. 
101. Schiffelers, R. M.; Mixson, A. J.; Ansari, A. M.; Fens, M.; Tang, Q. Q.; Zhou, Q.; 
Xu, J.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Storm, G.; Woodle, M. C. 
"Transporting silence: design of carriers for siRNA to angiogenic endothelium" 
Journal Of Controlled Release 2005, 109, 5-14. 
102. Shafiee, A.; Penn, J. S.; Krutzsch, H. C.; Inman, J. K.; Roberts, D. D.; Blake, D. 
A. "Inhibition of retinal angiogenesis by peptides derived from thrombospondin-
1" Investigative Ophthalmology & Visual Science 2000, 41, 2378-2388. 
 
 32 
103. Tolsma, S. S.; Volpert, O. V.; Good, D. J.; Frazier, W. A.; Polverini, P. J.; Bouck, 
N. "Peptides derived from two separate domains of the matrix protein 
thrombospondin-1 have anti-angiogenic activity" Journal of Cell Biology 1993, 
122, 497-511. 
104. Reiher, F. K.; Volpert, O. V.; Jimenez, B.; Crawford, S. E.; Dinney, C. P.; 
Henkin, J.; Haviv, F.; Bouck, N. P.; Campbell, S. C. "Inhibition of tumor growth 
by systemic treatment with thrombospondin-1 peptide mimetics" International 
Journal Of Cancer 2002, 98, 682-689. 
105. Engelberg, H. "Actions of heparin that may affect the malignant process" Cancer 
1999, 85, 257-272. 
106. Yu, H. N.; Tyrrell, D.; Cashel, J.; Guo, N. H.; Vogel, T.; Sipes, J. M.; Lam, L.; 
Fillit, H. M.; Hartman, J.; Mendelovitz, S.; Panel, A.; Roberts, D. D. 
"Specificities of heparin-binding sites from the amino-terminus and type 1 repeats 
of thrombospondin-1" Archives Of Biochemistry And Biophysics 2000, 374, 13-
23. 
107. Bogdanov, A. A.; Marecos, E.; Cheng, H. C.; Chandrasekaran, L.; Krutzsch, H. 
C.; Roberts, D. D.; Weissleder, R. "Treatment of experimental brain tumors with 
trombospondin-1 derived peptides: an in vivo imaging study" Neoplasia 1999, 1, 
438-445. 
108. Harris, J. M.; Chess, R. B. "Effect of pegylation on pharmaceuticals" Nature 
Reviews Drug Discovery 2003, 2, 214-221. 
109. Grabarek, Z.; Gergely, J. "Zero-length crosslinking procedure with the use of 
active esters" Analytical Biochemistry 1990, 185, 131-135. 
110. McLean, F. C. "Applicaiton of the law of chemical equilibrium (law of mass 
action) to biological problems" Physiological Reviews 1938, 18, 495-523. 
111. Scatchard, G. "The attractions of proteins for small molecules and ions" Annals of 
the New York Academy of Sciences 1949, 51, 660-672. 
112. Carpenter, G.; Lembach, K. J.; Morrison, M. M.; Cohen, S. "Characterization of 
binding of I-125-labeled epidermal growth-factor to human fibroblasts" Journal 
Of Biological Chemistry 1975, 250, 4297-4304. 
113. Wiley, H. S.; Cunningham, D. D. "A steady-state model For analyzing the 
cellular-binding, internalization and degradation of polypeptide ligands" Cell 
1981, 25, 433-440. 
114. Alonso, M. J., Nanoparticulate drug carrier technology. In Microparticulate 
systems for the delivery of proteins and vaccines, Cohen, S.; Bernstein, H., Eds. 
Marcel Dekker: New York, 1998; pp 203-242. 
 33 
115. Prokop, A.; Kozlov, E.; Carlesso, G.; Davidson, J. M. "Hydrogel-based colloidal 
polymeric system for protein and drug delivery: physical and chemical 
characterization, permeability control and applications" Advances in Polymer 
Science 2002, 160, 119-173. 
116. Fatouros, D. G.; Piperoudi, S.; Gortzi, O.; Ioannou, P. V.; Frederik, P.; 
Antimisiaris, S. G. "Physical stability of sonicated arsonoliposomes: Effect of 
calcium ions" Journal of Pharmaceutical Sciences 2005, 94, 46-55. 
117. Schatz, C.; Domard, A.; Viton, C.; Pichot, C.; Delair, T. "Versatile and efficient 
formation of colloids of biopolymer-based polyelectrolyte complexes" 
Biomacromolecules 2004, 5, 1882-1892. 
118. Reihs, T.; Muller, M.; Lunkwitz, K. "Preparation and adsorption of refined 
polyelectrolyte complex nanoparticles" Journal of Colloid and Interface Science 
2004, 271, 69-79. 
119. Dautzenberg, H. "Polyelectrolyte complex formation in highly aggregating 
systems. 1. effect of salt: Polyelectrolyte complex formation in the presence of 
NaCl" Macromolecules 1997, 30, 7810-7815. 
120. Debuigne, F.; Cuisenaire, J.; Jeunieau, L.; Masereel, B.; Nagy, J. B. "Synthesis of 
nimesulide nanoparticles in the microemulsion epikuron/isopropyl 
myristate/water/n-butanol (or isopropanol)" Journal of Colloid and Interface 
Science 2001, 243, 90-101. 
121. Dev, V.; Eigler, N.; Fishbein, M. C.; Tian, Y. Q.; Hickey, A.; Rechavia, E.; 
Forrester, J. S.; Litvack, F. "Sustained local drug delivery to the arterial wall via 
biodegradable microspheres" Catheterization and Cardiovascular Diagnosis 
1997, 41, 324-332. 
 
 
 34 
CHAPTER II 
 
EXPERIMENTAL PROCEDURES AND CHARACTERIZATION METHODS 
  
PEC Chemistries 
Anionic solutions contain 0.5 mg/ml low molecular weight (LMW) or high 
molecular weight (HMW) polyions that were dissolved in type I distilled water.  The 
components and their respective molecular weights are listed in Table 2-1.  The HMW 
anionic solution contained HMW sodium alginate, Mr=540 kDa, (Kelco, San Diego, CA) 
and cellulose sulfate, Mr=1200 kDa, (Janssen Chimica, Geel, Belgium).  For LMW 
formulations, LMW alginate, Mr=12 kDa (FMC Biopolymer, Drammen, Norway) and 
chondroitin sulfate, Mr=15 kDa, (Sigma Chemical Co., St. Louis, MO) were applied.  
The cationic solution contained 0.5 mg/ml spermine tetrahydrochloride, Mr=0.348 kDa, 
(Sigma Chemical Co., St. Louis, MO), poly (methylene-co-guanidine) hydrochloride 
(PMCG), Mr=5 kDa (Scientific Polymer Producs, Ontario, NY), calcium chloride (Sigma 
Chemical Co., St. Louis, MO), and 1% m/v Pluronic F-68 (Sigma Chemical Co., St. 
Louis, MO).  All solutions were filtered through 0.22 µm nylon filters (Nalgene, 
Rochester, NY).  With the exception of PMCG and Pluronic F-68, components all were 
derived from biological systems.  PMCG is a synthetic oligomer composed of arginine 
side chains (guanidinium moieties).  Table 2-2 describes the polymeric sources and 
current applications. 
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Table 2-1.   Components of similar (LMW) and dissimilar (HMW) molecular weight 
PEC chemistries.   PECs are prepared with and without the use of frequency dispergation 
to determine the effect of polyion molecular weight on efficiency of complexation 
determined by physicochemical observations.  The cationic baths for both LMW and 
HMW PEC formulations contained 1% m/v Pluronic F-68. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-2.  Polyion sources and common uses.      
 
 
Polymer Source Current Application 
Sodium Alginate Algal cell walls Controlled release and 
bioadhesive systems1 
Cellulose Sulfate Plant-derived  anti-HIV clinical trials2 
Chondroitin Sulfate Animal cartilage, ligaments, 
tendons 
Osteoarthritis 
management3 
Spermine 
Tetrahydrochloride 
Mammalian sperm Cancer diagnosis and 
treatment4 
Calcium Chloride Ubiquitous salt in all organisms Cell and tissue 
polyelectrolyte 
maintenance5 
PMCG Synthetic Microencapsulation6-8 
 
 
 
Anion 
LMW 
HMW 
LMW Sodium Alginate 
   Chondroitin Sulfate 
HMW, HV Sodium Alginate 
Cellulose Sulfate 
Cation 
Spermine Tetrahydrochloride 
Poly-[Methylene co-Guanidine] (PMCG)  
Calcium Chloride 
Precursor Component MW (Da) 
12000 
15000 
540000 
1200000 
348 
111 
5000 
Pluronic F-68 8400 
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PEC Fabrication 
A batchwise, nonstoichiometric process was used to create the PECs. The solution 
of two anionic polyions (2 ml) was titrated into a cationic bath (20 ml), containing 
Pluronic F-68, with or without 20 kHz (maximum) frequency dispergation under 
conditions of mild mechanical stirring, as described in Figure 2-1, defined as “one batch”.  
The system consisted of a needle (#26 gauge) connected to a 5 ml syringe, which was 
inserted into an ultrasonic, hollow, titanium probe with a 1.85 mm ID conical tip.  The 
probe was connected to a transducer and power generator (Misonix, Farmingdale, NY).  
Anionic solution was slowly extruded via controlled air pressure (3 psig) at 1 ml/min.  
The complexes formed instantaneously9-11. 
 
 
 
 
 
 
 
 
 
Figure 2-1.  PEC fabrication. PECs can be formed instantaneously by extruding 2 ml 
anionic solution into the 20 ml cationic bath under mild stirring, defined as one batch.  
An ultrasonic dispergator converts anionic droplets into a fine mist via frequency input 
(0-20 kHz) where 0 kHz describes a dropwise titration under mechanical stirring. 
 
 
Air Flow 
 37 
Colloidal Stability 
In preparation for biological study, stability of PEC systems was evaluated by 
suspending centrifuged preparations into various pH media and measuring their 
physicochemical response.  After preparation of LMW and HMW PECs with and without 
frequency dispergation, the 22 ml reaction suspension was transferred to 50 ml 
polypropylene ultracentrifuge tubes (Nalgene, Rochester, NY), the pH was measured 
(Fisher Accumet, Fairlawn, NJ), and the colloidal suspension was pelleted 3 times at 
35000xg at 4°C for 10 min (Beckman, Model L5-50, Rotor Type 60 Ti). Subsequent to 
the first two centrifugations, the pellet was resuspended in 1 mM sodium acetate buffer, 
pH 4.2. The final centrifugation was followed by dispersion in 10 ml of 1 mM buffer:  pH 
4.2 and 5.2 (sodium acetate/acetic acid), pH 6.2 (sodium citrate/citric acid), pH 7.2 and 
8.2 (Trizma/HCl), or pH 9.2 (carbonate-bicarbonate).  Each buffer was prepared in type I 
distilled water and filtered with a nylon 0.22 µm filter.  Subsequent to washings and final 
preparations, PECs were sonicated using a 1.045 liters (L) water bath in a sonication 
cylinder (Laboratory Supplies, Model #G1128P1G, Hicksville, NY) for 30 s in 10 s 
intervals. 
 
Transmission Electron Microscopy (TEM)  
Reaction mixture preparations were analyzed for morphology and ZetaSizer 
validation by pipetting a 20 µl sample volume onto a dry, Formvar coated, 400 mesh 
copper grid (Electron Microscopy Sciences, Hatfield, PA).  The volume was allowed to 
adsorb onto the grid surface for 30 s, after which the excess liquid was blotted carefully 
with filter paper.  The specimen was then viewed with a Philips CM-12, 120 keV electron 
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microscope equipped with a CCD camera.  PEC diameter was evaluated by using point-
to-point pixel based measurements for a minimum of 280 individual observations using 
software complementary to the TEM CCD camera (Advanced Microscopy Techniques, 
Danver, MA). 
 
PEC Size and Zeta Potential 
Following colloidal preparations, washing and dispersion at varying pH, a 1 ml 
sample was removed for size and zeta potential measurement with the Malvern ZetaSizer 
Nano ZS (Malvern Instruments, Worcestershire, UK).  Each measurement was performed 
in triplicate within 24 h of preparation. A 750 µl aliquot was added by micropipettor to a 
Malvern disposable polystyrene cell (Malvern Instruments, DTS0012, Worcestershire, 
UK).  The cell is inserted into the Malvern ZetaSizer Nano ZS located in the Vanderbilt 
Institute for Nanoscale Science and Engineering (VINSE).  A standard operating 
procedure (SOP) was set up on the instrument to measure size and charge consecutively 
in triplicate after a one-minute temperature equilibration time.  
The particle-sizing device uses non-invasive back scattering  (NIBS) with photon 
correlation spectroscopy (PCS), which has a particle sensitivity in the range of 0.6 nm to 
10 µm.  The instrument applies the concept of Brownian motion, the random movement 
of particles due to the bombardment of surrounding solvent molecules.  The Brownian 
motion of particles inside the measurement cell, based on its size, is directly related to the 
intensity of light scattered in the area in which the NIBS is applied.  The intensity of 
light, measured by a digital auto correlator, is reflected back and fluctuates over time 
based on the size of particles.  Large particles will have a smaller change in intensity, 
 39 
while small structures will induce large oscillations.  The changes in these oscillations are 
related to the diameter by a correlation function and the Stokes-Einstein equation (2-1) 
where k is Boltzmann’s constant, D is the diffusion coefficient, T temperature, µ 
viscosity, and dH the hydrodynamic radius of the particle. 
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Size-related measurements are reported as z-average mean, hydrodynamic 
diameter, and polydispersity index (PDI).  The z-average mean is classically the 
parameter most comparable to diameters measured by transmission electron 
microscopy12.  PDI is a dimensionless number that describes the heterogeneity of the 
sample, and it is scaled such that values less than 0.05 are rarely seen.  The maximum 
value is 1.000.  Values greater than 0.700 indicate a very broad size distribution and a 
lack of sample homogeneity.  
Zeta potential measurements involve laser doppler velocimetry (LDV) and fast 
field reversing (FFR) to reverse the electrical field, which induces an effective particle 
electroosmotic flow inside the cell.  Eventually the particle will migrate back to its 
original position and the effective mobility between these two locations is used to 
calculate the electrophoretic mobility.  The electrophoretic mobility is then used to 
directly calculate the zeta potential of the particles by a proprietary means. 
  
Protein Iodination 
 Drug loading and release was simulated by radioactively labeling ‘dummy’ 
proteins of different charges, adding them to the anionic stream for passive incorporation, 
and monitoring the release of the protein in biological media. The prototype proteins used 
(2-1) 
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were β-lactoglobulin (BLG), soybean trypsin inhibitor (STI), and cytochrome c (Cyt C).  
BLG,  (Sigma Chemical Co. St. Louis, MO) are proteins with well-established primary, 
tertiary, and quaternary structures with no biological activity13-16.  Table 2-3 displays the 
proteins and their respective molecular weights and isoeletric points.  All protocols 
involving radioactive materials were carried out in Medical Center North (MCN).     
 
 Table 2-3.  Properties of prototype proteins used for entrapment and release studies. 
 
Protein Molecular Weight (Da) Isoelectric Point (pI) 
β-lactoglobulin 18362 5.35 
soybean trypsin inhibitor 12000 10.8 
cytochrome c 21345 4.50 
 
 Proteins were labeled with I-125 through the use of IODO-BEADS® iodination 
reagent/kit (Pierce Biotechnology, Rockford. IL) and gel permeation chromatography.  
The IODO-BEADS® are N-chloro-benzenesulfonamide (sodium salt) immobilized on 
nonporous, polystyrene beads.  Two beads were washed twice with 100 mM phosphate 
buffered saline (Invitrogen/Gibco, Carlsbad, CA), pH=7.2 twice.  The beads were then 
transferred to a 1.5 ml microcentrifuge tube (Fisher, Fairlawn, NJ) and 150 µl fresh 
phosphate buffered saline (PBS) added. To the 10 µl carrier-free isotope solution (1 mCi, 
Amersham Biosciences, Pittsburgh, PA), 150 µl of PBS was added and the 160 µl 
pipetted to the separate IODO-BEADS/PBS mixture.  The solution, IODO-BEADS and 
I-125, was incubated 5 min at room temperature.  500 µg of protein was subsequently 
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mixed and the reaction was allowed to proceed for 15 min.  The reaction was stopped by 
removal of the solution from the microcentrifuge tube.  The resultant volume was then 
eluted with distilled water through a Sephadex G-50 GPC column over 18-20 0.500 ml 
fractions (Millipore, 2.6 cm ID x 40 cm, Billerica, MA).  After the column 
chromatography, the radioactivity each fraction (2 µl aliquot) was measured using a 
multi-purpose scintillation/gamma counter (Beckman Coulter LS 6500, Beckman 
Coulter).  Fractions with protein, labeled and unlabeled, appeared after the void volume 
followed by a peak corresponding to unreacted I-125 (Figure 2-2).  The peak containing 
protein was pooled and assayed for total protein content by the Micro BCA protein assay 
kit (Pierce Chemical Co., Rockford, IL).   
 
 
Figure 2-2.  Chromatogram for the preparation of iodinated cytochrome c.  Ordinate axis 
represents the radioactivity in terms of counts per minute (CPM). 
 
 
 42 
PEC Protein Loading and Release Monitoring 
Protein release and entrapment was monitored by incorporating radioactive, 
iodinated STI, BLG, or Cyt C into PECs.  The PEC system was defined by initial 
physicochemistry and response to pH.  Therefore, the complexes used for these 
experiments were only formulation(s) that fit specific engineering criteria. 
PECs are prepared as described above in PEC Fabrication with 15 µg I-125 
protein mixed into the standard anionic solution.  The radioactivity of each sample 
accumulated during the course of an experiment was measured by multi-purpose 
scintillation/gamma counter with an output in terms of counts per minute (CPM).    The 
PECs were isolated by centrifugation three times as outlined in Colloidal Stability.  
Subsequent to each centrifugation, 1 ml of the supernatant was sampled.  Following the 
final centrifugation, supernatant decantment and sampling, the pellet is suspended in 1 ml 
of 100% fetal calf serum (Invitrogen/Gibco, Carlsbad, CA) to simulate mammalian blood 
plasma.  The suspension was removed, transferred to sterile 1.5 ml microcentrifuge tubes 
(Fisher, Fairlawn, NJ), added to a rotisserie spinner (Labquake Rotisserie Shaker, 
Dubuque, IA) and incubated at 37°C, 5% CO2, and 95% relative humidity.  Prior to 
incubation, a 10 µl volume was removed to calculate the protein incorporation efficiency.  
The entrapment efficiency (%EE) was calculated by equation 2-2.  PEC size of this 
volume was also measured as outlined in PEC Size and Zeta Potential after dilution with 
750 µl fetal calf serum (FCS). 
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Release was assessed every 24 h for seven days by centrifugation at 15000xg, 4°C 
under vacuum and supernatant sampling (1 ml). The PEC pellet is then resuspended in 1 
ml fresh fetal calf serum and re-incubated until experiment termination.  At the outset of 
the experiment, 1 ml of FCS was added to the final pellet and the percent retained (%R) 
was analyzed by equation 2-3. 
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The supernatants collected over the seven days can be used to calculate the percent 
released daily (%REL). 
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The cumulative protein released (%CUM) was represented by equation 2-5.    
                                               
! 
%CUM = %RELsup er
n=1
7
"                                                    (2-5) 
Additionally, the radioactivity was proportionally converted to represent protein by mass 
with equation (2-6).  Therefore, the quantities described by equations 2-2, 2-3, 2-4, and  
2-5 were plotted against mass vertical axes. 
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 44 
Polymer Labeling 
 Two different fluorescent molecules, conjugated to the terminal amine of PMCG, 
were applied for tracking PEC behavior in vitro and in vivo.  Fluorescent conjugates 
allowed the creation of colored particles and rapid, simple way to quantify cell-associated 
nanoparticles17.  Fluorescein isothiocyanate (FITC, Sigma Chemical Co., St. Lous, MO) 
while AlexaFluor 750 (AF750, Molecular Probes/Invitrogen, Eugene, OR) was utilized 
for longitudinal, in vivo imaging.  In both cases, fluorescent fractions were pooled for 
preparation of fluorescent PECs. 
 First, the amount of PMCG, adjusted to pH=9.0 with 100 mM NaOH, for a 15:1 
FITC/polymer molar ratio was dissolved in the reaction buffer, 10 mM carbonate-
bicarbonate, pH=9.0.  The FITC powder was then added to a foil-wrapped beaker and 
allowed to react under stirring for 2 h.  After 30 min of mixing, the solution was 
centrifuged at 15000xg for 30 min. The supernatant was removed and separated from 
unreacted FITC in a Sephadex G-50 GPC column (Millipore, 2.6 cm ID x 40 cm, 
Billerica, MA) using distilled water as elution solvent.  Eighty 0.450 ml fractions are 
collected in 12x25 borosilicate glass tubes (VWR, Westchester, PA).  The FITC labeled 
polymer is evaluated by measuring the fluorescence intensity of the fractions in a 96-well 
plate (Nunc, Rochester, NY) at λex 485 nm, λem 530 nm (FL600 Bio-Tek Instruments, 
Winooski, VT).  Again, the first peak that emerged after the void volume corresponded to 
the fractions of labeled constituent (Figure 2-3). 
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Figure 2-3.  Separation of FITC-PMCG from unreacted FITC. 
 
AF750 was conjugated to PMCG in 10 mM carbonate-bicarbonate buffer, pH=9.  
AF750 was suspended, first, in 100 µl 99% dimethyl sulfoxide (DMSO, Sigma Chemical 
Co., St. Louis, MO), then added to PMCG in a 200:1 PMCG/AF750 mass ratio with 
carbonate-bicarbonate buffer in a foil-wrapped beaker, total volume 2 ml.  The reaction 
proceeded, under stirring, for 24 h at room temperature.  The mixture is then spun down 
at 15000xg, 30 min. The supernatant was removed and separated from unreacted AF750 
in a Sephadex G-50 GPC column (Millipore, 2.6 cm ID x 40 cm, Billerica, MA) using 
distilled water as elution solvent.  Eighty 0.450 ml fractions are collected in 12x25 
borosilicate glass tubes (VWR, Westchester, PA).  Conjugated and free AF750 peaks 
were visualized by pipetting a small volume of each fraction to a 96-well plate.  The 
fluorescence was measured with the iodocyanine green (ICG) filter (λex 710-760 nm, λem 
810-875 nm) on the Xenogen IVIS 200 Imaging System.  
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Fluorescent PEC Preparation  
Fluorescent PECs were prepared by first adding 250 µl of pooled FITC or AF750 
PMCG to the standard cationic solution, outlined in PEC Chemistries, under stirring for 
30 min, followed by filtration through a nylon 0.22 µm filter.  PECs are created as 
described by PEC Fabrication.  The complexes were isolated by centrifugation three 
times as outlined in Colloidal Stability.  After the final centrifugation and supernatant 
removal, the pellet was suspended in varied solutions depending on the application.  The 
stability and effect of exchange reactions was evaluated by suspension of fluorescent 
PECs in physiological solutions (cell growth media and 10 mM HEPES buffer, pH=7.4) 
and tracking the release in a similar experimental and analytical manner described in 
PEC Protein Release Monitoring.  The release of FITC in each buffer was less than 10% 
over 24 h. 
 
Incorporation of TSP521:  Direct Surface Coupling and Passive Entrapment 
PEG-conjugated TSP521 (MW~20000 Da), was supplied by the Davidson Lab 
(VUMC Department of Pathology).  TSP521 (Bio-Synthesis, Inc, Lewisville, TX) was 
synthetically prepared with one terminal cysteine. Upon PEGylation as described by 
Carlesso18, TSP521 was dissolved in distilled water and treated with a fresh water 
solution of 50 mM Tris(2-carboxyethyl)-Phosphine HCl (TCEP, Sigma Chemical Co., St. 
Louis, MO) for 30 minutes at room temperature, in order to convert the peptide disulfide 
dimer to reactive monomer.  After 30 min, the pH was adjusted to 6.5 and freshly water 
dissolved PEG-maleimide (provided by Dr. Yasuhiko Iwasaki of the Tokyo Medical & 
Dental University, Japan) was added in an equimolar ratio.  The reaction was allowed to 
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proceed for 4 h at room temperature. The resulting PEGylated peptides were dialyzed 
using a Slidealizer Cassette (Pierce Chemical Co., Rockford, IL) with 5 kDa cutoff 
against four changes of 10 mM Tris-HCl, pH 7.3 at 4°C to remove free peptide.  
PEGylated TSP521 was incorporated into the PEC by addition of 0.750 mg PEGylated 
TSP521 to the anionic solution.  PECs, fluorescent or standard, were prepared as 
described in PEC Fabrication. The complexes were isolated by centrifugation three times 
as outlined in Colloidal Stability.  After the final centrifugation and supernatant removal, 
the pellet was suspended in varied solutions depending on the application.  Additionally 
the incorporation of PEGylated TSP521 was evaluated by using FITC-labeled TSP521 
(Bio-Synthesis, Inc, Lewisville, TX) followed by PEG conjugation.  The incorporation 
efficiency of conjugate was calculated by equation 2-7, where F0,TSP521 is the fluorescence 
of the anionic or cationic stock and Ffinal,TSP521  is the fluorescence of the final suspension. 
The fluorescence intensity of the preparation was measured in a 96-well plate (Nunc, 
Rochester, NY) at λex 485 nm, λem 530 nm (FL600 Bio-Tek Instruments, Winooski, VT).   
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 TSP521 was coupled directly to the PEC surface using 1-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide (EDAC)/N-hydroxysuccinimide (NHS) two-step, zero-length 
cross-linking.  TSP521 only contains one amino acid with a reactive carboxylic acid, 
aspartate, which allowed for its direct conjugation.  One PEC batch, fluorescent or 
standard, was coupled to 0.100 mg TSP521 by a procedure described by Grabarek and 
Gergely19.  The third centrifugation was followed by PEC suspension in 500 µl 100 mM 
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2-[N-morpholino]-ethane sulfonic acid (MES, Sigma Chemical Co. St. Louis, MO), pH 
6.0.   
Separately, 100 µg 1 mg/ml TSP521 (Biosynthesis Inc., Lewisville, TX), 100 µl 4 
mg/ml 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDAC, Sigma 
Chemical Co., St. Louis, MO), and 60 µl 4 mg/ml N-hydroxysuccinimide (NHS, Sigma 
Chemical Co., St. Louis, MO were mixed in a total volume of 500 µl MES buffer, 
pH=6.0.  This step, activation of TSP521, was allowed to react for 30 min at room 
temperature on a rotisserie spinner (Labquake Rotisserie Shaker, Dubuque, IA).  The 
reaction was terminated by addition of 3 µl 99% β-mercaptoethanol.  
TSP521/EDAC/NHS was then added to the 500 µl PEC suspension, followed by 
incubation at room temperature for 2 h.  The 1 ml suspension was transferred to 50 ml 
polypropylene ultracentrifuge tubes (Nalgene, Rochester, NY) and centrifuged once at 
35000xg at 4°C for 10 min.  The supernatant was discarded and pellet suspended in 
various buffers or biological media.   Analogous to the determination of incorporation 
efficiency of PEGylated TSP521, the effectiveness of direct conjugation was calculated 
by an identical expression.   
 
Cell Line and Maintenance 
The cell line used for these studies is a human microvascular endothelial cell line 
(HMVEC-1) generously provided by R. Swerlick of Emory University.  The cells are 
maintained in MCDB 131 medium supplemented with 5% FCS (Invitrogen/Gibco, 
Carlsbad, CA), 20 mM L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 500 
µg/ml hydrocortisone, 0.001 µg/ml epidermal growth factor (maintenance medium).  
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During maintenance, the cells are cultured in T-flasks (Corning, Corning, NY) at 33°C, 
5% CO2, and 95% relative humidity.  After 3-4 days, cells are detached using 0.25% 
trypsin/0.1% EDTA, counted by hemacytometer, and resuspended in fresh growth 
medium.   
 
Confocal Microscopy 
FITC-labeled PECs were prepared as described in Fluorescent PECs.  The PECs 
were suspended in 20 ml MCDB 131 complete media in preparation for microscopic 
studies.  One day prior to PEC fabrication, confluent cells at approximately day 4 of 
culture, viability of 90% or greater by trypan blue exclusion, are detached from one T-75 
cm2 parent flask, diluted, and seeded to 8-well microscope slides (Lab-TekTM II Chamber 
Slide System, Electron Microscopy Sciences, Hatfield, PA) at 5000 cell/well.  Cells are 
allowed to attach overnight at 37°C, 5% CO2, and 95% relative humidity in regular 
maintenance medium.  After the 24 h incubation, FITC-PMCG complexes (400 
µl/chamber) were added.  Cells were allowed to interact with PECs for up to 24 h, 
followed by aspiration and three washing steps with 4°C PBS.  The cultures were then 
fixed with cold methanol (200 µl) at -20°C for 30 min.  The nuclei were stained with 
TOPRO-3 (Molecular Probes/Invitrogen, Eugene, OR), 150 µl 200 ng/ml, for 10 min.  
The stain was then removed along with the chambers and mounted with a glass coverslip.  
Images were then visualized and collected with a 3-track confocal microscope (Zeiss 
LSM-510, Thornwood, NY) using the appropriate fluorescence filters:  λem=488 nm 
(FITC), λem=543 nm (Rhodamine), λem=633 nm (AlexaFluor 647, Cy-5).  A technique 
called z-sectioning, was applied to determine if PECs localized in the same optical plane 
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as cells. By varying the distance between the objective pinhole and the specimen over 
fixed increments, a ‘z-series’ was generated that dissects and collects images through the 
specimen. 
 
 
Flow Cytometric (FACS) Detection of PEC/Cell Interactions 
Flow cytometry measures and then analyzes multiple physical characteristics of 
single particles, usually cells, as they flow in a fluid stream through a beam of light.  The 
properties measured include a particle’s relative size, relative granularity or internal 
complexity, and relative fluorescence intensity.  These characteristics are determined 
using an optical-to-electronic coupling system that records how the cell or particle 
scatters incident laser light and emits fluorescence.   
A typical flow cytometer is made up of 3 systems:  fluidics, optics, and 
electronics.  In a flow cytometer, particles or cells are carried to the laser intercept in a 
fluid stream.  Any suspended material from ~0.200 µm to 150 µm in size is suitable for 
analysis.  When particles pass through the laser intercept, they scatter laser light.  Any 
fluorescent molecules present on the particle fluoresce.   The scattered and fluorescent 
light is collected by appropriately positioned lenses.  A combination of beam splitters and 
filters steers the scattered and fluorescent light to the appropriate detectors.  The detectors 
produce electronic signals proportional to the optical signals striking them.  Two types of 
scattered light, in addition to the fluorescence, are analyzed and displayed in Figure 2-4: 
• Forward-scattered light (FSC):  proportional to cell surface area or size 
• Side-scattered light (SSC):  proportional to cell granularity or internal 
complexity.   
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Figure 2-4.  Light-scattering properties of a cell.  Correlated measurements of FSC and 
SSC can allow for differentiation of different cell types. 
 
 Flow cytometric evalution of cellular interactions with PECs were performed by 
first, seeding cells to 48-well plates (Nunc, Rochester, NY) 24 h previous to the 
experiment.  Confluent cells at approximately day 4 of culture are detached and counted 
by hemacytometer from 2 T-75 cm2 parent flasks.  The volumes were combined and 
volumes equivalent to 50000 cell/well are added to each well.  HMVECs were permitted 
to attach overnight at 37°C, 5% CO2, and 95% relative humidity in complete MCDB131.  
Following the ~24 h incubation, experiments were performed by exposing HMVECs to 
PECs under various concentration and inhibitor schemes (detailed later).  At the outset of 
an experiment, the test media containing PECs was removed and the cultures washed 
thrice with 4°C PBS.  Cells are then detached with 200 µl 0.25% trypsin/0.1% EDTA (2 
min) or 5 min exposure to 5 mM EDTA in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Sigma Chemical Co., St. Louis MO), depending 
on the experiment.  The majority of experiments were detached with EDTA as discussed 
in later chapters.  Detachment was terminated by the addition of FACS buffer (3% FCS 
Light source 
SSC detector 
FSC detector 
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in PBS).  The detachment was followed by cell suspension transfer to 4 ml FACS tubes 
(BD Falcon, San Jose, CA) and centrifugation at 200xg for 10 min.  The supernatant was 
removed and cells suspended in 200 µl FACS buffer.  The tubes were kept on ice until 
arrival at the FACS instrumentation.  Excitation of samples was performed with a 15 mW 
488 nm (λex 485 nm ) argon ion laser and detected with either λem =515-545 nm (FITC) 
or λem =564-606 nm filters. 
 A standard experiment included acquisition of HMVECs in the absence of PECs 
to establish a background.  The samples exposed to PECs were then acquired.  SSC, FSC, 
and FITC outputs were collected in list mode form and analyzed with FloJo  (Treestar, 
Inc., Ashland, OR).  The first round of acquisition yielded the total amount of cell-
associated fluorescence (MFtotal), due to FITC PECs.  MF also represents the median 
fluorescent index (MFI).  The internalized fluorescence was determined by adding 120 µl 
0.4 mg/ml trypan blue (TB, Mediatech, Herndon, VA) and re-acquiring the sample to 
give MFinside.  TB quenches extracellular FITC20-22, giving the opportunity to evaluate the 
cellular compartmentalization of PECs (equation 2-8): 
                                               
! 
MFtotal = MFsurface + MFinside                                              (2-8) 
 
Saturation PEC-Cell Association Kinetics 
 Fluorescent PECs were prepared as described above and suspended in 20 ml 
complete MCDB 131.  Cell exposure, in 48-well plates, to 400 µl PECs was monitored 
for t=0, 5, 10, 15, 20, 30, 60, and 120 min.  The 2 h incubation was followed by 
aspiration, washing, detachment, centrifugation, and addition of FACS buffer.  Flow 
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cytometric measurements, minimally 10000 events, with and without TB were performed 
within 30 minutes using a 4-color FACSCalibur (BD Biosciences, Mountain View, CA)  
 
PEC Acute Toxicity by Propidium Iodide (PI) 
 Acute toxicity of fluorescent PECs was detected by propidium iodide (PI, 
Molecular Probes/Invitrogen, Eugene, OR) as described by Rasola, and Geuna23.  Cells 
were exposed to PECs as described in Saturation PEC Cell Association Kinetics, 
detached after 2 h PEC exposure using 0.25% trypsin/0.1% EDTA, centrifuged and 
resuspended in 200 µl FACS buffer.  PI, 40 µl 0.01 mg/ml, was added to each sample 1 
min prior to FACS acquisition.  The cytometer applied was the 4-color FACSCalibur 
(BD Biosciences, Mountain View, CA) cytometer.  For each sample, 10000 events were 
collected.  The PI fluorescence was collected through a λem =564-606 nm filter after 
excitation of the fluorochrome at 488 nm (λem).  The toxicity was represented as percent 
control, control being cultures without PECs. 
   
Treatment of Cells with Various Inhibitors   
HMVEC-1 cells were prepared as described above. At the end of the exposure, 
cells were washed, detached and analyzed by flow cytometry (see above).  Inhibition 
strategies include extracellular heparin, reduced temperature (thermodynamics), 2-
deoxyglucose/azide (metabolism), cytochalasin D (actin filaments), HSPG biosynthetic 
effects (4-nitrophenyl xylopyranoside), and surface receptor proteolysis (trypsin).  
Fluorescent PEC concentrations were one batch suspended in 20 ml MCDB 131 complete 
media.  Wells received 400 µl PECs in media or media alone.  In each case, at least one 
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well was maintained at normal cell culture conditions.  Inhibitors were applied for 30 
minutes at standard incubatory conditions (37°C, 5% CO2, and 95% relative humidity), 
unless otherwise indicated previous to detachment by 5 mM EDTA. Flow cytometric 
measurements with and without TB were performed within 30 minutes using a 4-color 
FACSCalibur (BD Biosciences, Mountain View, CA) cytometer.  For each sample, 
10000 events were collected.  Inhibitors did not elicit any cellular toxicity as defined by 
PI measurements. 
  To evaluate the effect of free glycosaminoglycans24,25 on PEC association, two 
hours previous to PEC exposure, cultures were pre-incubated with 200 U/ml USP grade 
heparin (Celsus Laboratories, Cincinnati, OH) followed by a PBS wash, and a cocktail of 
200 U/ml heparin, particle concentration indicated above, and growth media. 
Energy dependence was assessed by 2-deoxyglucose/sodium azide26 and reduced 
temperature (4°C)27.  For temperature effects, HMVECs were pre-incubated in a 
refrigerator at 4°C for 1 h in complete MCDB 131.  The media was then removed and 
PECs added followed by refrigeration.  50 mM 2-deoxyglucose (2-DOG, Sigma 
Chemical Co., St. Louis, MO) and 0.05% v/v sodium azide (Sigma Chemical Co., St. 
Louis, MO) was prepared in complete media and added to HMVEC-1 cultures 1 h 
previous to PEC exposure.  PECs and 2-DOG/azide were then pipetted to the plate after 
aspiration of pre-incubatory media. 
The effect of actin on PEC association was evaluated by exposure to 10 µM 
cytochalasin D28,29 (Sigma Chemical Co., St. Louis, MO).  Cell pre-incubation prior to 
PEC/cytochalasin D treatment elapsed 2 h.  Cells were then treated with PECs for the 
time period indicated above. 
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24 hours after HMVEC-1 seeding to 48 well plates, cells are washed and exposed 
to 500 µM 4-nitrophenyl-α-xylopyranoside (α-xyl) or 4-nitrophenyl-β-xylopyranoside 
(β-xyl) overnight to elucidate the role of HSPG in PEC association.  β-xyl at µM-mM 
concentrations has been found to suppress proteoglycan biosynthesis while α-xyl does 
not30,31.  The overnight exposure to α-xyl or β-xyl was followed by exposure to PEC.  
Comparison of these two xylopyranoside isomers provided the appropriate controls. 
 Tryptic cleavage of PEC association was measured by detaching cells with 0.25% 
trypsin/0.1% EDTA and comparison to 5 mmol/l EDTA monolayer removal.  PECs were 
added to culture for the time period indicated above.  Subsequent to the washings, 
HMVECs are removed with either trypsin or EDTA. 
 
Particle Counting 
  Particle concentration, in terms of PEC/ml, was determined by flow cytometry 
(FACS Aria, BD Biosciences).  The FACSAria was fitted with SSC, FITC, and FSC 
detection lasers.  In particular, the FSC laser was adapted with a photomultiplier tube to 
magnify the signal generated from PEC size.  Firefli 200 nm fluorescent green (ex 
468/em 530 nm) polystyrene microspheres (Duke Scientific Corporation, Palo Alto, CA) 
of known concentration were processed and detected using forward and side scatter 
lasers.  The number of events recorded over fixed period of time (60s) was used to 
develop a standard calibration curve.  This calibration curve was then used to evaluate 
PEC recorded events and thus concentration over four logs of arbitrary dilution for one 
batch of fluorescent PECs.  The populations of PECs were analyzed for fluorescence by 
FACSDiva software (BD Biosciences, Mountain View, CA) to normalize fluorescence 
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units in terms of PEC/ml.  Free and bound particle concentrations are defined based on 
ordinary linear interpretation and proportionality.  Resultant PEC concentrations for 
direct association and inhibitor experiments were determined to be 1.54x109 PEC/ml.  In 
each case, media and cell fluorescent backgrounds were established. 
 
PEC Effects on HMVEC-1 Proliferation 
 One day before PEC exposure, cells are plated to 48 well plates at a density of 
25000 cell/well, successive to detachment of 2 T-75 cm2 flasks at day 4 culture.  After an 
~20 h attachment and acclamation period, cells were exposed to serial dilutions of non-
targeted and targeted PECs (PEGylated and EDAC/NHS coupled TSP521) for 72 h 
without media change.  Subsequent to the 72 h exposure, media for all wells were 
removed and HMVEC-1 cell growth was measured using the Titer 96® Aqueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI, USA).  Each well then 
received 300 µl fresh MCDB 131, followed by 20 µl of dye solution, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).  Incubation for 40 min at 
37°C, 5% CO2, 95% relative humidity ensued.  Absorbance at 490 nm was determined by 
microplate reader (µQuant, Bio-Tek Instruments, Winooski, VT).  All results were 
normalized to the control (no PECs). 
 
Scatchard Plots 
Scatchard titrations were prepared by exposing HMVEC-1 cells to serial dilutions 
of targeted, PEGylated and EDAC/NHS ligated TSP521, and non-targeted PEC for 3 
hours at normal incubatory conditions.  One day previous, 50000 cells/well were seeded 
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and incubated at 37°C, 5% CO2, 95% relative humidity after detachment of 2 T-75 cm2 
flasks at approximately day 4 of culture.  Separate plates were incubated at 4°C to shut 
down the endocytosis of PECs32.  The exposure was followed by detachment and 
acquisition of MFI by FACSAria (BD Biosciences, Mountain View, CA). For each 
sample, 10000 events were collected by list-mode data that consisted of side scatter, 
forward scatter, and fluorescence emission centered at 530 nm (FITC).  Bound median 
fluorescence indices (MFI) were determined using FACSDiva software.  Free, unbound 
median fluorescence indices were evaluated by mass balance.  These values were then 
converted to PEC concentration.  Scatchard plots were prepared by plotting bound 
PEC/free PEC versus bound PEC as described classically33. 
 
In Vivo Imaging 
 Non-invasive, longitudinal, whole animal imaging of mice was performed with 
AF750-PMCG fluorescent PECs.  Animals procedures, performed in VUMC, followed 
the Vanderbilt University Institutional Care and Use Committee.  Male BALBc, 
approximately 4-6 weeks of age, were obtained from Charles River Laboratories 
(Cambridge, MA).  Prior to injection, animals were shaved and anaesthetized.  Retro-
orbital injections were then administered:  100 µl AF750-PMCG PECs suspended in 1 ml 
5 mM HEPES, pH=7.6 (one batch).  Animals were imaged immediately after injections, 
3 h, 6 h, 24 h, and 48 h with the IVIS 200 small animal imaging system fitted with an 
ICG filter (λex 710-760 nm, λem 810-875 nm).  Each time point was followed by animal 
sacrifice by cervical dislocation and organ extraction.  Individual organs (bladder, 
kidneys, heart, lungs, liver, spleen) were transferred to 6 well plates (Nunc, Rochester, 
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NY) and imaged.  The fluorescence of each well was extracted using the Living Image 
software package integrated with IgorPro 5  (Wavemetrics, Lake Oswego, OR) in terms 
of pixel flux. 
 
Histology 
Following animal euthanasia, sections of animal organs were prepared for 
delivery to the VUMC Immunohistochemistry Core (IHC).  All organs were fixed 
overnight on 10% buffered neutral formalin. Tissue paraffin blocks were made by 
embedding the tissue in melted paraffin.  Paraffin-tissue section were cut and mounted 
onto the glass slides. Sections were deparaffinized and stained with hematoxylin and 
eosine for staining nuclei and cytoplasmic components, respectively. Slides were then 
examined using an upright light microscope (Olympus BX50, Olympus, Center Valley, 
PA) and documented using QCapture Software (QImaging, Barnaby, BC, Canada). 
 
Process Scale Up with Kenics Static Mixer 
To evaluate the scale up ability of the PEC production process, Kenics static 
mixer technology was applied because it has the potential to yield large product titers as 
opposed to small batch volumes.  The particles are created by simple stream mixing over 
alternating right and left hand elements.  Static mixers are tubular reactors and are 
advantageous because they can offer high residence times, liquid phase plug flow at low 
Reynolds Numbers, and are adaptable to aseptic processing.  These types of mixer arrays 
have been suggested as an alternative to traditional stirred tank reactors and preliminary 
evidence has been found that the static mixer can hold promise for the synthesis of 
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pharmaceuticals34.  The Kenics mixer applied herein was 6.35 mm I.D., 21 cm in length, 
and made of stainless steel (Chemineer, North Andover, MA).  Polyionic solutions were 
prepared as described in PEC Chemistries and complexed using the same stoichiometry.  
Solutions were pumped from reservoirs through 16 gauge polypropylene tubing (Cole 
Parmer, Vernon Hill, IL) using a peristaltic pump (Cole Parmer, Vernon Hills, IL).  The 
flow rate ratios (ml/min), cation to anion, included 200:20, 160:16, 120:12, and 90:9.  
Aqueous particle suspensions were allowed to accumulate for 30 s in a 250 ml glass 
beaker (Kimble, Vineland, NJ) under moderate stirring.  The process was repeated for 
each ratio of flows and at the outset of 30 s, a 1 ml sample is removed for size and zeta 
potential measurement with the Malvern ZetaSizer Nano ZS and physciochemical 
properties as described in PEC Size and Zeta Potential. 
 
Qualitative Assessment of Static Mixer Efficiency 
The mixing efficiency of the Kenics static mixer was evalulated by a parallel 
competing reaction scheme at various Reynolds numbers representative cation to anion 
stoichiometries encountered during continuous LMW and HMW PEC production.  The 
two competing reactions, established by Fournier35 and further applied by Fang and 
Lee36, are borate neutralization and the Dushman reaction, both of which compete for 
hydrogen ions.  Equations 2-9, 2-10, and 2-11 describe the system: 
H2BO3- + H+                   H3BO3   
 
                                    5I- + IO3- + 6H+            3I2 + 3H2O  
 
                            I- + I2                I3     
 
(2-9) 
(2-10) 
(2-11) 
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The amount of iodine produced depends on the efficiency of the mixer when acid is the 
limiting reagent.  If the mixing efficiency is high, then the H+ ions would be dissipated 
through 2-9, a quasi-instantaneous reaction, and no iodine would form.  On the other 
hand, if the mixing efficiency is low, most of the injected protons would be consumed by 
reactions 2-10 and 2-11, orders of magnitude slower reactions than 2-9.  The iodine, upon 
formation, goes to tri-iodide, which can be detected spectrophotometrically. The bulk 
solution, a mixture of H2BO3/IO3-/I-, will mimic the cation while the anion will be H+ in 
the form of low concentration sulfuric acid.  These conditions will simulate the 
limiting/excess reactant conditions applied in the PEC production process.   
The H2BO3/IO3-/I solution was prepared by dissolution of 0.75 g H3BO3 in 700 ml 
water using a 1 L beaker.  The pH was then adjusted to 9.14 with NaOH.  This ensured 
equimolar concentrations of H2BO3- and H3BO3.  In a separate beaker, 0.500 g KIO3 and 
1.93 g KI were freshly dissolved in 100 ml water.  The two solutions were then combined 
and final volume diluted to 1 L with approximately 200 ml water.  0.005 M H2SO4 was 
used as the acid source.  All chemicals were purchased from Sigma Chemical Co. 
 Solutions were pumped from reservoirs through 16 gauge polypropylene tubing 
using a peristaltic pump.  The flow rate ratios (ml/min), H2BO3/IO3-/I to H2SO4 included 
200:20, 160:16, 120:12, and 90:9.  Reynolds numbers were calculated by equation 2-12:   
                                                           
! 
Re =
"VD
µ
                                                        (2-13) 
where v was velocity of fluids through the mixer (m/s) and D the diameter (m).  ρ (g/m3) 
and µ (g m-1s-1) were the density and viscosity of water at room temperature.  
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Aqueous particle suspensions were allowed to accumulate for 20 s in a 250 ml glass 
beaker (Kimble Vineland, NJ) under moderate stirring.  A 200 µl volume of effluent was 
removed and the absorbance measured at 353 nm using a microplate reader (µQuant, 
Bio-Tek Instruments, Winooski, VT).  The concentration of tri-iodide ion was calculated 
by equation 2-12 (Beer’s Law): 
                                                
! 
[I
3
] =
A
353
"a
                                                        (2-13) 
with an ε equal to 26.06 L mmol-1cm-1 and a, the path length, of 0.646 cm as defined by 
Guichardon and Falk37.
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CHAPTER III 
 
DEVELOPMENT OF IMPROVED NANOPARTICULATE POLYELECTROLYTE 
COMPLEX PHYSICOCHEMISTRY BY NON-STOICHIOMETRIC MIXING OF 
POLYIONS WITH SIMILAR MOLECULAR WEIGHTS 
 
 
 
Introduction  
Efficient nano- and micro-scale therapeutic vehicles are ideally, nontoxic, 
nonimmunogenic, and made from versatile building blocks that allow optimal delivery to 
specific cells and tissues. The potential of polymer nanostructures as targeted drug 
delivery vehicles has led to the creation of multitudes of colloidal formulations.  This 
technology results from a collaboration of medicine and engineering for the delivery of 
macromolecular drugs that cannot be efficiently administered systemically1.  Integration 
of pharmacological agents, vectors including peptide segments, proteins, and DNA 
vectors, into nanoparticulate polymer matrices, together, with both targeting and 
therapeutic abilities offers many benefits, including controlled drug release and 
protection, prolonged blood circulation times, and other tunable characteristics2,3.  
 Many current research strategies in polymer drug delivery involve the use of 
solvent emulsion as a reaction environment leading to potential problems in final product 
formulations4. Water-soluble, biodegradable, polymeric, polyelectrolyte complex 
dispersions (PECs) have evolved because of the limitations of the currently available 
systems.  The nanoparticulate architecture of PECs permits the environmentally attractive 
use of water as a solvent, a major advantage for products that may be used as drug 
delivery systems in humans.  PECs result from strong electrostatic interactions between 
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charged microdomains of at least two oppositely charged polyelectrolytes5.  The most 
predominant forces for PEC assembly are strong electrostatic interactions, but hydrogen 
bonding, hydrophobic interactions, and van der Waals forces complement PEC 
formation, and they are related to physical considerations presented previously6.  
Reaction phase environmental parameters dictate PEC physicochemical 
properties, and, specifically, complexation between polyelectrolytes having significantly 
different molecular weights leads to formation of water-insoluble aggregates7-9. The 
creation of large water-insoluble aggregates is undesirable because particles greater than 
1000 nm can lead to circulatory limitations and tissue inflammation10-12.  Conversely, 
particles which are too small quickly leave systemic circulation, cleared by the 
reticuloendthelial system (RES), without reaching target tissues13.   
Using these facts as a starting point, this study compares PEC systems with 
similar (LMW) and dissimilar (HMW) molecular weights to identify a suitable and 
controllable product for biological use.  Several PEC characteristics are favorable for 
colloidal stability and provide the benchmarks for definition of an advantageous PEC 
system, including hydrodynamic diameter less than 200 nm12,14, empirical surface charge 
of greater than 30 mV or less than -30 mV, spherical morphology, and a low 
polydispersity index indicative of a homogeneous distribution15-17.  Maintenance of these 
properties, particularly size and shape, is critical for cellular uptake18,19.  The current 
technology applied herein has utilized a water-based approach for producing PECs under 
the prevailing assembly and complexation theory.  These biocompatible, non-toxic PECs 
are produced using a multipolymeric mixture with a minimum of two polyion pairs for 
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enhancement of thermodynamic stability and controlled incorporation of molecules such 
as proteins or targeting peptides. 
 
Experimental Procedures 
 PECs were prepared per Chapter II, PEC Fabrication, using the LMW and HMW 
formulations.  PECs were made with (20 kHz) and without frequency dispergation for 
both HMW and LMW systems followed by the evaluation of integrity as a function of pH 
as described in Chapter II, Colloidal Stability.  Hydrodynamic diameter, zeta potential, 
PDI (PEC Size and Zeta Potential), and morphology by TEM provided the 
physicochemical markers. 
 
Statistical Analysis 
All statistical analyses were performed using JMP-IN 5.1 (SAS, Cary, NC).  
Reaction mixture formulations with and without dispergation were compared by two-
sample t-test to evaluate the differences between sizes, zeta potentials, and polydispersity 
indices (PDI) within and between PEC systems.  Hydrodynamic diameter and surface 
charge was tested for significant differences from 200 nm and +30 mV by a one-tailed t-
test.  TEM size distributions were tested using the Kolmolgorov-Smirnov two-sample test 
to determine whether the PEC populations were distributed identically as a function of 
frequency dispergation.  Kurtosis and skewness for the TEM distributions were evaluated 
by one-tail t-test to evaluate deviations from normality.  Colloidal stability for 
hydrodynamic diameter was first tested by one-way ANOVA to determine variations in 
the means as a function of pH.  The one-way ANOVA was followed by Dunnet’s Test, 
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which compared each mean to the reaction mixture.  A one-tailed t-test was applied to 
determine at which pH instabilities in preparations, as measured by zeta potential, 
deviated from the empirical standard for stability ±30 mV17.  Each analysis was evaluated 
at the 95% confidence level.  
 
Results and Discussion  
 
PEC Physicochemical Aspects 
The components of the anionic solution were altered to determine the effect of 
low molecular weight polymers on the hydrodynamic diameter, surface charge, and PDI 
of polyelectrolyte complexes.  Polyelectrolyte concentrations for non-stoichiometric 
addition of HMW anions into cations were established previously1,14.  Increased polymer 
concentration and further anion titration lead to PEC size increase, aggregation, and 
precipitation as the overall complex charge nears neutrality.  Lower polymer 
concentrations lead to significantly lower PEC yields.  Thus, the chosen concentrations 
represent a practical compromise1,20.   In both LMW and HMW formulations, the molar 
anion/cation charge ratio, 0.168, was constant, as calculated from the structures and 
molecular weights provided by the manufacturers.  The criteria for acceptance of PEC 
systems for biological testing were:  hydrodynamic diameter statistically less than or 
equal to 200 nm12,14, surface charge >|±30 mV|15-17, and a low PDI, indicative of a narrow 
size distribution.  The physicochemical characteristics of both LMW and HMW PECs 
were studied by titrating, non-stoichiometrically, anions into a cationic bath without or 
with (20 kHz) frequency dispergation.  The spontaneous complexation resulted in 
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cationic particles, regardless of PEC formulation, that exhibited a colloidal, Tyndall 
effect.  PECs, as prepared in their native state, had a measured pH of 4.2 due to excess 
cations present in the reaction mixture.  The complexation led to a core-shell 
morphology, with the excess cation dominating the corona surface and a neutralized inner 
phase of oppositely charged polyions. 
The z-average size, PDI, and zeta potential for PEC preparations with LMW and 
HMW polyions are shown in Figure 3-1(A-C), respectively.  LMW formulations 
provided PECs with superior characteristics independent of frequency dispergation, an 
outcome related to polymer molecular weight.  Statistical differences in PDI, zeta 
potential, and hydrodynamic diameter of PECs were observed among the two titration 
conditions and chemistries.  Both LMW titration conditions provided PECs with 
hydrodynamic diameters averaging statistically less than 200 nm, while the dispergated 
HMW formulation was the only dissimilar molecular weight chemistry with appropriate 
physicochemical properties.  Frequency dispergation reduced HMW and LMW PEC 
hydrodynamic diameter by 25% and 12%, respectively.  When comparing titration 
frequencies between systems, LMW PECs resulted in a 33% and 21% decrease in size for 
formulations without and with frequency dispergation, respectively.  The PDIs measured 
for HMW PECs, 0.410 and 0.378, indicated very heterogeneous populations of particles 
within the desired size range, as well as aggregate structures with much greater diameter, 
while the reduced PDI for LMW PECs, 0.142 and 0.145, indicated more homogeneous 
preparations.  For reference, a monodisperse distribution of standard latex beads yields a 
PDI of 0.0521.  This reduction in polydispersity helps to minimize the possibility of in 
vivo circulatory limitations.  Zeta potential was reduced for LMW PECs, but the systems 
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were stable.  In fact, a decreased positive surface charge has shown reduced toxicity at 
cellular and systemic levels22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1.  Size and zeta potential measurements for similar (LMW) and dissimilar 
(HMW) weight components.  (A) and (B) correspond to measurements of z-average 
diameter and polydispersity index for PECs obtained with (+) and without (-) ultrasonic 
dispergation for similar and dissimilar molecular weight components.  (C) describes the 
zeta potential for dissimilar (HMW) and similar (LMW) molecular weight components.  
Asterisks indicate pairs of means that differ statistically by two-sample t-test at the 95% 
confidence level for 10 replicates. 
 
The improved physicochemical properties observed with and without frequency 
dispergation may be due to the difference in sequential addition of anion to cation.  
Frequency dispergation provides the anionic solution as an aerosol, upon yielding a 
smaller core template for subsequent cationic interactions and nucleation of the 
complexes.  However, LMW PECs, suitable biological preparations were formed 
(A) (B) 
(C) 
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independent of frequency dispergation.  Therefore, LMW anions needed no modified 
titration to provide polyions in the appropriate conformation for efficient PEC creation. 
 
 PEC Morphology by TEM 
TEM micrographs presented in Figure 3-2 provided verification of LMW and 
HMW PEC size with and without frequency dispergation.  Unstained TEM specimens 
were used, since the PECs had enough contrast and superstructure for visualization.  
Observations of PEC morphology were followed by point-to-point, pixel based diameter 
evaluation to develop a size distribution to compare with PCS measurements.  Similar 
structures and size for PEC structures have been reported in the literature2,23 
Figure 3-2A(i)-(iv) showed the heterogeneity of populations created under both 
dispergation conditions for the HMW preparations.  These images provided a physical 
illustration of classic PEC models dictated by the characteristics of the polyion groups, 
stoichiometry and molecular weights:  (1) the ladder-like structure, where complex 
formation takes place on a molecular level via conformational adaptation, and (2) the 
scrambled-egg model where, a high number of chains are incorporated into the particle 
architecture24.  Figure 3-2A(ii) showed the ladder-like structures formed as a result of 
mixing polyelectrolytes having large differences in molecular dimensions, polymer 
shielding, and zipperlike assembly due to adjacent polyions24,25.  HMW PECs prepared 
with frequency dispergation, Figure 3-2A(iii)-(iv) showed compact, scrambled-egg 
architectures, which appeared to be highly aggregated. This morphology is typical for 
PECs formed between polyelectrolytes having different molecular weights9.  Figure 3-
2B(i-iv), for complexes formed with low molecular weight constituents, describes more 
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homogeneous populations of condensed, compact structures, which only displayed 
scrambled-egg behavior. The more uniform morphology was consistent with their 
lowered PDI. Again, this was likely due to more efficient interactions between polyions.  
The particles exhibited a condensed, opaque core, surrounded by a thick, fluffy coat.  
This opacity may be due to the presence of divalent cations in the formulations.  Similar 
behavior has been previously observed for chitosan/PEO-PPO nanoparticles26. 
Instrumentation that is complementary to the TEM CCD camera was used to 
measure manually and estimate the diameter of the PECs for validation of the z-average 
mean diameter.  Only spherical structures were sized, since the aggregate/filament 
structures provide no discernible points of reference for accurate diameter evaluation.  
Figure 3-3 displays the histograms for LMW and HMW PECs created with and without 
frequency dispergation. Number average sizes were 152.4 nm and 141.5 nm for LMW 
PECs without and with frequency dispergation, respectively, while HMW PECs had 
mean diameters of 201.5 (without) and 177.5 (with).  The results correlated to 
measurements performed using PCS insofar as the effect of both precursor chemistry and 
dispergation according to two-sample Student’s t-tests at the 95% confidence level. None 
of the distributions were normally distributed as determined by statistically testing the 
skewness and kurtosis of each distribution. The PDI measured by the ZetaSizer was 
qualitatively verified by coefficient of variance, an indication of the variabilities of the 
populations. Calculations performed on the distributions ranged from 34.9% (LMW 
without) to 49.0% (HMW with).  Conversely, Kolmogorov-Smirnov tests showed that 
HMW and LMW size distributions were significantly different for the two frequency 
dispergation conditions.  This result detected differences between formulations, with and 
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without dispergation, while this difference could not be detected by two-sample t-tests 
using PCS data.  Although, the two statistical tests yielded different interpretations, the 
algorithms for evaluation of PEC diameter are quite different.  PCS uses a combination of 
light scattering as a function of Brownian motion to derive diffusion coefficients, which 
can then be used to calculate hydrodynamic diameter from the Stokes-Einstein equation.  
The measurement of diameter via TEM was a more direct method for evaluating diameter 
not convoluted by the aqueous parameters that affect PCS measurements, as discussed 
below. 
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Figure 3-2.  TEM micrographs for PECs prepared with and without frequency 
dispergation for HMW (A) and LMW (B) precursors.  Images assigned (i) and (ii) are 
PECs created without dispergation.   (iii) and (iv) represent PECs fabricated with 
dispergation. 
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Figure 3-3. TEM PEC diameter evaluation.  PEC diameter measured using TEM CCD 
camera software for suspensions prepared from HMW (A) and LMW (B) precursors.  For 
HMW, 784 and 284 events were tabulated with and without dispergation settings, 
respectively.  1486 and 1860 observations were recorded for LMW PECs created with 
and without, respectively.  Distribution shifts were statistically evaluated by the 
Kolmogorov-Smirnov test.  
 
Figure 3-4 shows the agreement between PCS measurements and TEM diameter 
evaluation.  TEM estimates were consistently 71%-85% lower than PCS measurements.  
The ZetaSizer algorithms assume that the particle population only contains spherical 
structures; therefore microfilaments are assumed to be large, round objects.  Besides the 
assumption of uniform morphology, the ZetaSizer values include surface structure and 
electrical double layers surrounding the particle, which contributed to the increased 
diameter measured by PCS.  Previous studies on polymeric nanoparticles show similar 
TEM/PCS ratios2,27,28.  In conclusion, TEM was suitable for discerning PEC morphology 
(B) 
(A) 
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and quantitative diameters, but the ZetaSizer provides a higher throughput, unbiased 
method.  Both types of analysis need to be considered when characterizing these types of 
physicochemical phenomena. 
                                       (A)                                                              (B) 
                                                                                                                             
 
         
                                                                                                                                                      
  
 
 
 
 
 
 
 
 
Figure 3-4.  Comparison of PEC diameter measured by Malvern ZetaSizer Nano ZS and 
TEM for HMW (A) and LMW (B) polymer PECs.  The above figure details percent 
agreement between the two techniques along with a side-by-side graphical comparison.  
Asterisks indicate pairs of means which differed according to a two-sample t-test at the 
95% confidence interval, but not at 90% indicating an equivalence amongst means for the 
two physicochemical characterization methods. 
 
 
Colloidal Stabilty as a Function of pH. 
The addition of electrolytes or the change in the pH affects the colloidal stability 
of colloidal dispersions. These modifications are significant considerations for further use 
of any nanoparticulate system in biological media29.  The alteration of surface groups in 
electrostatic complexes between anions and cations can lead to a large size change, 
dependent upon the extent of ionization30.  Any ionizable groups in the charged domains 
presented at the nanovehicle periphery can act as electrostatic stabilizer, which is 
mediated by repulsive Coulombic interactions between particle surface charges31,32.  As 
  * 
dispergation TEM Malvern %
(nm) (nm) TEM/Malvern
- 201.5 282.1 71.4
+ 177.5 211.3 84.0
dispergation TEM Malvern %
(nm) (nm) TEM/Malvern
- 152.5 188.2 81.0
+ 141.5 165.8 85.4
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shown in Figure 3-1, reaction mixture PECs yielded stable, positively charged structures 
with zeta potentials greater than +30 mV.  However, this condition occurred at low pH 
(~4.2) and may not be a suitable suspension for in vivo or in vitro use.  The cationic 
charge of the PECs indicated that the surface-exposed polymeric groups were in a highly 
protonated state, causing repulsive forces to propagate and prevent particle coalescence in 
solution.  In addition, the delicate balance between electrostatic double layers and Van 
der Waals forces likely contributed to the maintenance of colloidal stability, signified by 
zeta potential33.   
 The stability of the four PEC systems was evaluated by PEC collection and 
resuspension at various pH, low salt and ionic strength media.  Salts can cause secondary 
aggregation and flocculation, as well as a disintegration of the complexes34.  Therefore, if 
the salt concentration is low, the effect of pH on PEC physicochemistry is isolated.   
Because of the presence of positively charged, pH ionizable, primary amino groups that 
were present as a result of excess PMCG and spermine of the cationic shell, a pH 
variation should modify the electrical state and thus the stability of the complexes.  
Hydrodynamic diameter (z-average size) and zeta potential were used as stability indices.  
Figures 3-5 and 3-6 show the variation of PEC diameter and zeta potential, 
respectively, as a function of pH.  The two properties were directly related and 
consecutively measured by the ZetaSizer immediately after colloidal resuspension and 
pH measurement.  Surface charge stabilities were empirically defined as values greater 
than±30 mV.  For z-average, statistical stability was defined by one-way ANOVA and 
then by comparison of means to the reaction mixture by Dunnet’s test.  Figure 3-5 shows 
a progressive reduction in statistical stabilities moving from HMW without dispergation 
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to HMW with dispergation, LMW without dispergation, and LMW with dispergation.  
Figure 3-6 shows a similar trend, but LMW systems provided greater colloidal stability as 
a function of pH.  In general, the behavior for Figures 3-5(A-C) and 3-6(A-C), showed a 
clear tendency towards aggregation as pH approached neutrality, corresponding to 
changes in surface charge.  Therefore, the maintenance of ideal dimensions was governed 
by electrostatic contributions.  For these particular systems, PECs coalesced, rather than 
swell, and the effect was irreversible.  If particles aggregate, then they have reached an 
endpoint state.   The increase in pH from 4 to 7 brought about a rapid decrease in zeta 
potential and colloidal stability, as shown by fusion of PECs as the repulsive surface 
charges were reduced.  As the resuspension pH was increased beyond a transition point, 
(~7.8), the suspension appeared to become more stable as shown by preservation of the 
Tyndall effect and negative zeta potential less than -30 mV.  This type of behavior, with 
zeta potential shoulders on either side of neutrality, indicated the possibility that these 
PECs exhibit zwitterionic behavior.  Therefore, PECs upon assembly contain both 
positive and negative ionizable groups and behave as acidic or basic groups of monoacids 
or monobases.  At low pH, pendant amino and carboxyl groups remain in a protonated 
state, leading to a predominance of positive charges.  Following resuspension at 
increasing pH, the protons from the charged groups dissociate.  The decreasing total 
surface charge depletes the PECs’ ability to repel each other and they effectively 
coalesce.  However, adequate negative charge appeared to be generated at basic 
conditions when sufficient protrusion and ionization of the carboxyl groups from anion 
may occur35.  Figure 3-7(A-C) schematizes this phenomenon.   In all cases, an 
experimental PEC isoelectric point (pI), the pH where dispersions carry no net charge and 
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is in its least stable state, was determined by fitting a line through the most linear portion 
of the zeta potential versus pH curve (Figure 3-6).  The calculated x-intercept was 
designated as the experimental pI.  pIs for the systems ranged from 5.76 (LMW without 
dispergation) to 5.90 (LMW with dispergation) and 5.79 (HMW without dispergation) to 
5.89 (HMW with dispergation) .  The variability in pIs between systems and/or titration 
conditions, including possibly two regions of instability exhibited in Figure 3-6(A,C), 
may be directly due to the assembly mechanisms and presentation of charged groups for 
complexation. 
                          - Dispergation                                     +Dispergation 
                                                                                                                  
Figure 3-5.  Response of PEC diameter in varied pH, low salt environments.  (A) and (B) 
show the effect of pH on HMW PECs prepared without and with frequency dispergation, 
respectively, while (C) and (D) display the response of LMW PECs.  Raw data are 
represented by squares, while the average of at least 3 replicates by circles and error bars 
corresponding to standard error.  The asterisks indicate means which differ from the 
reaction mixture at the 95% confidence interval using Dunnet’s Test. 
HMW 
LMW 
(B) 
(D) 
(A) 
(C) 
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                          - Dispergation                                     +Dispergation 
                                                                                                                 
Figure 3-6.  Response of PEC zeta potential in varied pH, low salt environments.  (A) 
and (B) show the effect of pH on HMW PECs prepared at without and with frequency 
dispergation, respectively, while (C) and (D) display the response of LMW PECs.  Raw 
data is represented by squares, while the average of at least 3 replicates by circles and 
error bars corresponding to standard error.  Asterisks denote zeta potentials that deviate, 
statistically, from the empirical stability criterion of |30 mV|, defined by dashed lines, 
according to a one-tail t-test at the 95% confidence interval.  Arrows indicate 
experimental pIs. 
 
The most interesting results were obtained for LMW PECs prepared with 
dispergation, as shown in Figures 3-5D and 3-6D.  Even though the zeta potential-pH 
curve exhibited a typical behavior, there appeared to be some intra-particle forces, which 
allowed the complexes to retain their dimensions even when the zeta potential neared 
neutrality.  The maintenance of hydrodynamic diameter may also be related to the 
presence and incorporation of Pluronic F-68, assumed to be a steric stabilizer with no net 
charge36. The long chains of flexible tri-block copolymer polyethylene 
oxide/polypropylene oxide (PEO/PPO), when adsorbed to the surface, could create an 
osmotic and entropic barrier to particle-particle interactions induced by pH alterations37.  
HMW (B) 
(D) 
(A) 
(C) 
LMW 
pI=5.89 
pI=5.76 
pI=5.79 
pI=5.90 
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Pluronic F-68 may discourage surface adhesion and conceivably inter-particle 
interactions.  Intimate blending of PEO/PPO polymers into core-shell nanomatrices has 
been shown to attenuate hydrodynamic diameter and enhance structural integrity38,39.  
The electrically neutral copolymer, composed of hydrophilic and bydrophobic segments, 
is mechanically entrapped when present in cationic bath.  The incorporation of PEO/PPO 
was possibly facilitated by the intermolecular bonding between electropositive amino 
hydrogens of the constitutive cationic polymers and the electronegative oxygens of 
PEO/PPO40.  The interaction between the oxygen atom of PEO/PPO and the amino 
groups of the corona solution is weak, but could still have an effect on PEC stability and 
formation.  The retention of ideal dimensions denotes the LMW dispergated formulation 
for biological application.  Preliminary in vitro testing has shown PEC stability in 
endothelial cell growth media (MCDB131, pH=7.4) supplemented with 10% fetal calf 
serum, supporting their use for specific cell binding and internalization applications.  The 
hydrodynamic diameter for this LMW nanoparticulate system was 235.9±30.5 nm 
(mean±standard error).  Although the size falls outside of the benchmark of less than 200 
nm, it is still expected to efficiently interact with biological systems.  In fact, it was 
statistically equivalent to the diameter at pH=7.4 (432.6±84.1 nm), as measured in Figure 
3-5(D), for a low salt buffer dispersion.  This increase in size is most likely due 
interactions with media components41.   
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Figure 3-7.  Schematic representation of PEC charge modification.  The left figures are 
the PEC suspensions immediately after preparation.  The native state has a surface 
dominated by excess cationic charge as shown by the significantly positive zeta potential.  
The presence of sufficient acid maintains a stable protonation state as shown in (A). As 
pH changes and nears the pI and neutrality, the ionizable states of the complexes are 
modified.  The decreasing total surface charge depletes the complexes’ ability to repel 
each other and they effectively coalesce, displayed by (B).  But, if adequate base is 
present, the carboxyl groups become ionized and the colloid remains stable as denoted in 
(C). 
 
Sufficient acid 
pINP<pH<7.6 
Sufficient base 
(A) 
(B) 
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Conclusions 
This work, through the use of TEM and PCS technology, shows the effect of 
polyanion size reduction on PEC physicochemical properties that are essential for 
developing a biocompatible system for targeted drug delivery.  As shown, the titration of 
nonstoichiometric amounts of HMW anions, compared to LMW anions for equivalent 
total molar charges, into cations formed larger complexes with marked size 
heterogeneity.  In addition, HMW formulations resulted in decreased physicochemical 
stability. A system has been further optimized for size and charge properties that are pH 
insensitive, making it a useful system for optimal delivery to a range of tissues.  The 
surface density of PEO/PPO may ensure sufficient steric stabilization, phagocytic 
resistance and prolonged systemic circulation38,39,42,43.   This new formulation is an 
improvement over a previous non-toxic system44-46 which has been shown to effectively 
deliver genes to cells of hematopoietic origin14. 
 The pH and serum insensitivity, self-assembly, modular nature, and unique 
polymeric architecture of dispergated LMW PECs allows for surface groups to be 
independently modified to impart desired characteristics without substantial alteration of 
existing properties.  The polycationic nature of the PEC periphery, predominantly 
polyamine and guanidinium moieties, may also facilitate their cellular uptake and 
transport via cell surface heparan sulfate proteoglycans or polyamine-based transport47-49. 
Taken together, the favorable characteristics of this system suggest that these PECs may 
be utilized as safe and highly efficient bioactive drug delivery systems.  This system was 
further applied in the following chapters to evaluate biological and protein 
release/incorporation properties.  
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CHAPTER IV 
 
 
 
ENTRAPMENT AND RELEASE PROPERTIES FOR LOW MOLECULAR WEIGHT 
NANOPARTICULATE POLYELECTROLYTE COMPLEXES 
 
 
 
Introduction 
 Proteins are often marginally stable and consequently easily damaged during their 
formulation as drugs. Nanoparticle and polymer delivery systems, first introduced by 
Langer and Folkman1 in 1976, have been developed which have the potential to improve 
protein stability, increase the duration of the therapeutic effect, and permit administration 
through non-parenteral, possibly oral, routes2.  Encapsulation of proteins within 
biodegradable polymers has been shown to enhance the half-life in vitro3,4 and in vivo4-6.  
It is critical to control the liberation of drugs entrapped in polymeric supports under 
defined pharmacological and physicological conditions.  Payloads can be delivered 
intracellularly in two ways:  internalization of the PEC followed by release inside or 
particle docking at the cell surface and liberation through a bystander effect7.  The release 
should when and where the drug is required and in the appropriate concentration for the 
desired therapeutic effect8. 
 Previous studies have investigated the drug releasing response from polymeric 
matrices as a function of pH9, electric field10, temperature11, ultrasound12, or light13.  
Several PEC systems8,14-18 have incorporated proteins and analyzed the release kinetics 
and entrapment.  PECs allow the loading of proteins by polyion coacervation between 
charged groups.  The purpose of the current study was to explore the protein loading and 
release for multi-component LMW PECs.  PECs were prepared with 3 different iodinated 
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proteins to trace their fate and address the effect of protein charge on entrapment and 
discharge in a simulated physiological environment under external sink release 
conditions:  100% fetal calf serum (FCS) was added after replacement of fluid at each 
time point.  Soybean trypsin inhibitor (STI), β-lactoglobulin (BLG), and cytochrome C 
(Cyt C) were selected because they have high water solubilities and a fairly wide range of 
isoelectric points (pI).  Radioactivity (I125) was chosen because isotopes do not quench 
which is a common problem for fluorescent tracers in combination with microplate 
readers.  The radioisotope also allowed for mass balance closure. 
 
Experimental Procedures 
 The protocols applied from Chapter II were as follows:  PEC Fabrication with 
LMW polyions at 20 kHz frequency dispergation, PEC Size and Zeta Potential, Protein 
Iodination, and PEC Protein Loading and Release Monitoring.  Equations 2-2, 2-3, 2-4, 
2-5, and 2-6 were used to analyze the release and loading measurements.  Additionally, 
the rate of release, RateREL, (µg/day) was calculated by Equation 4-1: 
    
  
 
where Masst=n, and Masst=n-1 were the mass of protein released over the specified time 
interval. 
 
! 
Rate
REL
=
Mass
t=n " Masst=n"1
t
n
" t
n"1
(4-1) 
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Statistical Analysis 
Statistical analysis was carried out with JMP-IN 5.1 (SAS, Cary, NC). Reaction 
mixture formulations and final preparations in FCS were compared by two-sample t-tests 
to evaluate the differences between sizes, zeta potentials, polydispersity indices (PDI), 
loading efficiencies, and 7 d retainment percentages.  All statistical tests were performed 
at p<0.05 (95% confidence level).  Results are displayed as average ± standard error. 
 
Results and Discussion 
 
 Measurement of Size, Zeta Potential, and Polydispersity Index 
 Sizes, polydispersity indices (PDI), and zeta potentials (ZP) of PECs with Cyt C 
(pI=10.8), STI (pI=4.5), and BLG (pI=5.1) loaded into the anion core were shown in 
Figure 4-1 for reaction (Rxn) mixtures and final formulations in FCS.  Isolation and 
resuspension in FCS led to an increase in hydrodynamic diameter and PDI, but a decrease 
in ZP.  Incorporation of protein and dissolution in FCS, in all cases, resulted in statistical 
changes for each physicochemical property.  Hydrodynamic diameter increased in FCS 
with sizes ranging from 252.4 nm (STI) to approximately 330 nm for Cyt C and BLG.  
The zeta potentials for PECs in FCS were similar in absolute magnitude, but the sign was 
reversed.  There was no visible aggregation in FCS, but these properties were likely 
influenced and altered due to the presence of heterogeneous serum particulates. 
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Figure 4-1. Physicochemical properties of the reaction (Rxn) mixture and final 
preparations, in 100% FCS, for multi-component PECs prepared with various proteins 
loaded into the anionic solution.  (A), (B), and (C) correspond to hydrodynamic diameter, 
zeta potential, and polydispersity index, respectively, measured by PCS. The double 
asterisks indicate means (Rxn Mixture versus Final) that differ statistically by two-
sample t-test at the 95% confidence interval (n=3). 
 
 
 Encapsulation Efficiency of STI, BLG, and Cyt C 
 The effect of proteins with different pIs on PEC loading is shown in Figure 4-2.  
The pH of the anionic solution before PEC fabrication was 6.85 meaning that STI and 
BLG were negatively charged, while Cyt C was net positive.  Assembly of PECs resulted 
in a pH of 4.2 due to excess cations, which reverses the charged state of STI and BLG. 
The encapsulation efficiency of 15 µg I125-labeled STI, BLG, and Cyt C was not 
dependent on the nature of the protein; all loading efficiencies were statistically 
(A) (B) 
(C) 
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heterogeneous and ranged from 6.0% (STI) to 7.4% for Cyt C and BLG.  The loading of 
proteins has been found to be largely dependent on several molecular and environmental 
parameters:  amount, molecular volume, polarity, charge, and degree of ionization19.  In 
this case, only the charge and degree of ionization was studied; none of which affected 
the incorporation.  
 
 
Figure 4-2.  Effect of protein on the protein entrapment efficiency (EE%) for PECs.  
Radioactive (I125) protein associated with PECs was measured after particle preparation, 
isolation by centrifugation and resuspension in 100% FCS, for n=3.  No statististical 
difference was indicated at p<0.05. 
 
 
 In Vitro Release Kinetics and Protein Retainment 
 The ability of PECs to release the protein over a sustained period of time is 
critical20.  Hence, a comparison of STI, BLG, and Cyt C loaded PEC release was carried 
out over the course of 1 week at room temperature (20°C), followed by the determination 
of the amount retained.  External sink conditions were applied which involved the 
replacement of the solvent gradient at every day. 
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 Figure 4-3(A,B) shows the percent cumulative release and release rate, 
respectively.  Figure 4-3(A) indicated a ‘burst’ release over the first 24 h and then a 
plateau leading to an irreversibly bound phase.  BLG-containing PECs exhibited a 43% 
loss of protein after 1 day, while STI and Cyt C showed 34% and 21% released over the 
same period.  These types of initial ‘bursts’ have been seen widely and, again, largely 
controlled by environmental (temperature, pH) and molecular variables (polymer 
molecular weight, internal cross-linking)20.  Protein release rates, Figure 4-3(B), showed 
that STI, BLG, and Cyt C demonstrated first-order release kinetics as a function of time 
and approached zero-order relationships at longer times (t=4d-7d).  BLG displayed the 
largest initial rate (0.42 µg/day) and Cyt C (0.24 µg/day), the lowest, which could be a 
consequence of more intimate charged interactions maintained over the first 24 h. 
 
 
Figure 4-3.  (A) In vitro, iodinated protein release from PECs and (B) rate of release, 
both measured over the course of 7 d (n=3). 
(A) (B) 
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 The protein discharge was modeled with an one-dimensional, empirical equation 
developed by Ritger and Peppas21 for Fickian and non-Fickian diffusional release 
(Equation 4-2), where Mt and Minf represented the masses of total protein released at time 
(t) and total amount of incorporated drug, respectively.  k was the correlation constant 
incorporating characteristics of the macromolecular network and n the diffusional 
constant which defined non-Fickian and Fickian activity regimes. Equation 4-2 is an 
expression derived from a heuristic solution of Fick’s second law.   Fickian diffusion 
would describe the change in concentration over time is equal in terms of changes in 
local diffusion flux22.  The diffusing species flux will follow a square root trend until an 
equilibrium is reached at long times (n=0.5).  Case II transport follows a zero-order 
kinetics where the release is independent of time and a nominal n equal to 1.  Anomalous 
transport processes do not fit either Fickian or Case II transport, but include sigmoidal, 
two-stage, and pseudo-Fickian  (n≠1, n≠0.5) mass transfer23 .     
 
 
 
The constants were determined experimentally by preparing a log-log plot which yielded 
a linear correlation with a slope of n and y-intercept of log k.  Table 4-1 shows the 
calculated n and k values for each protein, while Figure 4-4 the experimental and 
modeled data.  The units of k were day-n.  
! 
M
t
M
inf
= kt
n (4-2) 
 97 
Table 4-1.  Tabulated power law constants (average ±s.e., n=3) for STI, BLG, and Cyt C 
loaded PECs. 
 
 
Protein n k 
STI   0.33±0.01 0.25±0.04 
BLG 0.33±0.04 0.42±0.08 
Cyt C 0.20±0.03 0.32±0.03 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4.  Empirical modeling of release data based on Equation 4-2.  Points 
represented experimental data while solid lines were calculated based on the power law 
model. 
 
  
 The data modeled in Figure 4-4 confirmed that the release of protein was not 
controlled by strict Fickian diffusion as each n was less than 0.5 (Table 4-1).  Therefore, 
it can be concluded that I125-labeled protein does not follow a pattern which will 
eventually reach equilibrium.  The anomalous diffusion in this system may be 
confounded by polyelectrolyte exchange reactions between serum macromolecules and 
the loaded proteins or PEC degradation.  Regardless, the model appears to fit the data 
appropriately. 
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Further evidence that the amount of protein released does not reach Minf was seen 
in Figure 4-5.  Figure 4-5 displayed the amount of bound protein after 7 d.  Because the 
rates of release reached 0.02 µg/day, 0.01 µg/day, 0.02 µg/day for STI, BLG, and Cyt C, 
respectively, the formulations became a more controlled release depot, following the 
burst regime.  After 7 d, a significant amount of protein persisted:  54.77% (Cyt C), 
28.59% (BLG), and 44.33% (STI). 
 
 
 
  
Figure 4-5.  Percent protein remaining after 7 d release experiments.  No statistical 
difference was detected (p<0.05, n=3). 
 
 
Conclusions  
 Depending on their design, in vitro entrapment and release studies may be used to 
simulate the mechanistic release behavior and carrier-drug physicochemical relationship 
in vivo24.  The PECs in this study (LMW 20 kHz) showed interesting features as protein 
delivery systems.  PECs maintained appropriate physicochemical parameters for 
biological applications in physiological media (100% FCS), although charge reversal and 
some increase in hydrodynamic diameter were observed.  The complexes incorporate the 
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proteins, independent of their nature, under mild conditions in a water-soluble 
preparation.  The networks formed by PECs could entrap the proteins through 
intermolecular interactions and electrostatic forces between the proteins and the polyions.  
Unfortunately, the incorporation was relatively low due to the weak amphipathic nature 
of the proteins.  STI, BLG, and Cyt C cannot compete with stronger electotrolytes 
(PMCG, chondroitin sulfate, alginate, spermine) for sites in the complex, leading to 
eventual washout upon centrifugation.  According to the literature, alginate and 
chondroitin sulfate, constituents of the PEC core, are highly hydrophilic, owing to the 
presence of –OH, –COOH, and SO4 groups on the polysaccharide chains8, while 
spermine and PMCG comprise a hydrophilic outer shell.  Therefore, the entrapped 
proteins became sequestered outside of the inner core, but inside of the corona.  The 
incorporations were consistent with chitosan/PPO PECs developed by Calvo, et. al.14.  
The application of a more highly charged drug or protein would likely lead to higher 
entrapment levels19.  
 It was shown, through a simple power law model, that the release of STI, BLG, 
and Cyt C into 100% FCS exhibited anomalous, non-Fickian diffusion behavior.  This 
was not surprising since the PECs are multi-phase structures, whereby there could be 
release followed by re-adsorption to the surface or liberation into the external sink.  
Recently, Kamiya and Klibanov15, made an argument for PEC size and extent of release:  
larger complex diameter led to slower release.  PECs did not appear to adhere to that 
finding as the release profiles were independent of the hydrodynamic diameter.  
Additionally, because the PECs exhibited a burst release profile, they do not provide a 
good delivery system upon intravenous administration.  Further PEC processing, before 
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or after complexation, would have to be performed to further retain the protein to prevent 
the loss of the cargo.     In spite of the low entrapment efficiency and burst release, PECs 
are a still a promising candidate for drug delivery via a local application where the 
vehicles would be taken up by cells.  The drug could then be released by changes in the 
intracellular concentration gradients or through intrinsic enzymatic degradation of the 
PEC. 
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CHAPTER V 
 
FLOW CYTOMETRIC DETERMINATION OF NANOPARTICULATE 
POLYELECTROLYTE COMPLEX NON-SPECIFIC INTERACTIONS WITH 
ENDOTHELIAL CELLS 
 
 
 
Introduction 
Detailed mechanistic studies on binding and internalization of PECs, and 
nanoparticles for that manner, by cells have not been well characterized.  Multi-
component PECs, combined with Pluronic F-68 as a steric stabilizer, have been 
fabricated as a generic scaffold for incorporation of drugs and targeting moieties. We 
have developed a fluorescent approach, by application of a visible fluorophore, to 
describe the non-specific adsorptive mechanisms of nanoparticulate polyelectrolyte 
complex association in an endothelial cell (EC) model. 
EC were chosen as the model because of their importance in disease and 
pathlogical significance1.  EC line vascular systems:  capillary, vein, and artery networks 
through which the blood carries nutrients.  They are critical players in a number of 
pathological processes, many of which carry unique markers for targeted delivery:  
cancer (dysregulated angiogenesis), inflammation, oxidative stress, and thrombosis2,3.  
Moreover, and specifically related to cancer, solid tumors require access to blood vessels 
for growth and metastasis4. 
The use of fluorescently or radioactively labeled NP is the most common 
experimental approach found in the literature5-7.    Fluorescent labeling and fluorescence 
activated cell sorting (FACS) was chosen for the recent study to avoid radioactivity; 
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radioactive PEC components in this study were not currently available or the 
incorporation of an isotope was too cumbersome.  The limited toxicity and mechanisms 
of association are shown in the form of inhibitor studies.  A novel, flow cytometric 
Scatchard analysis was used to define the yield of the PEC production, nature of the 
binding and internalization, components ignored in all studies to date.  LMW PECs 
prepared with dispergation were applied because they met the engineering criteria 
defined in Chapter III. 
 
Experimental Procedures 
Various protocols were applied as defined in Chapter II.  LMW PECs were 
fabricated as described in PEC Fabrication, with 20 kHz frequency dispergation.  FITC 
was incorporated for fluorescence studies as per Polymer Labeling and Fluorescent PEC 
Preparation.  Physicochemical characteristics were characterized by TEM and PEC Size 
and Zeta Potential.  HMVECs were cultured as defined in Cell Line and Maintenance.  
Cytotoxicity was evaluated by PEC Effects on HMVEC-1 Proliferation.  Subsequent to 
fluorescent PEC preparation, various methodologies were applied:  Confocal Microscopy, 
Flow Cytometric (FACS) Detection of PEC/Cell Interactions, Saturation PEC-Cell 
Association Kinetics, PEC Acute Toxicity by Propidium Iodide (PI), Treatment of Cells 
with Various Inhibitors, Particle Counting, and Scatchard Plots. 
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Statistical Analysis 
Statistical analysis was performed using JMP-IN 5.1 (SAS, Cary, NC). Reaction 
mixture formulations and final preparations in cell growth media were compared by two-
sample t-test to evaluate the differences between sizes, zeta potentials, and polydispersity 
indices (PDI).  One-way ANOVA was used to compare cell proliferation data with 
controls (PEC-free exposures) while one-tail t-tests were applied to analyze statistical 
deviations of inhibitor responses from controls.  All statistical tests were performed at 
p<0.05 (95% confidence level).  Results are displayed as average ± standard error. 
 
Results and Discussion 
 
PEC Physicochemistry  
The non-stoichiometric titration, under 20 kHz frequency dispergation, of the 
anions chondroitin sulfate and sodium alginate into a multi-component cation bath, 
containing Pluronic F-68, led to the spontaneous assembly of cationic nanoparticulate 
complexes. Physicochemical attributes, hydrodynamic diameter and zeta potential, were 
assessed by photon correlation spectroscopy (PCS), while morpohological properties by 
TEM.  As shown in Figure 5-1(A-C), particles in their native reaction (Rxn) mixture had 
a mean diameter, of 164.6 nm, a polydispersity index of 0.199, and were positively 
charged (34.7 mV).  The significant zeta potential was indicative of a stable colloidal 
suspension as has been pragmatically defined8-10.  TEM images, represented in Figure 5-
1(D), showed that the complexes were spherical in nature and had a mean diameter of 
141.5 nm, averaged over several separate micrographs and observations (n=1484), 
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resulting in an 86% agreement (TEM/Malvern).  This finding was consistent with results 
from Chapter III. 
  
 
Figure 5-1.  Physicochemical properties of the reaction (Rxn) mixture and final 
preparations, in EC media, for multi-component PECs.  (A), (B), and (C) correspond to 
hydrodynamic diameter, zeta potential, and polydispersity index, respectively, measured 
by PCS.  (D) is a representative TEM image.  Asterisks indicate means that differ 
statistically by two-sample t-test at the 95% confidence interval. 
 
PEC isolation and resuspension in endothelial cell growth media (MCDB 131), 
before HMVEC-1 exposure, led to an increase in size and PDI, and a decrease in zeta 
potential as shown in Figure 5-1(A-C).  Two-sample t-tests did not indicate a statistical 
difference in size, but did for surface charge and PDI (p<0.05).  In addition, a one-way t-
test did not show any significant difference between the measured hydrodynamic 
(A) (B) 
(C) 
(D) 
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diameter and 200 nm, the empirical benchmark for efficient cellular uptake11-13.  The 
change in PDI was likely due to the presence of serum particles and proteins, which have 
intrinsic light scattering properties detected by PCS.  Alterations in PEC surface charge 
were attributed to changes in the extent of ionization of surface groups14 and the 
protrusion of ionized, core hydroxyl groups15.  Contributions to electrophoretic mobility 
were also due to the presence of serum particulates. The preservation of hydrodynamic 
diameter may be related to the presence and passive entrapment of Pluronic F-68, added 
to provide steric stabilization16, but has also been found to improve PEC-mediated gene 
transfer.  When adsorbed to surface the polymer could create osmotic and entropic 
barriers to particle-particle interactions and discourage adhesion of electronegatively 
charged serum molecules resulting in maintenance of structural integrity17,18. 
 
Determination of PEC Number by Flow Cytometry 
 Flow cytometry was used to evaluate the concentration of PECs.  This method 
was used for Scatchard analysis and for toxicity titration by MTT reduction.  Such a 
method would be less intensive and more accurate than an electron microscope-based 
technique where extrapolations based on Poisson distributions are necessary.  Therefore, 
serial dilutions of NIST traceable fluorescent nanospheres (stock=2.3x1012 beads/ml, 200 
nm nominal diameter) were prepared, diluted and processed using a FACSAria 
cytometer. This was important so that free PECs could be delineated from cell bound.  As 
beads moved at a constant flow rate through the detector (SSC and FSC PMT), events 
were counted and recorded until 60 s passed.  Dot plots of FSC versus SSC showed very 
little overlapping populations between 200 nm beads, FITC-labeled PECs, and HMVECs 
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as exhibited by Figure 5-2(A-C).    The number of events was then divided by the time 
elapsed comprising the ordinate of the calibration.  The quantity, threshold events per 
second, was then plotted against bead concentration, as in Figure 5-2(D).  In an 
analogous approach, one batch of FITC-PECs was prepared and suspended in 1 ml of 
standard MCDB 131.  This suspension was then diluted, arbitrarily, over 4 logs of 
concentration and the number of PECs was collected for 60 s.  This allowed a linear 
range from concentrations 1.54x109 to 9.80x106 PEC/ml, corresponding to a 1:20 and 
1:10000 dilutions, respectively, as shown in Figure 5-2(E,F).  Suspensions at lower 
dilutions (1:10, 1:5) resulted in concentrations, which were less than 1.54x109 PEC/ml 
related to saturation of the detector or aggregation due to a decrease in particle interstitial 
space.  Similar behavior was observed for the bead standards after an upper level of 
2.30x109 bead/ml was reached.  
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Figure 5-2.  Evaluation of PEC concentrations by flow cytometry.  FACS anlysis of (A) 
NIST traceable fluorescent green beads and (B) multi-component PECs suspended in 
HMVEC growth media; (C) gating of HMVECs showed little or no overlap between 
cellular and PEC gates, while PECs and 200 nm bead share similar FSC and SSC 
scattering.  (D) was the calibration (detected events v. bead concentration) generated for 
various dilutions of NIST beads.  (E) measured detected events versus arbitrary PEC 
dilutions per batch, while (F) calculated the concentration of PECs based on the bead 
standardization.  Error bars are the standard error for n=3. 
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Cytotoxicity 
 Multi-component PEC system biocompatibility was tested by MTT reduction and 
propidium iodide (PI) internalization.  Confluent HMVECs were seeded to 48 well plates 
(25000 cell/well) 24 h previous to PEC exposure.  Responses to PEC doses were 
compared to cells cultured in the absence of particles (untreated control=100%).  As 
shown in Figure 5-3(A), concentrations ranging from 400 to 60000 PEC/cell did not 
cause any statistical changes in MTT reduction as verified by one-way ANOVA and 
Dunnet’s Test.  For PI staining, Figure 5-3(B), HMVECs were exposed to 1.54x109 
PEC/ml, detached, and, over two hours, no change in viability was detected. The wide 
span of limited cytotoxicity validated this PEC system as a candidate for drug delivery to 
endothelial cells. 
 
Figure 5-3.  Relative toxicity profiles, chronic and acute, for multi-component PECs by 
(A) MTT reduction after 72 h incubation over various serial dilutions and (B) PI staining 
at a fixed concentration of particles (1.54x109 PEC/ml).  Statistical testing by one-way 
ANOVA showed no difference amongst samples, while Dunnet’s test showed that each 
mean was statistically the same as the control (no PECs), p<0.05.  Data are means of at 
least 3 experiments (mean±s.e.)  
 
 
 
(A) (B) 
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Suppression of Extracellular Fluorescence by Trypan Blue 
 The ability of trypan blue to abolish free FITC was evaluated by addition to a 
suspension of FITC-PMCG PECs.  This was critical to define intracellular fluorescence 
by FACS and has been previously applied19-23, as trypan blue is excluded from viable 
cells.  Figure 5-4(A) displayed the decrease in FITC distribution and complete shift from 
before (blue) and after (red) addition of trypan blue to a 200 µl suspension of 1.54x109 
PEC/ml in a 1:1 volumetric ratio.  Figure 5-4(B) represented the mean of three separate 
FITC PECs before and after trypan blue.  The mixing of trypan blue with the suspension 
of FITC PECs resulted in a 98% suppression in median fluorescence.  In terms of 
fluorescence, the medians dropped from 6142 a.u. (TB+) to 130 a.u. (TB-).  These 
experiments validated the use of trypan blue to characterize compartmentalization 
(surface versus inside) of multi-component PECs. 
 
 
Figure 5-4.  Suppression of free FITC via addition of trypan blue.  (A) and (B) establish 
the concept of using trypan blue to quench extracellular fluorescence.  Addition of 0.4 
mg/ml trypan blue completely abolished the fluorescence (A) of free PECs in suspension 
in the absence of cells where blue and red were the distributions of fluorescent events 
before and after exposure to trypan blue, respectively.  Histograms (B) and distribution 
(A), are the means ±standard error for three independent experiments and PEC 
preparations. 
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Kinetics of PEC Binding and Uptake:  Tryptic Degradation of Interactions 
 FACS tracked the binding and uptake of FITC-containing PECs in HMVECs, 
cultured in serum-containing media, at various intervals up to 2 h.  Exposure was 
followed by detachment by EDTA and the signals were expressed as median fluorescence 
in Figure 5-5(A,B) for both compartments (surface and internal).  The surface bound 
phase was calculated by, first, measuring the total fluorescence bound, followed by 
subtraction of the trypan blue quenched signal.  Figure 5-5(A) and 5-5(B) both indicated 
that particle binding and uptake was rapid and increased with the incubation time, despite 
the negative measured zeta potential in MCDB 131; shifts in fluorescence were seen as 
early as addition of PECs and immediate removal and washing (t=0).  However, both 
curves showed a plateau effect, due, possibly, to limited saturation24,25.  PEC association 
was also observed in mouse fibroblast (CRL-10225 and NIH3T3), CHO, CT26 colon 
carcinoma, primary human endothelial, macrophage, and hepatocyte cells. 
 Because the attachment and internalization appeared to reach saturation, the 
process was speculated to be receptor-mediated to some extent26,27.  The particles are not 
likely to be phagocytosed due to the hydrodynamic diameter28.  Even though the bulk 
surface charge was negative, microdomains of positive charge largely contribute to the 
attachment of PECs. PECs, in the absence of any targeting ligand, likely interacted with 
HMVEC through electrostatic interactions, particularly through PMCG.  PMCG, 
guandinium rich, induced PEC electrostatic adsorption via cell surface bidentate 
hydrogen bonding to distal polyanionic residues29,30.  Visual evidence of PEC/cell 
interactions, FITC-PECs were incubated with HMVECs for 2 h and observed by confocal 
laser scanning microscopy (CLSM).  Figure 5-5(D,E) showed evidence of perinuclear 
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accumulation of PECs (green), while CLSM z-sectioning indicated that PECs were in the 
same plane as cells. 
 Figure 5-5(C) indicated the tryptic degradation of PEC association, necessitating 
the use of EDTA as the cell monolayer removal method.  This type of study is commonly 
ignored in the literature that considers nanovehicle interactions with cells5,21,31-35. The 
tryptic proteolysis of the PEC association was analyzed by exposing HMVEC to FITC-
labeled complexes for 30 min followed by either detachment by 0.25% trypsin/0.1% 
EDTA or 5 mM EDTA in HBSS, pH=7.6. Trypsin decreased the total amount of surface 
bound and internalized PECs, compared to cells detached by EDTA.  PECs showed a 
60% reduction in surface attachment and a 40% decrease in internalization, both 
statistically significant (p<0.05) to cells removed by EDTA.  The result suggested that 
cellular surface proteins were involved in binding and uptake.  This treatment, which 
strips HSPG36, showed evidence that PEC associative properties may depend partially on 
HSPG, but does not address the dependence on calcium. 
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Figure 5-5.  Overall PEC association kinetics and trypsin sensitivity for HMVECs.  
Kinetics of rapid binding (A) and internalization (B) for 2 h PEC exposure measured by 
FACS showed a phenomena which appeared to be saturable (n=3).  The 30 min binding 
and uptake (C) were also sensitive to tryptic detachment (p<0.05, n=3) necessitating the 
use of EDTA in all in vitro experiments.  A one-sample t-test was applied to compare 
trypsinized samples to EDTA treated (control).  Confocal laser scanning microscopy 
imaging of PECs (green) incubated with HMVEC-1 for 2 h. (D) and (E) represented two 
separate fields of view. Complexes were incubated with HMVECs for 2 h and a 
perinuclear accumulation was observed qualitatively verifying FACS experiments.  
Nuclei were stained with TOPRO-3 (violet).   
 
(A) (B) 
(C) 
(E) (D) 
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PEC Association and Energy Requirement 
 The involvement of energy, both thermodynamic and metabolic, was probed by 
incubation at reduced temperature (4°C) and media addition of 0.05% sodium azide/50 
mM 2-deoxyglucose, respectively.  Prior to addition of PECs, cultures were pre-
incubated at 4°C for 1 h.  PECs were then dispensed and further incubation at 4°C 
proceeded for 30 min.  Exposure to 0.05% sodium azide/50 mM 2-deoxyglucose in 
MCDB 131 also elapsed 1 h previous to PEC exposure, followed by addition of particles 
in the presence of inhibitor for 30 min.  In both cases, cells were detached following the 
30 min exposure level by EDTA and analyzed by FACS; controls were HMVECs with 
PECs at normal incubatory conditions.  Incubation with these two inhibitors resulted in 
the largest decreases in uptake signifying energy’s important role in PEC intracellular 
transport. 
 Incubation of PECs at 4°C, (Figure 5-6, black) showed significant, statistical 
reduction in both binding and internalization after 30 min, compared to the control.  
Reduced temperature is a classical endocytosis and active transport inhibitor, where only 
passive PEC membrane fusion occurs.  Therefore, the results indicated the dependence of 
thermodynamic energy for dynamic PEC uptake6.  Additionally, decreased temperature 
reduces the motility of surface protein groups and the diffusion of PECs to the cell 
boundary.  There was not a complete shutdown in the endocytosis; internalization 
decreased 80%.  This was due to the presence of the basic surface molecule PMCG; 
integration of PECs into the plasma membrane and the cytosol was different than the 
process that occurs at 37°C, consistent with data on the internalization of arginine-rich 
peptides37. 
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 Further evidence of an energy-dependent adsorptive process was shown by 
incubation of cells with sodium azide/2-deoxyglucose, an inhibitor of glycolysis, (Figure 
5-6, gray) both before and during PEC exposure.  The decrease in bound (-55%) and 
internalized (-70%) PECs was statistically significant (p<0.05) through a mechanism 
mediated by depletion of ATP and membrane potential27,30.  This response provided 
further proof that PEC attachment and endocytosis was a dynamic process that begins 
with adsorptive fusion with the cell membrane38. 
 
Figure 5-6.  Energy mediated PEC internalization and binding.  The dependence on 
metabolic and thermodynamic conditions was evaluated by incubation with 2-
deoxyglucose (gray) and reduced temperature (black), respectively.  Statistically 
significant differences were seen at the 95% confidence interval for surface attachment 
and uptake (n=3).     
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Actin Disruption 
 The role of filament networks in binding and endocytosis was studied by addition 
of 10 µM cytochalasin D, found to sufficiently inhibit actin polymerization, thus blocking 
phagocytosis and pinocytosis37.  Cells were pre-treated with cytochalasin D for 2 h, at 
standard incubatory conditions, followed by PEC exposure for 30 min.  Figure 5-7 
showed statistical effects for (-58%, p<0.05) only the internalization of PECs.  This result 
would indicate the role of the actin cytoskeleton during endocytosis and was consistent 
with other studies5,23,37. 
 
Figure 5-7.  Actin facilitates the internalization of PECs.  Preincubation of HMVEC with 
10 µM cytochlasin D for 2 h statistically inhibited particle uptake, but not binding (one-
sample t-test p<0.05).  Data are the average of 3 replicates with error bars corresponding 
to standard error.    
 
 
Heparin and Heparan Sulfate Proteoglycans (HSPG) Affect PEC Transport   
The function of HSPG in PEC transport was characterized by two methods.  The 
first approach was competitive inhibition of PEC binding by adding the exogenous, 
anionic glycosaminoglycan heparin to the media before (2 h) and during (30 min) PEC 
exposure.  Biosynthesis of HSPG was perturbed by the 24 h incubation with 500 µM 4-
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nitrophenyl-α-xylopyranoside (α-xyl) or 4-nitrophenyl-β-xylopyranoside (β-xyl) 
overnight, where β-xyl disrupts HSPG elongation39,40.  The overnight treatment was 
followed by PEC introduction for 30 min. 
Addition of heparin, 200 U/ml, to the media containing PECs almost completely 
abolished cellular interactions, Figure 5-8(A), consistent with previous data using lipo- 
and polyplexes41.  Surface binding was reduced (93%), while internalization diminished 
by 58%.  Both effects were statistically significant.   Heparin, because of its highly 
anionic nature and as a HSPG mimetic, non-specifically adhered to the complexes, 
causing the neutralization of positively charged groups on the PEC corona; prospective 
cell binding sites were masked.  The neutralization was possibly followed by 
destabilization of complexes in solution preventing cell binding and entry42.  The 
destabilization simultaneously could have caused an increase in size, another obstacle for 
efficient PEC delivery43. 
Incubation with a HSPG biosynthesis inhibitor, β-xyl, supported the hypothesis 
that membrane-associated HSPG partly mediated the attachment and internalization of 
PECs, as shown in Figure 5-8(B).  HMVECs were incubated with either 500 µM β-xyl or 
α-xyl 24 h previous to PEC exposure.  After which, the cells are washed and PECs were 
added for 30 min. The two xylosides have the same molecular weight, but only the beta 
isomer competes with the proteoglycan core protein xylosyl residues for the 
galactosyltransferase I, inhibiting the construction of glycosaminoglycans.  The depleted 
HSPG by, addition of β-xyl, led to a 47% reduction in surface PEC binding compared to 
the control.  Exposure to the α-xyl isoform led to no statistical deviation in binding and 
uptake compared to the control, as expected.  Internalization was not statistically affected 
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for either xylopyranoside, although β-xyl did show an obvious decrease and possible 
HSPG role in endocytosis. The remaining portion of binding may be non-specific and 
electrostatic, but also due to sufficient amount of HSPG that persisted.  This result was in 
agreement with results published for cationic polyamines40 and DNA-loaded liposomes44. 
 
Figure 5-8.  HSPG dependence on cell binding.  (A) shows the competitive inhibition of 
attachment and binding by incubation of cells with PECs and 200 U/ml heparin.  (B) 
displays the role of HSPG in PEC binding.  HMVEC were 24 h pre-incubated with either 
4-nitrophenyl-α-xylopyranoside (α-xyl, black) or 4-nitrophenyl-β-xylopyranoside (β-xyl, 
gray), where the α-isomer does not inhibit HSPG biosynthesis.  Only the surface binding 
differed statististically from the control (p<0.05, n=3). 
 
 
Non-Specific Binding Verified by Scatchard Plots 
Using FITC-labeled PECs, a FACS-based Scatchard equilibrium experiment for 
the detection and characterization of non-specific binding was developed for titrations 
performed at 37°C and 4°C.   The conventional binding curves are shown in Figure 5-
9(A,B).  Scatchard titrations were prepared by exposing HMVEC-1 cells to serial PEC 
dilutions over 3 orders of magnitude, over the concentration range tested for toxicity by 
MTT, for 3 hours at 37°C and 4°C.  Efforts were made to cover as wide a range of PEC 
concentrations as possible and to carry the measurements to the highest allowable 
(A) (B) 
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concentrations by solubility and practical circumstances, i.e. PEC aggregation.  The ratio 
of PECs added to initial cell density ranged from 32000:1 down to 200:1; proportion of 
PEC bound to initial cell density varied from 30000:1 to 5:1, both of which were 
calculated experimentally.  The time was defined by the kinetic experiments, Figure 5-
5(A,B), and the FACS acquisition performed on a FACSAria system fitted with a 
photomultiplier tube on the forward scattering laser for more sensitive detection of cell 
bound PECs. The exposure was followed by detachment, acquisition of MFI, and 
conversion of bound (total associated fluorescence) indices to particle concentrations.  
This was possible after calibration of our ~200 nm PECs with known concentrations of 
NIST-traceable beads.  The approach allowed the Scatchard transformation (bound/free 
versus bound) and also provided a verification of non-specific, adsorptive binding seen in 
kinetic experiments shown in Figures 5-9(C,D) for incubations at 37°C and 4°C, 
respectively. Also it was the first such FACS based Scatchard representation of non-
specific interactions of a polymeric drug delivery system.    
In both cases, the binding isotherms, Figure 5-9(A,B) form the lower half of the 
standard S-curve saturation seen in steady-state experiments; there was no apparent 
saturation of cell surface receptors interacting with PECs.  However, the curves never 
approach saturation. The data transformations for Figure 5-9(C,D) showed an inverse 
relationship for the apparent binding constant due to extensive cooperativity, an atypical 
response in Scatchard plots. In many documented in vitro binding experiments, the initial 
positive slope goes to a maxima followed by a monotonic decrease in slope as the total 
ligand increases in concentration45-48.  Similar behavior to Figure 5-9(A,B) has been 
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observed in human serum albumin binding49,50, but no inflection point was observed in 
this study.  
 
 
Figure 5-9.  PECs exhibit non-saturable binding and positive cooperativity for 3 h at 
37°C and 4°C.  Incubations for (A) and (C) were performed at 37°C, while (B) and (D) at 
4°C.   (A) and (B) are dose-dependent binding curves. (C) and (D) represented Scatchard 
plot analysis.  Curves were determined by flow cytometry (n=3).  The ratios of bound and 
free PECs for each concentration were determined based on the MFI of each dose in the 
absence of cells, followed by correlation to calibration curves determined as in Figure 5-
2.   Y-error bars represent the average ± s.e. in calculated bound PECs, while X-error bars 
are the free PEC concentration ± s.e.  by difference between initial dose and bound.  
 
 
 
 
 
(A) (C) 
(B) (D) 
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Conclusions 
 This study provides a comprehensive study of naked PEC interactions with 
endothelial cells in vitro through the use of applications ideally suited for nanoscale 
system:  PCS and FACS.  Effective delivery of PECs is of paramount significance for the 
development of systems that target the vascular endothelium, the nutrient supply line for 
tumor environments2.  While many of the current PEC delivery systems have focused and 
reported on gene delivery51-54, there has been little focus on the process of PEC 
interactions that occur before the expression of DNA.  Therefore, in order to improve 
polyelectrolyte drug delivery systems, it is critical to understand the mechanisms and 
barriers for successful interactions with target cells. 
 The architectures described herein provide a media-stable, core-shell 
nanoparticulate structure with physicochemical properties ideal for use in vitro.  PCS 
measurements provided proof that instantaneous complexation of oppositely charged 
polyelectrolytes led to nanoparticle structures with ~200 nm hydrodynamic diameter and 
robust serum stability, verified by no statistical change in size after isolation and 
resuspension, appropriate for systemic delivery.  Moreover, the presentation of outer shell 
amine groups may allow the presentation of ligands for targeted accumulation in disease 
sites.  A lack of long term cytoxicity was first demonstrated by MTT, while short term 
effects diagnosed by no intercalation of PI with DNA for concentrations of PECs that 
were orders of magnitude larger than the cell population.    
 The incorporation of a fluorescently-labeled polymer constituent allowed the use 
of flow cytometry to evaluate cellular interactions.  Through the use of trypan blue, flow 
cytometry can distinguish between surface associated and internalized PECs.  This 
 124 
facilitated the understanding cellular compartmentalization of PECs without cell lysis, a 
method commonly used in other studies25,38,55,56.  Initial binding and internalization 
studies showed that the associative phenomena were saturable and sensitive to proteolytic 
enzymes.   
The mechanisms of PEC attachment and entry were further probed through the 
use of various inhibitors at concentrations and levels prescribed in the literature:  
cytochalasin D37,57, azide/2-deoxyglucose27, reduced temperature5, exogenous 
heparin42,43, and two xylopyranoside enantiomers39.  No data exists to date on the specific 
mechanisms of PEC uptake, although liposomes have been found to be endocytosed5,58,59.   
The use of reduced temperature and depletion of cellular ATP by azide/2-
deoxyglucose slowed uptake and binding.  This would indicate that both active processes 
are energy-dependent.  However, some residual attachment and internalization persisted 
in an energy-independent manner, indicative of a process other than endocytosis.  
Transduction, or direct PEC entry, may contribute to this portion of the internalization 
after diffusion of complexes to the cell surface60.  PMCG, a polymer with repeating 
guandinium residues and structural similarity to arginine resides likely facilitated 
penetration across the plasma membrane61,62. This result was consistent with a previous 
finding for DNA complexed with a sequence of the HIV-Tat protein63. 
The inhibition of uptake by cytochalasin D identified the role of macropinocytosis 
and non-clathrin, non-caveolae dependent endocytosis in the trafficking of PECs to the 
cell interior.  Macropinocytosis is lipid raft-mediated with macropinosomes often larger 
than 1 µm and dependent on cytoskeletal rearrangements64.  Clathrin and caveolae 
dependent endocytosis rely on clathrin coated pits (~120 nm) or caveolae invaginations 
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(~60 nm), respectively65.  The PEC system applied in this study had hydrodynamic 
diameters consistently around 200 nm making them too large for the latter processes. 
There is increasing evidence that HSPGs play a role as cellular entry gateways for 
positively charged molecules and synthetic delivery vehicles.  It has already been 
reported that HSPG facilitate the entry of polyamines and cationic liposomes7,42. HSPG 
biosynthetic inhibition of cell-associative properties by 4-nitrophenyl-β-xylopyranoside 
further verified the role of macropinocytosis66.  Interactions between HSPG and PECs 
carrying very cationic chemical groups are inevitable because the anionic cell surface 
proteoglycans encompass the entire cell surface67.  The remaining amount of PECs bound 
suggests that, apart from HSPG, there are other cell surface receptors, possibly sialylated 
glycoproteins or glycolipids, that may account for PEC attachment.  
Because HSPGs, in the form of syndecans and glypicans, are involved in 
adhesion, migration, and cytoskeletal organization, it was no surprise that the inhibition 
of HSPG binding coordinated with actin microfilament affected uptake.  Cytoplasmic 
tails and actin filaments are connected inside the cell through linker proteins.  Therefore, 
binding to adhesion receptors provides the initial step for particle engulfment mediated 
by membrane rufflings caused by networks of cortical actin fibers29. 
The evaluation of nanoparticle concentrations, in terms of PEC/ml, allowed the 
determination of binding isotherms and Scatchard transformations for multi-component 
PECs.  Scatchard plots are largely ignored for polymeric drug delivery systems, but 
characterizations of the type of binding occurring in biological systems is critical for the 
development of target-specific nanovehicles.  Non-specific PEC binding was further 
verified by the shape of the Scatchard plots.  Independent of temperature, the curves have 
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positive slopes, where PECs bind to a heterogeneous group of receptors with 
cooperativity. Because PECs are not hard objects, their amorphous nature leads to 
conformational flexibility and adaptability, further facilitating the cell association.  The 
positive slopes have been interpreted to indicate possible cooperativity and interaction 
with multiple binding sites and do not lend themselves to the analyses generally 
performed with typical Scatchard curves in terms of calculation of binding parameters68.  
The positive cooperativity would suggest that the binding of one PEC to any receptor on 
the cell surface created an energetically favorable site for another PEC. 
Mathematically, the total concentration of bound PEC, [Bound], to a single class 
of receptors can be defined by the Michaelis-Menten equation below: 
 
where [LFree], [Rtotal], and Kd the concentration of free PEC (ligand), total receptor 
concentration (constant), and equilibrium binding constant, respectively.  In the case of 
the naked PECs, the free ligand was at concentrations much lower than the Kd, leading to 
a linear relationship between bound and free PECs with a slope of Rtotal/Kd.  Breakdown 
in mass action laws may also be a contributing factor to PEC binding:  receptor 
heterogeneity, cooperativity, and irreversible binding.  PECs bind promiscuously to any 
receptor on the cell surface, as shown by PECs in the presence of depleted HSPG.     
 Brodersen and coworkers49 argue that if the interactions were saturable, the 
binding isotherm should have an inflexion point indicating the existence of such a limit.  
PECs appeared to bind cells without the possibility of displaceability, likely until 
effective charge neutralization between the anionic cell surface (functioning only as a 
! 
[Bound] =
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Free
]
K
d
+ [L
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]
(5-1) 
 127 
charged entity) and cationic microdomains of the PEC, but saturation does not appear to 
be possible. 
In conclusion, when considering the binding and internalization mechanisms of 
PECs, the particular types of interactions must be considered for developing effective 
targeting approaches. Additionally, systems must be non-toxic both in cell culture and 
upon systemic administration and have physicochemical characteristics to facilitate 
cellular uptake.  For multi-component PECs, HMVECs showed no appreciable toxicity 
and are internalized through non-specific macropinocytosis.  The binding and association 
was deemed totally non-specific by a combinatorial FACS and Scatchard design.  The 
system presented in this study further provided a platform which can be subsequently 
modified for a targeted delivery approach due to its favorable physical attributes and 
rapid intra- and extracellular accumulation.  Classical methods, like the Scatchard plots, 
combined with more current technologies, FACS, are critical for the further design and 
application of nanoscale delivery architectures.  Meeting requirements such as low 
cytoxicity and significant uptake into a target cell line, this system provides a promising 
candidate for further development and study.  Moreover, the chemical nature and 
presence of common functional groups (carboxyls and amines) allows for simple 
incorporation of small drugs or non-viral payloads and targeting vectors.    
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CHAPTER VI 
 
 
 
ENHANCED BINDING TO ENDOTHELIAL CELLS BY TARGETED 
NANOPARTICULATE POLYELECTROLYTE COMPLEXES 
 
 
 
Introduction 
 The site-specific delivery to cells or organs is a potentially attractive mode of 
treatment for increasing the therapeutic efficiency of drugs and reducing their toxicity1.  
Several strategies have been developed to employ specific ligands that interact with the 
endothelial cell (EC) surface to mediate delivery of drugs selectively to the tumor 
microenvironment without affecting normal tissue2-4.  Tumor vasculature targeting is a 
promising strategy, as both primary tumor maturation and metastasis depend on the 
survival and growth of new blood vessels, termed angiogenesis.  Additionally, intimate 
contact with the blood makes the tumor endothelial cell a uniquely accessible target 
within the tumor5.  Extensive research has led to the identification and isolation of several 
regulators of angiogenesis, some of which represent therapeutic targets6,7. 
 EC in the angiogenic vessels are known to overexpress several markers, which are 
either barely detectable or entirely absent in normal blood vessels8-11.  A number of 
extracellular matrix molecules possess sites that interact with the tumor endothelium and 
play key roles in the regulation of angiogenesis12.  Anti-angiogenic strategies have 
evolved that utilize this strategy, but the affinity and specificity of this interaction can be 
used as part of a targeting approach13,14.  One such molecule, thrombospondin-1 (TSP-1) 
is a large glycoprotein composed of three identical subunits, which are covalently linked 
by interchain disulfide bonds and has intrinsic antiangiogenic activity15. 
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TSP-1 has been proposed to play a role in numerous biological processes 
including embryonic development, angiogenesis, and hemostasis16,17.  The ability of TSP-
1 to regulate these processes has been attributed to its capacity to bind to matrix proteins, 
proteinases, growth factors, and cell surface receptors through specific domains.  The 
receptor-mediated binding and endocytosis of TSP-1 is controlled by heparan sulfate 
proteoglycans (HSPGs)18, cell surface receptors which are recognized by metastatic 
tumor cells upon their binding19, and overexpressed in tumor milieu20-23.  Further clinical 
use of TSP-1 is inhibited by the inability to synthesize large quantities of pharmaceutical 
grade protein and potentially off target side effects12.  However, peptide sequences 
derived from certain TSP-1 domains show antiangiogenic activity and mimic the function 
of the intact macromolecule with high affinity binding.  One such peptide (TSP521) 
specifically binds HSPGs and has been shown to target the vasculature of an 
experimental glioma model24.   It also has been shown to impede the translocation of 
fibroblast growth factor-2 (FGF-2) to its tyrosine kinase receptor, resulting in inhibition 
of cell proliferation25.  These properties led to the selection of TSP521 as a potential 
neovascular targeting platform. 
 Significant effort has been devoted to develop novel, nanoparticulate polymeric 
carriers for targeted drug delivery to specific cells and especially the tumor vasculature26, 
many of which were listed in Chapter I.  The development of pH and serum stable LMW 
PECs, prepared with frequency dispergation, in Chapter III, followed by their biological 
characterization and rapid cellular uptake (Chapter V), lend themselves as candidates for 
incorporation of TSP521.  Two methods of incorporation of TSP521 were applied 
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followed by fluorescence techniques to evaluate peptide loading and study the cellular 
interactions with human microvascular endothelial cells (HMVECs):   
•  passive entrapment after TSP521 conjugation to polyethylene glycol 
(PEG) to achieve both a geometric and flexible presentation27, decreased 
susceptibility to circulatory proteolytic enzymes, and improved 
phamacokinetic properties28 
• direct, covalent coupling by 1-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide (EDAC)/N-hydroxysuccinimide (NHS) two-step, zero-
length cross-linking29 of the aspartic acid carboxylic acid to surface PEC 
amines. 
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Experimental Procedures 
Many procedures were applied as defined in Chapter II.  LMW PECs were 
fabricated as described in PEC Fabrication, with 20 kHz frequency dispergation.  FITC 
was incorporated for fluorescence studies as per Polymer Labeling and Fluorescent PEC 
Preparation.  Physicochemical characteristics were characterized by PEC Size and Zeta 
Potential.  HMVECs were cultured as defined in Cell Line and Maintenance.  
Cytotoxicity was evaluated by PEC Effects on HMVEC-1 Proliferation.  Subsequent to 
fluorescent PEC preparation and Incorporation of TSP521:  Direct Surface Coupling and 
Passive Entrapment, various methodologies were applied:  Flow Cytometric (FACS) 
Detection of PEC/Cell Interactions, Saturation PEC-Cell Association Kinetics, Treatment 
of Cells with Various Inhibitors, and Scatchard Plots.  Compartmentalization (surface 
bound versus internalized) was analyzed by extracellular FITC quenching with trypan 
blue. 
 
Statistical Analysis 
Statistical analysis was performed using JMP-IN 5.1 (SAS, Cary, NC).  Final 
preparations, with and without TSP521, in cell growth media were compared by two-
sample t-test to evaluate the differences between sizes, zeta potentials, and polydispersity 
indices (PDI).  One-way ANOVA was used to compare cell proliferation data with 
controls (PEC-free exposures) while one-tail t-tests were applied to analyze statistical 
deviations of inhibitor responses from controls.  All statistical tests were performed at 
p<0.05 (95% confidence level).  Results are displayed as average ± standard error. 
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Results and Discussion 
 
 Synthesis and Characterization of TSP521-Loaded PECs 
 PEC self-assembly led to the spontaneous incorporation of PEGylated TSP521 
(PEGp521), which was loaded (750 µg) into the anionic solution pre-fabrication.  The 
other strategy involved TSP521 (100 µg), without PEG, linkage to the PEC corona post-
production and isolation by centrifugation.  The loading efficiency for PEGylated peptide 
entrapment was 2% (15 µg), verified isotopically and with fluorescence, whereas surface 
engineering by EDAC/NHS led to 10% immobilization (10 µg).  Suspension of the two 
strategies in MCDB 131 (EC growth media) led to stable suspensions and showed no 
statistical difference (p<0.05) in size and zeta potential compared to non-targeted PECs 
(Table 6.1).  The improved properties, reduced PDI, exhibited by PECs containing 
PEGylated TSP521 was due to the presence of PEG which increases the resistance to salt 
induced aggregation and provided a steric stabilization30.  The residual increase in size 
shown by EDAC/NHS treated PECs was due to a small amount of cross-linking between 
PECs that may have occurred between protruding anionic carboxyl groups and amines. 
 
Table 6-1.  Targeted and non-Targeted PEC physicochemistry in EC growth media. 
 
Platform Size (nm) PDI Zeta Potential (mV) 
non-Targeted 192.3±16.6 0.393±0.186 -18.4±4.3 
Targeted PEGp521 194.2±23.6 0.167±0.024 -25.2±5.6 
Targeted EDAC/NHS 240.0±17.1 0.287±0.033 -27.4±1.6 
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 Cytotoxicity of Targeted and non-Targeted PECs 
 Cytoxicity of targeted and non-targeted PECs was investigated using the MTT 
assay on HMVECs over the same conditions applied in Chapter V. Experimental 
observations, PEC doses, were compared to cells without PEC.  One-way ANOVA was 
first applied to determine the heterogeneity in means while Dunnet’s test evaluated the 
statistical response of each observation in comparison to the control.  As shown in Figure 
6-1, no statistical effect (p<0.05) on 72 h HMVEC cell viability was detected for serial 
PEC concentrations over three orders of magnitude.  Additionally, the PEC to initial cell 
density ratio ranged from approximately 60000:1 down to 400:1. The wide span of 
limited cytotoxicity validated this PEC system as a candidate for targeted delivery to 
endothelial cells. 
 
 
 
Figure 6-1.   Relative viability of HMVEC-1 cells incubated 72 h with various 
concentrations of non-targeted (nT, gray), Targeted, PEGylated TSP521-containing (T 
PEGp521, black), and TSP521 coupled by EDAC/NHS PECs (T EDAC/NHS, white).  
Control cells are untreated.  All results are given as the average ± standard error (n=3).  
No statistical differences in MTT reduction (p>0.05) were seen by one-way ANOVA 
(deviations amongst experimental means) and Dunnet’s Test (experimental reductions 
compared to control). 
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 Tryptic Effects on Targeted and non-Targeted PEC Interactions 
 Analogous to Chapter V, tryptic effects on PEC association was analyzed by 
exposing HMVEC to FITC-labeled complexes followed by either detachment by 0.25% 
trypsin/0.1% EDTA or 5 mM EDTA in HBSS, pH=7.6.  Trypsin decreased the total 
amount of surface bound and internalized PECs, compared to cells detached by EDTA 
(Figure 6-2).  Coincidentally, for non-targeted and targeted PECs (EDAC/NHS and 
PEGp521), an approximately 75% reduction in surface attached PECs and a 50% 
decrease in internalization, both statistically significant (p<0.05) to cells removed by 
EDTA, were effects independent of the targeting strategy.  The result suggested that 
extracellular matrix proteins were involved in PEC binding and internalization.  Trypsin, 
which strips HSPG31, showed evidence that PEC associative properties may depend 
partially on surface proteoglycans, but, again, does not address the dependence on 
calcium. 
 
 
Figure 6-2.  PEC binding and internalization sensitivity to trypsin exposure.  The percent 
inhibition was defined as the ratio of MFItrypsin/MFIEDTA.  Error bars represent the 
standard error for n=3.  Asterisks indicate statistical effects at p<0.05 on both PEC 
internalization and surface binding. 
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 Binding and Internalization Kinetics 
Flow cytometry provided evidence of upregulated HMVEC binding and 
internalization for PECs with TSP521 loaded by both strategies (Figure 6-3).   PECs 
(1.54x109 PEC/ml) were incubated with cells for up to 2 h.  At the outset of the exposure, 
cells were detached using EDTA and analyzed by FACS for binding and internalization 
by trypan blue32,33.  The level of binding for non-targeted PECs was relatively low while 
targeted PECs showed a 10 and 40 fold increase for EDAC/NHS and PEGp521 
approaches, respectively.  Uptake exhibited a 5 fold upregulation for both targeting 
platforms compared to non-targeted complexes.  The enhanced binding and 
internalization kinetics of PEGylated and EDAC/NHS TSP521 PECs may be due to 
specific interactions with HSPG robustly expressed on endothelial cells20-23, consistent 
with the activity of the free peptide34.  Both PEC-containing compartments, surface and 
internal, appeared to reach saturation for platforms with and without targeting after an 
initial 20 min linear increase in the two compartments.  This phenomenon indicated that 
both uptake mechanisms, non-targeted and targeted, were receptor-mediated35,36.  Non-
targeted PECs likely interacted with HMVEC through electrostatic interactions, 
particularly through PMCG37, as described in Chapter V.  
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Figure 6-3.  TSP521 incorporation enhances PEC association with endothelial cells.  
Kinetics of A) surface binding and B) internalization for PECs with and without the two 
TSP521 incorporation strategies were obtained by incubating HMVEC-1 cells with 
1.54x109 PEC/ml for up to two hours, detachment, and acquisition by FACS.  All median 
fluorescent indices are the average ± standard error (n=3).  
 
 
Exogenous Heparin Abolishes PEC Interactions 
Recent studies have shown that extracellular glycosaminoglycans (heparin, 
chondroitin sulfate, dermatan sulfate) are a barrier to successful gene delivery via 
polymeric, cationic carrier vehicles38-40.  The effects of extracellular glycosaminoglycans, 
200 U/ml heparin, on binding and uptake on targeted and non-targeted PECs were clear 
and independent of TSP521 loading as shown in Figure 6-4(A,B), where Figure 6-4(B)  
displays the data with an expanded abscissa.  Heparin blocked the interactions of PECs 
with HMVECs. Surface binding was reduced for non-targeted (97%), targeted PEGp521 
PECs (95%), and targeted EDAC/NHS (88%) while internalization diminished by 69%, 
86%, and 85%, respectively.  No statistical effect was observed for comparisons between 
naked and TSP521-containing PECs.  As detailed in Chapter V, heparin non-specifically 
adhered to the PECs causing the saturation and neutralization of positively charged 
A) B) 
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groups on the PEC corona and complex destabilization40.  The presence of TSP521 also 
contributed to this effect as TSP-1 and the peptide have an affinity for heparin19,41.  
 
 
 
 
 
Figure 6-4.  Exogenous heparin eliminated PEC/cell interactions.  Incubation of PECs in 
the presence of 200 U/ml heparin completely inhibited surface binding and 
internalization of PECs (average±standard error, p<0.05). 
 
 
 Perturbation of HSPG Biosynthesis 
 Incubation with a HSPG biosynthesis inhibitor, 4-nitrophenyl-β-D-
xylopyranoside (β-xyl), supported the hypothesis that membrane-associated HSPG partly 
mediated the attachment of PECs, as shown in Figure 6-5(B).  β-xyl  competes with 
xylose-substituted core proteins as a substrate for galactosyltransferases leading to 
inhibition of HSPG elongation whereas the α isomer has no inhibitory activity42,43.  
Figure 6(A) showed no statistical changes in PEC binding or internalization for HMVECs 
pre-incubated with 4-nitrophenyl-α-D-xylopyranoside (α-xyl). The inhibition of HSPG 
biosynthesis caused a 54%, 69%, and 42% decrease in surface PEC binding compared to 
the control for non-targeted, targeted PEGp521, and targeted EDAC/NHS PECs, 
A) B) 
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respectively.  The 15% difference in surface binding between non-targeted and targeted 
PEGp521, although not statistically different, does show a higher dependence on the 
HSPG cell surface presentation.  Internalization was not statistically affected for any 
system, although decreased in all cases, indicating that uptake of PECs may share a 
common endocytic pattern (macropinocytosis), a surprising finding since the 
internalization of TSP-1 has been found to be inhibited by overnight β-xyl treatment18.  
The remaining portion of binding may be non-specific and electrostatic, but also due to a 
sufficient amount of HSPG that persisted. 
 
 
Figure 6-5.  HSPG partly mediated PEC association.  24 h pre-incubation with A) 
inactive and B) active xylopyranoside isomers followed by 2 h PEC exposure led to 
inhibition of surface binding for n=3 (average ± standard error, p<0.05) 
 
 
Detection of Targeting by FACS-based Scatchard Plots 
 The FACS-based Scatchard equilibrium experiment developed in Chapter V was 
applied to detect receptor-mediated binding for ligand-functionalized PECs. Scatchard 
titrations were prepared by exposing HMVEC-1 cells to serial PEC dilutions, over the 
concentration range tested for toxicity by MTT, for 3 hours at 37°C and 4°C.  The 
A) B) 
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exposure was followed by detachment, acquisition of MFI, and conversion of bound 
indices to particle concentrations.  This was, again, possible after calibration of our ~200 
nm PECs with known concentrations of NIST-traceable beads. The approach also 
provided a verification of upregulated binding seen in kinetic experiments (Figure 6-3) 
and the first such FACS based Scatchard representation.  Figure 6-6(A,B) represented the 
binding isotherms at 37°C and 4°C, while (C) and (D) Scatchard transformations at the 
same temperatures, respectively.  Experiments at 4°C were performed to look at only 
binding, as discussed in Chapter V.  These particular figures did not represent any 
saturable binding or receptor-mediated activity correlating to data represented in Figure 
5-9.   
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Figure 6-6.  Targeted EDAC/NHS(△), Targeted PEGp521(◇), and non-targeted 
PECs(□) exhibit non-saturable binding and positive cooperativity for 3 h at 37°C and 
4°C when displayed over all concentrations tested.  Incubations for (A) and (C) were 
performed at 37°C, while (B) and (D) at 4°C.   (A) and (B) are dose-dependent binding 
curves. (C) and (D) represented Scatchard plot analysis.  Curves were determined by flow 
cytometry (n=3).  The ratios of bound and free PECs for each concentration were 
determined based on the MFI of each dose in the absence of cells, followed by correlation 
to calibration curves determined as in Figure 5-2.   Y-error bars represent the average ± 
s.e. in calculated bound PECs. 
 
(A) (C) 
(B) (D) 
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Further analysis of Figure 6-6 by isolation of the low concentration data, showed 
receptor mediated activity at 37°C and 4°C, upon Scatchard transformation as displayed 
in Figure 6-7(A,B).  Through this limited concentration range, targeted PEGp521 PECs 
follow the laws of mass action.  Algebraic rearrangement of equation 5-1 leads to 
equation 6-1:   
 
 
 
 
The single monotonic transformation observed at both temperatures indicated a single 
class of binding sites44, correlating to the weak affinity HSPG receptor for fibroblast 
growth factor-2 (FGF-2) binding45.  This transformation allowed the calculation of an 
equilibrium dissociation binding constant, in terms of PEC/ml for 37°C (1.00x108 
PEC/ml) and 4°C (2.00x108 PEC/ml).  This verified the enhanced binding activity of 
targeted PEGp521 PECs seen in Figure 6-3(A,B) and limited saturation binding inside of 
this region shown in Figure 6-7(C,D).  Further titration of the PEGylated TSP521 PECs 
showed positive cooperativity and no receptor-mediated binding, identical to the non-
targeted system and targeted EDAC/NHS complexes. This indicated that as PECs were 
titrated to a ‘breakthrough’ concentration, the electrostatic nature of the PEC dominated 
the binding and effectively reduced the ability of TSP521 to interact specifically with 
HSPG.  A breakdown in the mass action assumptions resulted, further verifying the 
electrostatic interaction between the anionic cell surface and PECs in the absence of a 
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ligand. Interestingly, direct zero-length ligation of TSP521 to amines on the PEC corona 
showed Scatchard plots with a positive slope, similar to the non-targeted system.  This 
would imply, over the concentration range for Figure 6-7(A,B), that the presentation of 
PEGylated TSP521 was important, that possibly the peptide was sufficiently arranged on 
the surface to minimize electrostatic interactions.  The behavior of non-targeted (all 
concentrations), targeted EDAC/NHS (all concentrations) and PEGp521 PECs (after 
[Bound]=2x106 PEC/ml at 37°C and [Bound]=7x105 PEC/ml at 4°C) denoted that 
concentrations never approached the equilibrium binding constant for a second regime of 
binding.  Figure 6-7(C,D) showed that there was a limited range   The limitation of that 
consequence was high concentrations resulted in PEC aggregation, and therefore, 
deviation from a nanoscale delivery system.      
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Figure 6-7.  Scatchard representations for low concentration binding at A) 37°C and B) 
4°C.  Linear regressions were fitted to validate receptor-mediated activity for n=3.  
Targeted and non-targeted PECs were incubated with HMVECs for 3 h at 37°C, 5% CO2, 
and 95% relative humidity.  After washing steps, cell-bound PECs were analyzed by 
FACS.  The ratios of bound and free PECs for each concentration was based on the MFI 
PECs in the absence of cells.  C) and D) indicated a limited region where saturation 
binding occurred for targeted PEGp521 PECs at 37°C and 4°C, respectively. 
 
 
(A) (C) 
(B) (D) 
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Conclusions 
 TSP521, a HSPG binding peptide derived from TSP-1, was associated with the 
PEC by two different loading methods.  It was found that these PECs had binding and 
internalization mechanisms that can be abolished by extracellular heparin that and were 
affected by trypsin exposure.  Surface attachment was found to be controlled partially by 
HSPGs.   
This study was undertaken primarily to confirm the theoretical expectation that 
Scatchard analysis could be performed satisfactorily with fluorescent PECs after 
incorporation of two targeting approaches.  This was the first study that not only applied 
Scatchard transformations in PEC binding, but also the first to detect receptor-mediated 
activity of a surface engineered system.  It was critical to derive the linear parameters 
after expansion of low concentrations of TSP521-containing PECs.  The demonstration 
by FACS that binding was enhanced was not enough to establish a true single receptor 
interaction as the coupling of TSP521 by EDAC/NHS direct ligation did not demonstrate 
a classical Scatchard transformation; equation 6-1 could not be used to calculate a Kd or 
[Rtotal]. 
The need for spacing that presents a molecule’s active binding region away from 
a nanoparticle surface has been shown to effectively target liposomes with folic acid46,47.  
PEGylation of polypeptides and proteins is a widely used method of prolonging their 
biological half-life28; however, in this application conjugation was designed to modulate 
the presentation of the peptide by increasing its molecular mass and flexibility.    The 
results showed that a key biochemical property of the peptide, HSPG affinity, was fully 
retained by PEGylated TSP521 conjugate.  This may be a steric effect mediated by 
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anchoring the peptide chain to the PEG polymer.   This would indicate that the peptide or 
targeting moiety must be at a length that can allow the molecule to interact specifically 
with its constitutive receptor and minimize the ubiquitous surface PEC electrostatic 
contributions.  This conclusion evolved due to the fact that, by mass, the loading of 
TSP521 was similar:  10 µg (EDAC/NHS) and 15 µg (PEGp521), therefore the cell was 
able to interface properly with the active region of the peptide through elongation with 
PEG.   The passive loading of TSP521, subsequent to its elongation with 4000 PEG 
molecules, permitted the docking of PECs through an assumed HSPG interface.  This 
type of finding should lead to the development of better PEC targeting strategies that 
would display higher affinity binding activities.   
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CHAPTER VII 
 
 
 
IN VIVO IMAGING AND BIOCOMPATIBILITY OF MULTICOMPONENT 
POLYELECTROLYTE COMPLEXES  
 
 
Introduction 
 The ability to localize PECs in vivo and monitor tissue distribution is critical to 
understanding their biocompatibility and behavior1.  Common techniques have involved 
radionuclide or magnetic resonance imaging (MRI).  These methods have several 
advantages including high sensitivity, capability of quantitation, and clinical translation.  
Unfortunately, they suffer from relatively low spatial resolution and high cost.  For 
radionuclide administration, positron emission tomography (PET), an on-site cyclotron 
and radiochemistry laboratory to produce short half-life tracers and radiolabeled agents 
are a prerequisite.  Therefore, optical imaging (bioluminescence and fluorescence 
imaging) has emerged as an attractive alternative approach to study biological and 
molecular events in both cell culture and small animals.   
Optical imaging modalities do not require ionizing radiation and are inexpensive2.  
Additionally, bioluminescence and fluorescence approaches are highly sensitive and 
allow for high throughput screening because the acquisition for obtaining an image can 
be as short as seconds3.  Because of the strong tissue penetration ability of light in the 
near-infrared region (NIR), near-infrared fluorescence (NIRF) imaging has emerged as a 
powerful tool for small animal imaging.  These fluorescence tracers emit or absorb light 
in the 650 nm-900 nm wavelengths.  NIRF imaging has a great potential for clinical use 
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in providing both real-time surgical, functional, and molecular information on disease 
states. Water and biological tissues have minimal absorbance and autofluorescence in the 
NIR window, thus allowing efficient photon penetration into, and out of tissue with low 
intra-tissue scattering.  NIRF probes are therefore under active investigation and has been 
demonstrated as a viable method to noninvasively monitor disease states at the molecular 
level, localize cancer, and even assess the antitumor efficacy of new therapeutics4-6. 
The extension of PECs as a drug delivery system must be proven in animal 
models where very few studies actually exist.  It is necessary to assess the 
biocompatibility to validate PEC suitability for systemic administration. Standard 
histological sections can be examined to verify the presence or absence of inflammation 
in tissues.  If PECs induce an inflammatory response, cells such as neutrophils, 
lymphocytes, and macrophages would be recruited and indicated by nuclei staining 
around the site.  The NIRF probes have reactive groups for functionalization of amines, 
aldehydes, and other active chemical moieties on polymers and proteins.  Therefore, 
AlexaFluor 750 (AF750), an NIRF probe carrying an N-hydroxysuccimidyl ester groups 
for linkage to amines, was incorporated into LMW PECs created with dispergation for 
further examination of biodistribution by state-of-the art imaging technology.  The 
imaging further established the feasibility of LMW PECs as a template for nanoparticle-
mediated targeted drug delivery. 
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Experimental Procedures 
 Chapter II defines all protocols applied in this section.  Incorporation of AF750 
PMCG was performed using Polymer Labeling, followed by PEC Fabrication of 
fluorescent PECs (Fluorescent PEC Preparation).  One batch was made, isolated by 
centrifugation, suspended in 1 ml of isotonic buffer.  100 µl was then injected retro-
orbitally into male BALBc mice (n=3 per time point) and biodistribution tracked before 
and after sacrifice as described in In Vivo Imaging.  Tissue inflammation was investigated 
by examination of histological slides (Histology) for liver, spleen, kidney, lungs, and 
heart.  Additionally intramuscular and subcutaneous injections were performed followed 
by histological sectioning. 
 
Statistical Analysis  
 Excised organs were used to measure the biodistribution of the fluorescent PECs.  
All data are given as the mean ± standard error (n=3 mice per time point for PBS and 
AF750 PECs).  Statistical significance was determined by a two-sample t-test (PECs 
versus PBS per organ) where a critical t was calculated to determine when the 
fluorescence signal diminished enough to agree with the null hypothesis.  For 
determining organ PEC distribution, fluorescence intensities (pixel/s), fluxes of light 
collected by the imaging instrument after excitation and emission, were calculated by the 
region of interest (ROI) function of the Living Image software integrated with Igor Pro 
(Wavemetrics, Lake Oswego, OR).  ROIs were drawn for each organ and a section of the 
image (for background subtraction) outside of the 6-well plate; the same size ROIs were 
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copied and applied in each animal at every time point. All statistical analyses were 
performed using JMP-IN 5.1 (SAS, Cary, NC). 
 
Results and Discussion 
 
 PEC Fluorescent and Physical Properties.   
After incorporation of AF750 PMCG and fabrication of fluorescent PECs, 
physicochemical properties were assessed by PCS.  Size, zeta potential, and PDI (average 
± s.e., n=3) were 185.78 nm ± 63.34 nm, -30.9±1.00, and 0.247 ± 0.081, respectively.  
These results were statistically consistent with previous findings.  One batch was 
concentrated to 1 ml of isotonic buffer for injection into animals.  Figure 7-1 showed 
verification of fluorescent signal for AF750, indicating that AF750 PMCG was 
successfully incorporated into PECs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1.  Detection of NIR fluorescence in PECs containing AF750 PMCG. PECs are 
imaged using the ICG filter (λex 710-760 nm, λem 810-875 nm) on the Xenogen IVIS 200 
Imaging System.   Fluorescent and photographic images are overlapped after a 1 s 
exposure. 
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 Whole Animal Optical Imaging 
 The ability to detect AF750 PMCG-containing PECs was accomplished by retro-
orbital injection of 100 µl of the above suspension (~3x109 PECs) and imaging at various 
time points up to 48 h in mice.  The mice were first shaved to prevent signal dampening. 
There was no acute reaction after intravenous administration, indicating bulk PEC 
biocompatibility.  Intrajugular, tail vein, intraperitoneal, and direct heart injections were 
tested with no ill effects.  Figure 7-2 (A-D) shows the PECs in circulation, but rapidly 
cleared to the bladder, as shown in the strongest signal.  No fluorescence was detected in 
animals injected with PBS.   Images for Figure 7-2(A-B) showed that this process 
happened between the time of injection and imaging (~10 min).  Significant bladder 
fluorescence persisted at 3 h, but some signal was localized to the upper chest cavities 
(liver, lungs, spleen, kidneys).  The signal completely disappeared at 24 h.  This was 
indicative of a partial destabilization of PECs by polyelectrolyte exchange reactions 
leading to fast clearance of PMCG and AF750 PMCG from the bloodstream.  The low 
molecular weight of PMCG (5000 Da) is well below the kidney clearance limits7, but the 
fluorescent signal also could be indicative of the clearance of other PEC components.  
Following intravenous administration, naked PECs are exposed to a variety of factors that 
may have compromised their integrity and caused partial decomplexation, including 
interactions with proteoglycan-containing extracellular matrices and high concentrations 
of very anionic serum proteins or other molecules present in blood plasma 
(opsonization)8,9.  Suspensions of AF750 PECs in 100% fetal calf serum verified these 
results as 40% of the fluorophore conjugated PMCG was released in the first 30 min. 
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Figure 7-2.  In vivo fluorescence imaging of retro-orbitally injected AF750 PECs (A-D) 
or PBS (E-H) immediately after injection and 3 h later in male BALBc mice.  Dorsal 
imaging was performed in (A), (C), (E), (G) while ventral in (B), (D), (F), (H).  The 
intensity of the signals, light flux, is denoted by the respective color bars in terms of 
pixels/second.  10 s exposures were applied followed by the overlay of photographic and 
fluorescence images. 
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 Biocompatibility Assessed by Tissue Histology 
 PEC biocompatibility was assessed by several types of administration, after which 
animals were sacrificed and histological slides prepared.  Animals were either injected 
intramuscularly (directly into muscle) or subcutaneously (under the skin) with AF750 
PMCG PECs or PBS (50 µl, 1.5x109 PECs).  Three days later, the animals were 
sacrificed and muscle and skin extracted.  The histological slides comprise Figure 7-3.  
The hematoxylin and eosine staining of nuclei and cytoplasmic components, respectively, 
showed no distinguishable differences. 
AF750 PEC                               PBS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-3.  Histological examination of intramuscularly (A,C) and subcutaneously 
(B,D) injected AF750 PECs and PBS 3 d after administration. 
 
Further biocompatibility was characterized by sectioning of organs for mice kept 
5 days post-injection.  Liver, kidney, spleen, lungs, and heart stained with hematoxylin 
and eosine showed no morphological differences between PBS and AF750 PMCG PECs 
(Figure 7-4).  These two studies showed no inflammatory reactions, due to a lack of 
punctate blue staining, following PEC administration, and preparation of histologies. 
(A) 
(B) (D) 
(C) 
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Figure 7-4.  Histological sectioning of AF750 PEC and PBS injected BALBc mice 5 
days post administration for liver (A,F), kidney (B,G), spleen (C,H), lungs (D,I), and 
heart (E,J). 
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Organ Biodistribution 
The remaining intact complexes became rapidly sequestered into highly perfused 
and vascularized organs:  liver, lungs, and spleen.   This localization was followed by 
degradation of signals over a 48 h period as shown in Figure 7-5.  PBS treated animals 
provided the fluorescence background.  Each time interval involved the euthanasia of 3 
AF750 PEC and PBS animals and organ extraction.  The fluorescence of each organ was 
immediately imaged and the fluorescence extracted.   
It was not surprising that the fluorescence was contained in the liver, lungs, and 
spleen, after initial time points showed bladder localization.  The liver, lungs, and spleen 
contain highly vascularized networks composed of highly anionic endothelial cells 
facilitating PEC sequestration in these organs.  Specifically, the liver has open 
fenestrations that control the transfer of molecules from blood vessels to tissue, which are 
on the order of 150 nm.  These openings may also contribute to the extensive endothelial 
filtration of PECs in the liver.  Intravenous injection of colloidal carriers, such as 
liposomes and polymeric nanospheres, are recognized by the reticuloendothelial system 
(RES) as they circulate in the blood and bind opsoninizing macromolecules10. The RES, a 
component of the immune system, consists of phagocytic (greek for cell eating) cells, 
primarily monocytes and macrophages i.e. Kupffer cells.  These cells accumulate and line 
the spleen, liver, and lungs and capture foreign substances and eventually clear them 
from the bloodstream, as is displayed in Figure 7-5(A-D).  
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Figure 7-5.  Representative ex vivo images of organs extracted from male BALBc mice 
at the indicated time points after retro-orbital injection.  Either AF750 PECs (A-D) or 
PBS (E-H) was injected. 10 s exposures were applied followed by the overlay of 
photographic and fluorescence images.  Three animals were used in each time group. 
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Furthermore, the NIR fluorescence, up to 48 h, was quantified by measurement of 
the light flux induced after excitation of the fluorochrome for both PBS and AF750 PECs 
treated mice, as shown in Figure 7-6(A,B).  The figure shows a rapid clearance of PECs 
from organs, eventually washing them out after 48 h.  The short circulation time verified 
the RES response discussed previously.  To provide added evidence of the clearance of 
PECs, statistical tests between treatments were performed for every organ compared at 
each time point.  In Figure 7-6(C), the calculated test statistic (ttest) was plotted as a 
function of time.  The test statistic was calculated by equation 7-1: 
! 
t
test
=
µ
AF 750PEC
"µ
PBS
s
1
2 + s
2
2
n
 
where µAF750 PEC and µPBS were the mean fluxes, s12 and s22 the standard deviations, 
respectively, and n the sample size (3 mice).  The critical t for 4 degrees of freedom was 
2.776.  Any calculated test statistic less than 2.776 met the null hypothesis, µAF750 
PEC=µPBS; the PEC signal does not differ statistically from PBS and defined by the dashed 
line in Figure 7-6C.  Therefore, Figure 7-6C shows a steady, monotonic decrease in ttest 
for all organs.  AF750 PECs showed statistically significant signals for liver, lungs, 
kidney and spleen at t=3, but after 24 h, only lungs and liver show statistically unique 
fluxes.  As time further elapsed, only the liver had a ttest, which resulted in rejection of the 
null hypothesis.   
 
 
 
 
(7-1) 
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Figure 7-6.  Quantification of ex vivo organ distribution for (A) AF750 PECs and (B) 
PBS injected animals.  The fluorescence was recorded as photons/second after creation of 
a region of interest for each organ.  The background was subtracted by creating a region 
of interest away from the organ signals.  The statistical significance of each fluorescence 
measurement (n=3) was tested against its PBS counterpart.  The test statistic for each 
two-way comparison was plotted (C) as a function of time (n=3, p<0.05). 
 
 
Conclusions 
 A NIR probe was successfully incorporated into the PEC matrix and 
biodistribution followed by non-invasive longitudinal imaging.  Additionally, the 
biocompatibility was verified when indistinguishable tissue histologies were observed.  
Unfortunately, LMW PECs were rapidly cleared from circulation as seen by whole 
(B) (A) 
(C) 
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animal imaging, excised organ fluorescence, and statistical analysis of the measured light 
fluxes. 
 Studies have shown that the association of plasma proteins and opsonins, such as 
immunoglobulin G, fibrinogen, and fibronectin, with liposomes and other colloidal 
carriers contributed to circulatory clearance or non-specific accumulation in pulmonary 
capillary beds and the liver8,9,11.  Moreover, the extent of binding increases the likelihood 
of recognition by the RES12.   After intravenous injection of AF750 PECs, the cationic 
groups can react with plasma proteins, resulting in modified coronal chemistry and 
decreased adherence to anionic cell surfaces.  Opsonins may come into contact typically 
by Brownian motion, but when sufficiently close, van der Wals, ionic, 
hydrophilic/hydrophobic and other attractive forces dominate the interactions.  After 
opsonization has occurred the complex may destabilize through exchange reactions or 
phagocytic cells will recognize and bind this ternary PEC/opsonin structure.  In the 
absence of opsonins, phagocytes will not bind polymeric carriers.  Phagocytes will then 
ingest PECs and inherent secretory enzymes and oxidative-reductive agents leading to 
degradation of individual components and ejection7.   
 There are many approaches to stabilize AF750 PECs against opsonization.  One 
strategy would be to enshroud the PECs within a protective layer of hydrophilic 
polymers, such as polyethylene glycol (PEG)13, in addition to the Pluronic F-68 already 
present.  The surface modifications can be accomplished by activated linkages to 
sufficiently ‘coat’ the PECs, avoid phagocyte-mediated clearance, increase the 
circulatory time, and enhance complex stability.  
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CHAPTER VIII 
 
 
 
ASSESSMENT OF NANOPARTICULATE POLYELECTROLYTE COMPLEX 
PRODUCTION BY KENICS STATIC MIXER 
 
 
 
Introduction 
 The pharmaceuticals and fine chemical industry have shown an increasing interest 
in alternatives to batch and stirred tank reactor designs and reliable scale-up strategies.  
Although continuous processing technologies such as static and in-line mixers have been 
successfully applied in the petroleum industry, literature focusing on their application to 
the manufacture of excipients, active pharmaceutical ingredients, and nano- and 
microscale drug delivery systems is limited1. 
 Static mixers consist of a series of flow reorientation devices inserted along the 
axis of a pipe.  Pressure, as opposed to mechanical agitation, drives fluids through the 
device, providing the energy needed to accomplish mixing2.  They are simply cylindrical 
pipes with mixing elements fixed inside.  The mixing elements are formed by helically 
twisted rigid plates (usually of the same pitch) each dividing the pipe into two twisted 
semicircular ducts.  The inserts are placed tightly one after another so that the leading 
edge of the next insert is perpendicular to the trailing edge of the previous one; the length 
of the elements is one and a half tube diameters3, as displayed in Figure 8-1.  Solutions 
are radially mixed by rotational circulation around the hydraulic center of each semi-
circular channel.  Solutions are subsequently forced from the diameter to the outer wall of 
the element.  At the same time, the flow reverses its rotation at each element junction due 
to the alternate right- and left-hand alignment of the elements.  The overall effect is to 
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cause the stream to be continually inverted radially so that solutions entering at the center 
of the stream are forced to the outer wall and back again on a continuous basis.  Static 
mixers have achieved throughputs from 10000 m3/h to approximately 1 m3/h, offer the 
potential for achieving liquid-phase plug flow, and pseudo-turbulent conditions at 
relatively low Reynolds numbers (N Re), laminar flow conditions, and high residence 
times, without an increase in reactor volume or stream velocity1,4. 
 
 
 
 
Figure 8-1.  Schematic of Kenics mixer geometry. 
 
 Here, a new technology is introduced to prepare PECs by means of a Kenics static 
micromixer.  The Kenics static mixer has a bench-top setup, lacks moving parts, can be 
run continuously for fabrication of large volumes of PECs, and can be sterilized for 
asceptic processing5.  LMW and HMW PECs were made at increasing N Re and the 
physicochemical properties were compared with the goal of a monomodal distribution, 
decreased sizes, PDIs, and stable ZPs.  Furthermore, the mixing efficiency of the device 
was evaluated by a competitive reaction scheme.   
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Experimental Procedures 
 LMW and HMW PECs were fabricated and the mixing properties established, as 
described in Chapter II, Process Scale Up with Kenics Static Mixer and Qualitative 
Assessment of Static Mixer Efficiency, respectively.  Figure 8-2 depicts the device, inlets, 
and outlets.  Reynolds numbers were calculated assuming an empty pipe approximation. 
The Kenics mixer used was 6.35 mm I.D., 21 cm in length, and made of stainless steel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-2.  Kenics static mixer showing inlets and outlets for PEC production and 
evaluation of mixing efficiency. 
 
 
Statistical Analysis 
 Several statistical methods were applied for evaluation of PEC physicochemistry 
and the mixing efficiency with JMP-IN 5.1 (SAS, Cary, NC).  Subsequent to the 
fabrication of LMW and HMW PECs, size, polydispersity index (PDI), and zeta potential 
(ZP) were assessed by ANOVA to statistically determine the heterogeneity of both 
populations as a function of increasing flow rate.  Additionally, the Tukey-Kramer 
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Honestly Significant Difference (HSD) was used to compare mean properties at each N 
Re.  The same method was performed for tri-iodide production as a function of N Re.  
LMW and HMW systems were also evaluated by two-sample t-tests for every N Re to 
compare the polyelectrolyte platforms.  Linear regressions were calculated for 
physicochemical properties and tri-iodide concentrations as a function of N Re.  Each 
slope was statistically tested to see if it differed from zero or whether the data trends.  
Also, ANOVA was used to understand whether or not the metrics followed an upward or 
downward trend.  All analysis was assessed at the 95% confidence interval (p<0.05).  
 
Results and Discussion 
 
 Mixer Characterization by Competitive Reactions 
 The mixing efficiency of the Kenics static mixer used for continuous production 
of LMW and HMW PECs at stoichiometric ratios of 10:1 was evaluated by an ultrafast 
competitive acid-base reaction scheme originally designed for batch setups6 but modified 
for continuous designs7,8.  The anionic and cationic streams from the PEC process were 
mimicked by the sulfuric acid and borate/iodide/iodate solutions, respectively, as 
described in Chapter II, Qualitative Assessment of Static Mixer Efficiency.  The two 
solutions, H2SO4 and H2BO3/IO3-/I-, from the test reaction represented limiting and 
excess reactants in the same ratios as the PEC reaction.  The mixing efficiency was 
quantified by the equilibrium production of iodine (I3-) and measurement via 
spectrophotometer at 353 nm.  The first process, Equation 2-9, is a neutralization that is 
ultra fast and will always mask the slower second reaction (Equation 2-10), namely the 
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iodine formation as long as no local excess of the strong acid remained; the higher the 
absorption due to tri-iodide formation, the poorer the quality of mixing in the unit9. 
 A linear profile was observed as a function of Reynolds number in the laminar 
flow regime (Figure 8-3).  The slope of this line is statistically different from zero and the 
physical system exhibits a negative relationship between iodine concentration and 
Reynolds number as tested by ANOVA. One-Way ANOVA tests were also used to test 
the homogeneity of means as N Re increased. The analysis showed a 2% probability that 
all means are equal, therefore at least one mean is statistically significant.  This led to the 
use of the Tukey-Kramer HSD test to define pairs of means that are statistically different.  
Table 8-1 displays the results.  According to this test, Reynolds number does not induce a 
statistical effect on mixing until N Re reached 730.25. 
 
 
 
 
Figure 8-3.  Tri-iodide production as a function of Reynolds number for flow rates 
applied in PEC production.  Tri-iodide production with the Kenics static mixer is 
displayed as the mean±s.e. for 4 independent measurements.  Slope and y-intercept are 
displayed from linear regression analysis.  
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Table 8-1.  Comparison of tri-iodide concentrations using Tukey-Kramer HSD test.  
Designation of “yes” signifies a concentration in the column heading that is statistically 
different from the rate for its counterpart in the row heading.  “no” means two 
concentrations are means which are statistically the same.   
   
 
N Re 328.61 438.15 584.20 730.25 
328.61 -- no no yes 
438.15 no -- no no 
584.20 no no -- no 
730.25 yes no no -- 
 
  
 Properties of PECs Fabricated by Kenics Static Mixer 
 PECs were constructed by simple two stream contacting with the Kenics static 
mixer at laminar flow conditions.  The particles exhibited the Tyndall effect, consistent 
with observations in Chapter III for batchwise preparations.  After a 30 s accumulation 
time, under stirring, the product is sampled for analysis by the Malvern ZetaSizer Nano 
ZS.  Figure 8-4 was separated into two representations.  The first (left panels) displays 
the data as histograms to demonstrate the statistical differences between the LMW and 
HMW formulations.  HMW PEC particle diameter, Figure 8-4A, (250 nm-303 nm) was 
greater at each N Re in comparison to LMW suspensions (221 nm-250 nm), but none 
exhibited statistical significance. However, HMW PECs demonstrated greater variability 
in size as indicated by the standard error.  The standard error ranged from 26% (N 
Re=328.61) to 33% (N Re=584.20) which was indicative of a less reproducible result in 
comparison to LMW counterparts (standard error 2-4% of average).   For zeta potential, 
only Re=438.15 showed a statistically higher surface charge for HMW (41 mV-42 mV) 
compared to LMW (32 mV-36 mV), although each HMW ZP was higher as designated in 
Figure 8-4C.  LMW PECs provided statistical decreases for all conditions (Figure 8-4B), 
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excluding N Re=328.61.  The reduction in polydispersity was a sign that the population 
of LMW PECs became more homogeneous in contrast to the HMW products.  Similar 
results have been seen for other static mixer configurations10-12. 
 The second half of Figure 8-4 plots the physicochemical responses as a function 
of increasing N Re for detection of linearity between size, PDI, ZP, and the flow pattern.  
A plot of hydrodynamic diameter versus N Re (Figure 8-4D) for HMW PECs showed no 
statistically unique upward or downward trend while LMW showed a significant 
decreasing pattern.  In fact, this was the case for each characteristic.  This would indicate 
that HMW PECs had a random response to increasing N Re, whereas LMW complexes 
showed real effects to changes in the flow pattern.  Tests on the slopes derived from 
linear regressions showed that they were statistically different than zero, although 
ANOVA indicated that only LMW measurements showed a downward trend.   
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                           Histogram                                           Scatter Plot 
 
Figure 8-4.  Physicochemical properties of LMW and HMW PECs created using the 
static mixers at increasing Reynolds numbers.  Left panels represent histograms while 
right is the scatter data on a linear scale.  Size (A,D), PDI (B,E), and ZP (C,F) are the 
mean and standard error for at least 3 measurements.  Asterisks indicate pairs of means 
which differ at the 95% confidence level by two-sample t-test. 
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Conclusions 
 The results showed that only LMW PECs are affected by preparation by static 
mixer technology.  Also, a parallel competing reaction scheme provided proof that 
mixing efficiency was enhanced as N Re increased and that further increases in flow rate 
could result in better mixing. Regardless, the static mixer offered the potential for further 
improvements.  The current configuration of the system does not allow a further buildup 
of pressure.  Better pumps and more robust tubing would have to be used.  Additionally, 
the mixing could be improved by changing inlets to further segregate the streams until 
they reach the same element.   
 The more intense the mixing, the better physicochemical results were observed.  
Large volumes of particles of both systems were produced, ~100-200 ml/min, as opposed 
to the 22 ml yield for batchwise preparation.  This left that the possibility that static 
mixers could provide a reasonable scale up strategy.  Interestingly, only the LMW 
formulation was sensitive to the rotational mixing inside of the static mixer.  This may  
have implications for the mechanism and ordered assembly of HMW and LMW PECs.  A 
more intense mixing system might be needed to improve the properties of HMW 
complexes produced by continuous stream contact.    Neither static mixer dispersion had 
more favorable qualities than corresponding complexations by batchwise titration with 
and without frequency dispergation.  Freitas and coworkers5 argued that re-engineering 
the outlet section to avoid turbulent flow should reduce the PDI and particle diameter.  
Other possible improvements might involve reduction of the outlet slit9 or adding more 
mixing elements in series.  These types of alterations may lead to smaller particle size 
and reduced polydispersity.     
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CHAPTER IX 
 
 
 
CONCLUSIONS AND FUTURE WORK 
 
 
 
Conclusions 
 The overall work presented herein demonstrates the development and biological 
properties of a nanoparticulate platform based on the interactions of polyelectrolytes with 
similar molecular weights that can be prepared through an ultrasonic titration (LMW 
PECs).  The preparation avoids the use of harmful reaction environments, bulk phases 
such as methylene chloride and chloroform or mineral oils, through the use of water as a 
solvent, an obvious advantage over many polymeric nanoparticle systems being studied.  
Common nanotechnological techniques, such as TEM and PCS, can easily provide 
information on PEC physical properties. PECs have favorable and attractive 
physicochemical characteristics that are maintained at physiological pH and low 
concentration, serum-containing media: uniform, attractive size distributions, mean 
diameters statistically less than or equivalent to 200 nm, and surface charges indicative of 
stable colloidal suspensions.  LMW PECs also assemble into desirable structures without 
dispergation, a valuable finding for future, viable production and scale-up through simple 
two-stream, continuous mixing.  Such high throughput processing may allow further 
improvement in downstream manipulation, perhaps through removal of centrifugation as 
a product isolation method.  The system provides an improvement over a system shown 
to deliver genes to cells of a hematopoietic origin.  Additionally, these nanoparticulate 
architectures can entrap, release, and retain proteins, mimicking therapeutics, over the 
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course of several days, leading to the possibility of a drug depot for intravenous or 
systemic administration.   
 PECs exhibit little or no toxicity in a biological environment.  Because of the PEC 
modular and chemical nature, surface amines and inner core hydroxyl groups permit the 
efficient incorporation of targeting moieties, chemical linkage of classically insoluble 
drugs (doxorubicin).  The fluorophore incorporation strategy drives both visible and near-
infrared fluorescence characterization of PEC fates in cell culture and small animals. 
Flow cytometry can be utilized to extensively characterize and define the underlying 
mechanisms of PEC binding and uptake, in common disease state models (endothelial 
cells), through macropinocytosis.  Compartmentalization, uptake and surface binding can 
be delineated through extracellular FITC quenching; another advantage of flow 
cytometry.  Also, through flow cytometry, cationic PECs bind cells through strictly 
electrostatic interactions where cells provide an anionic sink to mediate the attachment.  
Also, a novel, flow cytometric, Scatchard analysis protocol, where the extent of receptor-
controlled interactions are dictated by adherence to underlying assumptions of mass 
action and equilibrium binding.  This is the first such flow cytometric Scatchard plot 
strategy for characterization for nanoparticulate architectures to define true targeting and 
receptor-ligand interactions; a critical feature due to misleading information from direct 
kinetic studies. The Scatchard plots can screen targeted delivery systems, in vitro, before 
expensive animal models are used.  This approach is ideal when radioactive nanoparticle 
components are not currently available or the incorporation of an isotope too 
cumbersome.  LMW PECs hold promise for medical uses and could be utilized as a 
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targeted drug delivery formulation and also as a non-invasive, real-time imaging 
construct in humans. 
 
Future Work 
 It is difficult to produce PECs that possess all ideal in vivo and in vitro 
performance related properties.  The PEC as a whole should exhibit physicochemical 
properties in biological environments defined pragmatically in the literature: including 
hydrodynamic diameter less than or equal to 200 nm1,2, surface charge of greater than 
±30 mV3-5, spherical morphology, and a low polydispersity index indicative of a 
homogeneous size distribution.  In this study, LMW PECs were shown to interact in a 
completely unspecific manner, unless the peptide strategy provided an appropriate 
geometric and flexible presentation.  Another complication was that TSP521 was a weak 
affinity ligand.  An alternative ligand may involve the use of addressins that bind to 
activated receptors via light, heat, or radiation.  Because direct, covalent linkage by 
EDAC/NHS of TSP521 did not exhibit receptor-mediated behavior, it can be concluded 
that the peptide was not extended sufficiently from the PEC corona to mitigate charged 
interactions with the cell surface.  This prevented TSP521 from interacting specifically 
with HSPGs.   Additionally, PECs need to be sufficiently modified to avoid uptake by the 
reticuloendothelial system (RES) to permit accumulation in target tissues. 
  Proper ligand presentation and a corona adaptation can be improved through the 
use of polyethylene glycol (PEG).  PEG not only provides a coating to prevent 
opsonization and subsequent recognition by macrophages of the RES, but can link a 
targeting moiety in a distal conformation to facilitate the appropriate receptor activation.  
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First introduced by Gref6, PEG introduction into poly(lactic-co-glycolic acid) 
nanospheres resulted in dramatic increases in blood circulation times and reduced liver 
accumulation in mice.  Since that discovery in 1994, PEG incorporation into nano- and 
microparticulate biomaterials has been used extensively in countless studies to improve 
polymer stability and prevent protein fouling. 
 Several theories have been proposed to explain the apparent protein resistance and 
stealth characteristics imparted to materials by grafting of PEG.  When opsonins and 
other plasma proteins are attracted to the surface of the particle, by van der Waals or 
electrostatic forces, they encounter the PEG chains and begin to compress them.  This 
compression then forces the PEG chains into a more condensed higher energy 
conformation creating a repulsion and steric hindrance of opsonin or protein adherence7.  
Most research indicates that PEG chains of 2000 molecular weight or greater is required 
to achieve increased RES avoidance characteristics6,8,9. 
 With this in mind, a bifunctional PEG linkage can be used for ligand presentation 
and introduction of ‘stealth’ properties.  PEG constructs with different activated linkages 
are available; a chain consisting of an N-hydoxysuccinimide on one end and a maleimide 
on the other, with at least a 2000 PEG molecular weight polymer in the middle, would be 
sufficient to link the PEC surface amines to cysteines on a ligand.  Previous and similar 
strategies have been used to link folate, for targeting  overexpressed folate receptors on 
cancer cells, to liposomes10,11.   Figure 9-1 represents a schematic of this design.  The 
hope is that this PEC chemistry would result in efficient targeting both in vivo and in 
vitro. 
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Figure 9-1.  Representative peptide modifications of PECs for A) naked, B) direct 
linkage by EDAC/NHS, and C) extension of peptide away from the surface with PEG.  
The flexible PEG chains provide a geometric presentation of the ligand and protection 
from destabilizing opsonins and proteins. 
 
 
 
(A) 
(B) 
(C) 
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APPENDIX 
 
 
 
FITC PMCG Release and Spermine Incorporation 
 
 
 
 
Figure A1.  FITC PMCG release depends on serum content.  FITC PMCG release was 
monitored in a similar manner as described in PEC Protein Release and Monitoring. For 
LMW PECs created with dispergation.  The release and, therefore, stability of PECs was 
directly dependent on serum concentration.  Cumulative release, after 6 h, in HMVEC 
media (5% serum) and FCS (100% serum) was 4.62% and 58.42%, respectively (n=1). 
 
 
 
Figure A2.  C14 spermine incorporation into LMW PECs with dispergation.  C14 
spermine (7 µg) was added to the cationic solutions.  PECs were fabricated as described 
in PEC Fabrication, centrifuged, and suspended in HMVEC growth media.  0.004% of 
the labeled material was present in the final suspension. 
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Early Observations of PEC Association in Mouse Fibroblasts 
 
 
 
 Brightfield                  Fluorescence (FITC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3.  FITC PMCG PECs associate with mouse fibroblasts.  FITC PMCG PECs, 
after suspension in growth media at [PEC]=1.54x109 PEC/ml, were incubated with 
mouse fibroblasts (CRL-10225) for 2 h. Growth media was Dulbecco’s Minimum 
Essential Media (DMEM) supplemented with 10% FCS, 4 mM L-glutamine, 0.05 mg/ml 
gentamicin, and 1 mM sodium pyruvate.  PEC incubations were performed as described 
in Confocal Microscopy.  Specimens were viewed with an Olympus BX60 fluorescence 
microscope.  Both brightfield (A,C) and FITC (B,D) filters were applied following a 2 h 
incubation.  Magnification was 400X.    
 
(A) 
(C) (D) 
(B) 
 190 
 
Detection of PEC Association in Mouse Fibroblasts by FACS 
 
 
 
 
 
 
 
 
Figure A4.  Initial observations of PEC/cell interactions by FACS for mouse fibroblasts 
(CRL-10225).  A 48-well plate containing 50000 cells/well were exposed to 1.54x109 
PEC/ml for 6 h in standard CHO growth media (C,D). Growth media was Ham’s F12 
supplemented with 10% FCS, 4 mM L-glutamine, 0.05 mg/ml gentamicin, and 1 mM 
sodium pyruvate.  Subsequent to the exposure period, cells were detached by 0.25% 
trypsin/0.1% EDTA, and analyzed by FACS.  Controls (A,B) were cells in the absence of 
PECs. 
 
(A) 
(C) (D) 
(B) 
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Detection of PEC Association in CHO Cells by FACS 
 
 
 
 
 
 
 
 
Figure A5.  Initial observations of PEC/cell interactions by FACS for Chinese Hamster 
Ovary cells  (CHO).  A 48-well plate containing 50000 cells/well were exposed to 
1.54x109 PEC/ml for 6 h in standard CHO growth media as described in Figure A3 
(C,D).  Growth media was Ham’s F12 supplemented with 10% FCS, 4 mM L-glutamine, 
and 0.1 mg/ml geneticin.  Subsequent to the exposure period, cells were detached by 
0.25% trypsin/0.1% EDTA, and analyzed by FACS.  Controls (A,B) were cells in the 
absence of PECs. 
 
 
 
 
 
 
 
 
 
(A) 
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Suppression of Surface FITC PMCG with Trypan Blue 
 
 
 
 
 
 
Figure A6.  Quenching of a secondary FITC peak with TB.  The acquisition of the total 
MFI (A) was followed by addition of 140 µl of 4 mg/ml TB (B).  The result was a 
disappearance of the peak present in the upper panel.      
 
 
 
 
 
 
(A) 
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Two Color FACS Revealed Linkage of TSP521 to PECs 
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7.  Direct linkage of TSP521 by EDAC/NHS verified by two-color FACS.  
Using the FACSAria system, PECs with (B) and without (A) tetramethylrhodamine 
(TMRA) TSP521 were analyzed with both TMRA and FITC filters.  TSP521 was 
ligated as elaborated in Incorporation of TSP521:  Direct Surface Coupling and 
Passive Entrapment.  After preparing dot plots of FITC (vertical) versus TMRA 
(horizontal), the change in TMRA MFI was calculated with the P1 gate, where P1 
described fluorescent indices greater than 103 a.u. 
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Detection of Apoptosis 
 During the earlier stages of apoptosis, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the 
plasma membrane, thereby exposing PS to the external cellular environment.  
Annexin V is a 36 kDa Ca2+ dependent phospholipid-binding protein that has a high 
affinity for PS, and binds to cells with exposed PS1.  When conjugated to 
allophycocyanin (APC), Annexin V binding to PS can be observed by FACS. 
 The effect of common toxins on HMVEC apoptosis was tested by incubation of 
epoxomicin (epox), pyrrolidine dithiocarbamate (PDTC), and human tumor necrosis 
factor alpha (hTNF) for 24 h at varying concentrations (Figure A8).  Both PDTC and 
epox induce apoptosis through inhibition of proteasome activity and NF-κB 
activation2, 3.  hTNF turns on apoptotic caspases4. This experiment was performed to 
establish a baseline for the presence or absence of apoptosis through PEC exposure. 
HMVECs, 5000 cell/well, were seeded to 12-well plates 24 h prior to the addition of 
Epox, PDTC, and hTNF.  After exposure, cells were then detached by 0.25% 
trypsin/0.1% EDTA and analyzed for Annexin V-APC (BD Pharmingen, San Jose, 
CA) expression.  After monolayer removal, low speed centrifugation, cells were 
resuspended in 200 µl binding buffer, pH 7.4, consisting of 0.01 M HEPES, 0.14 M 
NaCl, and 2.5 mM CaCl2. 5 µl of Annexin V-APC was then added and cells stained 
for 15 min at room temperature in the dark.  Cells in the absence of PDTC, epox, and 
TNF were used as backgrounds and indicated in Figure 8A.  Clear shifts were 
observed as concentrations increased. 
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PECs, non-targeted (nT PEC) and targeted EDAC/NHS (T PEC) were also 
tested for their ability to induce apoptosis by incubation at varying, increasing, high 
concentrations for either 6 h or 24 h (Figure A9).  The concentrations evaluated were 
1.60x109 PEC/ml, 1.54x109 PEC/ml, 1.01x109, and 6.32x108 PEC/ml.  Identical 
conditions were applied as described for PDTC, epox, and TNF exposures.  As shown 
in Figure 9A, no shift was detected as compared to cells without PECs.  The assay 
does not distinguish between cells that have already undergone an apoptotic cell death 
and those that have died as a result of necrosis.  
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Figure A8.  Apoptosis induction by epoxomicin (Epox), pyrrolidine dithiocarbamate 
(PDTC), and human tumor necrosis factor alpha (hTNF). 
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Figure A9.  Annexin V-APC expression of HMVECs in the presence or absence of 
nT or T EDAC/NHS PECs.   
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Confocal Imaging 
 
 
 
Figure A10. FITC PMCG PECs accumulate inside HMVECs after 24 h.  FITC 
PMCG PECs, after suspension in growth media at [PEC]=1.54x109 PEC/ml, were 
incubated with HMVECs overnight.  PEC incubations were performed as described in 
Confocal Microscopy.  Filters were (A) concanavalin A-AF647, (B) TMRA, (C) 
FITC, and (D) merged.  Concanavalin A was applied as a lectin stain to visualize the 
cell membrane  Additionally, 100 µg of TMRA TSP521 was coupled to PECs as 
outlined in Incorporation of TSP521:  Direct Surface Coupling and Passive 
Entrapment. 
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Figure A11. Targeted EDAC/NHS and FITC PMCG PEC confocal imaging.  After 
suspension in growth media at [PEC]=1.54x109 PEC/ml, were incubated with 
HMVECs for 2 h.  PEC incubations were performed as described in Confocal 
Microscopy. 100 µg of TMRA TSP521 was coupled to PECs as outlined in 
Incorporation of TSP521:  Direct Surface Coupling and Passive Entrapment. Filters 
were (A) and (E) concanavalin A-AF647, (B) and (F) TMRA, (C) and (G) FITC, and 
(D) and (H) merged.  Concanavalin A was applied as a lectin stain to visualize the 
cell membrane. 
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Figure A12. Non-targeted FITC PMCG PEC four-track confocal imaging.  After 
suspension in growth media at [PEC]=1.54x109 PEC/ml, were incubated with 
HMVECs for 2 h.  PEC incubations were performed as described in Confocal 
Microscopy.  Filters were (A) TOPRO-3, (B) TMRA, (C) FITC, (D) differential 
interference constrast and (E) merged.  TOPRO-3 was applied as a nuclear stain to 
visualize PEC intracellular localization.  
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Figure A13. Non-targeted FITC PMCG PEC three-track confocal imaging.  After 
suspension in growth media at [PEC]=1.54x109 PEC/ml, were incubated with 
HMVECs for 2 h.  PEC incubations were performed as described in Confocal 
Microscopy.  Filters were (A) and (E) TOPRO-3, (B) and (F) TMRA, (C) and (G) 
FITC, and (D) and (H) merged.  TOPRO-3 was applied as a nuclear stain to visualize 
PEC intracellular localization. 
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Figure A14. Targeted EDAC/NHS PEC three-track confocal imaging.  After 
suspension in growth media at [PEC]=1.54x109 PEC/ml, were incubated with 
HMVECs for 2 h.  PEC incubations were performed as described in Confocal 
Microscopy. 100 µg of TMRA TSP521 was coupled to PECs as outlined in 
Incorporation of TSP521:  Direct Surface Coupling and Passive Entrapment. Filters 
were (A) and (E) TOPRO-3, (B) and (F) TMRA, (C) and (G) FITC, and (D) and (H) 
merged.  TOPRO-3 was applied as a nuclear stain to visualize PEC intracellular 
localization. 
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